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SUMMARY 
 
 Cysteine proteases are a class of proteolytic enzymes, which are involved in a 
series of metabolic and catabolic processes, such as protein turnover, digestion, blood 
coagulation, apoptosis, fertilization and cell differentiation, and the immune response 
system.  The development of novel potent and selective inhibitors for cysteine proteases 
has therefore gained increasing attention among medicinal chemists.  In this thesis we 
have reported the design, synthesis, and evaluation of several peptidyl inhibitors for clan 
CA and clan CD cysteine proteases. 
 We have continued the investigation of dipeptidyl vinyl sulfones as potent and 
selective inhibitors for dipeptidyl peptidase I (DPPI), a lysosomal cysteine protease, 
which is involved in the processing of intracellular proteases, such as granzymes.  We 
have found that DPPI tolerates negatively charged amino acid residues in the P2 position 
with inhibition rates of 7,600 M-1s-1.  Dipeptidyl vinyl sulfones with positively charged 
amino acid residues at the P1 position, however, do not inhibit DPPI at all.   
 A second project focused on the epoxidation of the double bond of the vinyl 
sulfone moiety of the dipeptidyl vinyl sulfones.   Instead of epoxidizing the double bond, 
we found that an isomerization had occurred.  The newly formed compounds were 
determined to be allyl sulfones.  We tested this new class of inhibitors with clan CA 
proteases and obtained inhibition rates of 560 M-1s-1 for Cbz-Leu-Phe-AS-Ph with 
calpain I. 
 Two new classes of compounds for the clan CD protease S. mansoni legumain 
were designed, synthesized, and evaluated.  Aza-peptidyl epoxides were found to be 
 xviii
potent and selective inhibitors of S. mansoni legumain with IC50’s as low as 45 nM.  Aza-
peptide Michael acceptors were derived from the aza-peptide epoxide design and 
synthesized in an analogous fashion.  The aza-peptide Michael acceptors inhibited S. 
mansoni legumain with even lower IC50’s, as low as 10 nM.  However, the aza-peptide 
Michael acceptors react with thioalkylating agents contained in the buffer, such as DTT.  
The rates of degradation were determined spectroscopically, and half-lives of 3 to 20 
minutes were measured.  The degradation was also monitored in an 1H NMR study, and 
the site of attack of the thiol group on the double bond could be observed.  This 
observation gave us some insights into the enzymatic mechanism and lead us to conclude 
that the carbon of the double bond warhead which is closest to the P1 position is the point 
of attack for the legumain active site cysteine thiol.  
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CHAPTER 1 
 
BACKGROUND 
 
PROTEASES 
 
 Proteases are proteolytic enzymes, which catalyze the hydrolysis of peptide 
bonds.  Proteases are found in plants, bacteria, protozoa, fungi, and mammals, and are 
essential for viral replication, and are involved in a series of essential metabolic and 
catabolic processes, such as protein turnover, digestion, blood coagulation, apoptosis, 
fertilization and cell differentiation, and the immune response system.  However 
proteases are involved in a number of disease states and thus have gained tremendous 
attention as therapeutic targets with regards to viral and parasitic infections, stroke, 
cancer, Alzheimer’s disease, neuronal cell death, and arthritis.  They are designated either 
as endo- or exopeptidases, and cleave peptide bonds within a protein or peptide and 
remove amino acids from the N- or the C-terminus respectively.  Depending on the 
catalytic residue responsible for peptide hydrolysis, the proteases have been divided into 
serine, cysteine, aspartic, and metallo- proteases1.  However due to the growing number 
of proteases which are being discovered, a more in depth classification has become 
necessary.  Barrett and Rawlings have therefore established a classification system, 
which organizes the various proteases within their individual catalytic category into 
evolutionary families and clans 2,3, and which forms a comprehensive and continuously 
expanding catalog of proteases: the MEROPS database.  An individual protease is 
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assigned to a particular clan based on the three-dimensional structure, the arrangement of 
catalytic residues in the polypeptide chains and limited similarities in amino acid 
sequence around the catalytic amino acid residues.  The name of the clan is derived from 
the first letter of the catalytic type followed by a second arbitrary letter2,3, giving rise to 
clans SX, CX, AX and MX. 
 Proteases bind the substrate peptide chain along the active site cleft.  The enzyme 
subsites bind the peptide chain on either side of the site of hydrolysis, the scissile peptide 
bond.   The subsites are specific for the particular side chains or the peptide backbone of 
the peptide substrate.  Berger and Schechter have developed a nomenclature for the 
individual enzyme subsites and the complementary amino acid residues within the 
peptide substrate (Figure 1.1)4.  The subsites and the amino acid residues are assigned S1, 
S2, etc. and P1, P2, etc. respectively towards the N-terminus of the substrate away from 
the scissile peptide bond.  In symmetry to the scissile bond the S1', S2', etc. subsites and 
the P1', P2', etc. are directed towards the C-terminus. 
 
 
Figure 1.1.  Nomenclature for Protease Subsite Specificity. 
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 Cysteine proteases employ the sulfhydryl group of the side chain of a cysteine 
residue as the catalytic nucleophile.  Together with the imidazole side chain of a histidine 
residue a catalytic dyad is formed between the thiol nucleophile and a proton 
donor/general base, as the imidazole group of the catalytic His polarizes and deprotonates 
the Cys sulphydryl group.  Some families use a third residue to ensure proper orientation 
of the imidazolium ring of the catalytic His, thus forming a catalytic triad.  In the attack 
of the active site cysteine on the scissile amide bond of the peptide backbone a tetrahedral 
intermediate is formed.  This tetrahedral intermediate is stabilized by the oxyanion hole, 
which is found to be more rigid in serine proteases and more flexible in cysteine 
proteases.  The intermediate collapses to release the first product and the resulting acyl 
enzyme then undergoes hydrolysis.   
  
Cysteine Proteases
Clan CA
C1 Papain
      Cathepsins
      Cruzain 
C2 Calpains
Clan CD
C14 Caspases
C13 Legumains
C25 Gingipains
C11 Clostripain
Clan CB
Human Rhinovirus 
3C Protease
Aspartate Proteases
Serine Proteases
Metallo-Proteases
 
Figure 1.2.  Classification of Cysteine Proteases into Families and Clans. 
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The majority of cysteine proteases, such as papain, calpains, cathepsins, and 
cruzain belong to the clan CA (Figure 1.2).  According to the crystal structure of papain, 
Clan CA proteases are unique for their catalytic triad formed by Cys, His, and Asn.  The 
oxyanion hole is created by a preceding Gln residue.  Clan CA enzymes are inhibited by 
the natural product E-64 and cystatin.  Clan CB is formed by a group of viral cysteine 
proteases, such as the human rhinovirus 3C protease, which are believed to have evolved 
from an ancestor also related to the serine protease chymotrypsin due to similarities in 
their three-dimensional structure and their amino acid sequence.   Even though clan CD is 
the smallest of the clans, it contains some very important enzymes.  Among them are 
caspases, legumains, gingipains, and clostripain.  Clan CD enzymes are unique for their 
lack of inhibition by E-64, a natural inhibitor of cysteine proteases, and their specificity 
for the P1 amino acid residue.  There are several other clans among the cysteine 
proteases, however, for our research we will only focus on clan CA and clan CD 
enzymes. 
 
SUBSTRATE  SPECIFICITY 
  
 The specificity for substrates varies greatly between the individual families and 
clans of cysteine proteases.  The difference in electrostatic character and size of the 
enzyme subsites is responsible for the substrate specificity.  In order to determine the 
nature of the enzyme subsites the preparation of a comprehensive substrate library is very 
useful, especially when the crystal structure of an enzyme is difficult to obtain. 
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 Clan CA.  Papain.  Papain is a cysteine protease found in the latex of tropical 
papaya fruit.  It is the most extensively studied protease, and also the first enzyme to have 
its crystal structure determined5.  The substrate specificity of clan CA enzymes is 
primarily controlled by the S2 subsite.  Papain is considered to have a very broad 
specificity compared to other clan CA proteases.  Berger and Schechter have found that it 
can accommodate up to seven amino acid residues6.  It prefers a bulky, non-polar side 
chain at P2 (e.g. Phe)6, whereas the S1 subsite is less selective, but some preference for 
Arg and Lys over other residues such as Val has been observed7.  The S' subsite 
specificities of papain are very broad8.  The oxyanion hole is formed by the Cys 25 
backbone and the Asn-19 side chain.   
 Cathepsin B.  Cathepsin B is a lysosomal cysteine protease, which was first 
identified by its ability in cattle spleen to deamidate Bz-Arg-NH29.  It possesses both 
endopeptidase and exopeptidase activities.  The substrate specificity of cathepsin B is like 
papain also controlled by the restrictions of the S2 subsite.  Unlike papain however, the 
location of the Glu 245 residue within the S2 subsite, also allows an arginine side chain at 
the P2 position in addition to large hydrophobic residues10.  The S3 subsite prefers large 
hydrophobic residues and the S1 subsite a small residue or Arg.  On the P1' side large 
hydrophobic residues were found to be optimal in cathepsin B substrates. 
 Dipeptidyl Peptidase I.  Dipeptidyl peptidase I (DPPI) is a clan CA exopeptidase, 
which is found in the granules of cytotoxic lymphocytes, where it cleaves dipeptides from 
the N-termini of various zymogens in order to activate them.  Its crystal structure was 
recently determined by Turk et al11.  DPPI shows an absolute requirement for a free N-
terminus because of its N-terminal Asp 1, which locks the substrate in position, as will be 
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further described in chapter 2.  It prefers dipeptides over tripeptides and does not tolerate 
basic residues at the P2 position.  The optimal AMC (4-aminomethyl coumarin) assay 
substrates used are free N-terminal dipeptides, such as Gly-Phe or Gly-Arg12.   
 Calpains.  Calpains are a unique familiy of cysteine proteases within the clan CA, 
as they require calcium for their activation.  Their activity was first described as a 
calcium dependent neutral protease activity in rat brain by Guroff13.  They are located in 
the cytosol of mammalian cells and play an important role in physiological processes that 
control the degradation of the cytoskeleton as well as hormone receptors14,15.  The 
specificity of calpains is not fully understood, but it has been determined that 
hydrophobic residues (Tyr, Met, Leu, Val) as well as Arg are preferred by the S2 
pocket16.  Overall the substrate specificity is very restricted, and most oligopeptides are 
not cleaved.  
 Clan CD.  The members of the clan CD enzymes distinguish themselves from the 
clan CA enzymes by their α/β protein fold.  Unlike clan CA cysteine proteases, clan CD 
enzymes employ a catalytic dyad (His-Cys) for substrate hydrolysis.  Their specificity is 
controlled by the S1 subsite, and varies for each enzyme within the clan. 
 Caspases.  More than 15 enzymes belong to the only recently discovered family 
of caspases.  They are involved in cytokine processing, apoptosis, and inflammation, 
where they either act directly on the particular process or are remotely involved by 
facilitating the maturation of procaspases.  Caspases derive their name from their 
absolute specificity for an asparagine residue at the P1 position of their substrate 
(cysteinyl aspartate specific protease).  Their family can be further divided into groups 
according to the particular proteolytic function.  Group I (1, 4, 5, 11, 12, 13, and 14) 
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includes caspases which are mediators of inflammatory processes.  Group II (2, 3, and 7) 
contains caspases, which are late phase effectors of apoptosis.  Group III (6, 8, 9, and 10) 
caspases are responsible for upstream processing of the effector caspases.  In addition to 
the strict specificity of the S1 subsite for an Asp residue, caspases prefer four amino acid 
residues on the non-prime side of the scissile peptide bond.  The S4 subsite provides 
additional control for the specificity within the family of the caspases.  The optimal 
sequence for the group I caspases is Trp-Glu-His-Asp, Asp-Glu-X-Asp for group II, and 
Val- or Leu-Glu-X-Asp for group III.  The oxyanion hole is formed by the backbone 
amide protons of Gly 238 and Cys 285.   
 Clostripain.  Clostripain is a cysteine protease, which was first isolated in 1938 
from the Gram-positive bacterium Clostridium histolyticum.  This bacterium has been 
related to the gas gangrene syndrome17.  Clostripain requires calcium ions and DTT for 
its activation.  Like the other members of clan CD, clostripain is highly restricted in the 
S1 subsite.  Similar to the serine protease trypsin, it cleaves only after Arg or Lys at the 
P1 position, with some preference for Arg over Lys18.  Clostripain has a broad specificity 
on the P' side of the scissile bond, but will not accept Asp or Glu19.  Unlike other 
peptidases it also accepts a proline residue in the P1' position.  The dipeptide Z-Phe-Arg-
AMC was determined to be the optimal substrate for enzymatic assays20.   
 Gingipains.  Gingipains were first described in 1984 as enzymes produced by 
porphyromonas gingivalis, the oral pathogen, which causes gingivitis.  They require 
calcium ions and DTT for its activation along with a buffer medium at pH 8, similar to 
the periodontal cavity21.  The active site is formed by a catalytic triad, unlike other clan 
CD proteases.  According to the sequence homology and the crystal structure gingipains 
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show some relation to caspase-1 and caspase-3, but there are no similarities with any 
other cysteine proteases22.  Gingipain K cleaves exclusively on the C-terminal side of 
lysine residues and has some preference for hydrophobic residues at P2 and P3, whereas 
gingipain R only accepts arginine residues in the P1 position and has little specificity for 
the P2 positon21,23.   
  
INHIBITOR DESIGN 
 
 Since the early 1970’s inhibitors have been a useful tool in the characterization of 
binding sites, catalytic functional groups and transition-state geometries of cysteine 
proteases.  In addition they can be used as active site titrants to determine a more accurate 
quantity of active enzyme.  The design of highly selective inhibitors makes it possible to 
investigate the physiological function of a particular class of enzymes within an 
organism.  Finally, cysteine protease inhibitors have great medicinal potential in the 
treatment of various diseases.   
 The design of irreversible inhibitors for proteases generally involves a peptide 
chain with a so-called warhead replacing the scissile peptide bond.  The optimal peptide 
sequence for the inhibitor is derived from the best peptide substrate sequence, which can 
be determined through enzyme subsite mapping using a peptide library.  There is 
considerable variation in the sequence specificity between proteases between the clans 
and even within a particular clan.  As described earlier, the various enzyme subsites 
impose different requirements on their peptide substrates.  Clan CD for example is highly 
specific for the residue in the P1 position, whereas clan CA is more selective for the P2 
 9
position.  The length of the peptide portion also plays an important role for the 
specificity.  It is therefore possible to design inhibitors specific for a particular enzyme.  
The inhibitor can then be used to investigate the physiological significance of the target 
enzyme.   
 The warhead consists of a reactive functionality that is attacked by the enzyme’s 
catalytic nucleophile.  A covalent bond is formed between the inhibitor and the catalytic 
residue and hence the enzyme is irreversibly inactivated.  A variety of irreversible 
warheads have been developed so far.  Powers et al have extensively reviewed the 
irreversible inhibitors for serine, cysteine, and threonine proteases reported up to date24.  
Alkylating agents include halomethyl ketones, diazomethyl ketones, acyloxymethyl 
ketones, epoxides, aziridines, vinyl sulfones, and azodicarboxamides.  Among the 
acylating agents, aza-peptides, carbamates, acyl hydroxamates, β-lactams and a variety of 
heterocyclic inhibitors have been reported.   
 Once a peptide sequence and warhead are determined, a strategic SAR study is 
performed to optimize the parent compound in its inhibitory potency.  With the rise of X-
ray crystallography, the concept of the structure-based design has become a useful tool 
for the optimization of lead compounds.  The binding of an inhibitor in the active site of 
an enzyme can be visualized with the crystal structure of an enzyme-inhibitor complex.  
 
IRREVERSIBLE KINETICS 
 
 Irreversible inhibitors react with the target enzyme via an intermediate non-
covalent enzyme-inhibitor complex E·I to form a covalent enzyme-inhibitor complex E-I.   
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E + I E I E-I
Ki k2
, 
 
where Ki is the dissociation constant for the intermediate complex and k2 is the first-order 
rate constant for the formation of E-I.  Kitz and Wilson developed a method to determine 
the values of Ki and k2  by incubating enzyme and a large excess of inhibitor prior to 
diluting the sample into a buffer solution containing a good substrate25.  The residual 
enzyme activity vt can then be measured at time t of the incubation.  This method is 
referred to as the incubation method and described by the equation  
ln (vt/v0) = -kobst, 
where v0 is the initial rate of hydrolysis without the presence of the inhibitor and kobs is 
the pseudo-first-order rate constant for inactivation, which is described by 
kobs = k2[I]/(Ki + [I]) 
or in double reciprocal form:  
1/kobs = Ki/k2[I] + 1/k2 
Ki = [E][I]/[E·I]  
 Pseudo-first-order kinetics are however only accurate, if the inhibitor 
concentration is at least ten fold in excess of the enzyme concentration.  If the inhibitor 
concentration drops below, then second-order kinetics have to be applied using 
k2ndt = [1/(i – e)]ln[e(i – x)/i(e – x)], 
where i is the initial inhibitor concentration and e - x is the residual enzyme 
concentration.  The initial enzyme concentration is a requirement for second-order 
kinetics.   
 11
 For very fast inhibitors, where very low inhibitor concentrations are required, 
Tian and Tsou have developed an assay method, which monitors the substrate hydrolysis 
upon adding enzyme to a mixture of substrate and inhibitor26.  This method is referred to 
as the progress curve method.  It follows an exponential time course, where all the 
enzyme is inactivated and the product approaches a limited concentration [P]∞ :   
[P]t = [P] ∞(1 – e-tkobs),  
which can be rewritten in logarithmic form 
ln ([P] ∞ - [P]t) = ln [P] ∞ - kobst 
and values of kobs can be obtained from the slope of the plots ln ([P] ∞ - [P]t) versus t.  
However, this method is somewhat unreliable, since it requires an accurate estimate of 
[P] ∞ and that parameter is only given by an asymptotic approach.  However, the progress 
curve method is very practical for enzymes like calpain, which has low activity and 
therefore requires high enzyme concentrations.  In addition the assays are more 
convenient and less time consuming.  
The determination of the concentration of inhibitor required to decrease the 
activity of the enzyme by 50% (IC50) is the standard method to initially screen a large 
number of inhibitors.  However, the data only gives a crude comparison between the 
inhibitors, and does not allow to draw conclusions as to the reversibility of the inhibition 
mechanism.  The incubation time is an important factor for IC50 assays of irreversible 
inhibitors, and can be used to establish a mathematical relationship between the pseudo-
first order inactivation rate kobs and IC50 values: 
 
kobs = ln 2/t1/2 = 0.693/tassay 
 12
kobs/[I] = 0.693/(tassay x IC50) 
 
For irreversible inhibition a longer incubation time is reflected in a lower IC50 value.   
 The methods developed by Kitz and Wilson and Tian and Tsou efficiently analyze 
kinetic data.  However not all mechanisms of inhibition follow this simple model, but 
require a more complex treatment of the assay data.  Mechanism-based inactivators for 
example undergo a rearrangement before forming a covalent enzyme-inhibitor complex.  
Therefore kinetic data can also help to investigate a mechanism of inhibition.  
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CHAPTER 2 
 
DESIGN AND EVALUATION OF INHIBITORS FOR  
DIPEPTIDYL PEPTIDASE I 
 
INTRODUCTION 
 
Dipeptidyl peptidase I (DPPI, cathepsin C, EC 3.4.14.1) is a lysosomal cysteine 
protease.  It can sequentially remove dipeptides from the N-termini of various peptides 
and proteins1,2.  DPPI and other cysteine proteases such as cathepsin B, H, and L were 
found to degrade intracellular proteins2.  DPPI is widely distributed in a variety of 
tissues3  and is present in high levels in cytotoxic lymphocytes and mature myeloid cells4.  
DPPI and granzymes are found in the granules of cytotoxic lymphocytes4 and DPPI is 
responsible for processing and activating progranzymes (Figure 2.1).   
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CO2AA2-AA1signal peptide
CO2AA2-AA1
DPPI
CO2
progranzymes (sequence shown)
or zymogens of other serine proteases (procathepsin G)
granzymes
cathepsin G
Ile-Ile-Gly-Gly
Ile-Ile-Gly-Gly
signal peptidase
Ile-Ile-Gly-Gly
 
 
Figure 2.1.  Processing of Progranzymes by DPPI to form Active Granzymes. 
 
Granzymes, which are named for granule serine proteases, are found in the 
granules of activated cytotoxic T lymphocytes and natural killer cells.  These enzymes 
may play a functional role in cellular lytic activity5.  Lymphocytes cultured with a 
diazomethyl ketone DPPI inhibitor, Gly-PheCHN2, lack granzyme A activity4, have 
lower granzyme B activity6 and reduced cytolytic function7.  DPPI has been reported to 
activate the progranzymes A, B, and mast cell prochymase by removal of dipeptides from 
the N-terminus of their zymogens8-10.  DPPI has been shown to process and activate 
progranzymes A and B in vivo11.  
DPPI has been purified from several species such as human, rat, bovine, porcine 
and goat12-15.  DPPI is initially synthesized as a 55 kDa proenzyme and is converted to 
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the mature enzyme as a two chain form, a heavy chain of 25 kDa and a light chain of <10 
kDa.  These two chains have high similarity (30-40% sequence homology) to the heavy 
and light chains of papain-like cysteine proteases16.  Unlike other cysteine proteases, 
which are monomeric proteins with a molecular mass of 20-30 kDa, DPPI exists as an 
oligomeric structure with a molecular mass of 200 kDa2.  It has been shown that human 
DPPI consists of 4 identical subunits and each subunit is composed of three different 
polypeptide chains, a heavy chain, a light chain, and a propeptide.  The heavy chain and 
the light chain are linked by disulfide bonds, and the pro region of the enzyme remains 
bound to the mature enzyme.  The regulation of processing and assembly of DPPI is still 
unknown, but the x-ray structure of DPPI has recently been determined17. DPPI has four 
active site clefts.  The catalytic residues Cys 234 and His 381 are situated above the 
oxyanion hole as expected.  The S2 binding site has the shape of a deep pocket and is 
formed by the side chains of Ile 429, Pro 279, Tyr 323 and Phe 278.   A chloride ion is 
located on the bottom of this pocket.   
In an effort to characterize the substrate specificity of DPPI, the Powers 
laboratory has recently reported kinetic data for a series of dipeptide substrates for 
DPPI18.  It was found that the free amino group at the N-terminus of DPPI substrates 
plays an important role.  Turk et al have shown that the carboxylic acid group of Asp 1 
locks this N-terminal amino group of the substrate into position.  It was also found that 
DPPI was unable to cleave substrates with a P1 Ile.  The enzyme generally prefers large 
hydrophobic or aromatic sidechains at the P1 residue, and small less bulky substituents at 
the P2 position.   
 DPPI was inhibited by several general inhibitors of cysteine proteases13 and by 
E-64 slowly19.  The most potent inhibitor of DPPI found up to date was Gly-PheCHN220.  
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However, due to the high reactivity of the diazomethyl ketone group, more stable 
dipeptide inhibitors are needed.   
Chih-Min Kam has previously synthesized a series of highly potent dipeptidyl 
vinyl sulfone inhibitors with the general formula AA2-AA1-VS-R in our laboratory.  
Similar to the synthetic substrates by Tran et al, the better inhibitors have large 
hydrophobic or aromatic residues at the P1 position, a free N-terminus and amino acids 
with small side chains at the P2 position.   
Some of the vinyl sulfones were found non-toxic to cells and effective toward 
intracellular DPPI6.  Thus, these vinyl sulfones are suitable for functional studies of 
DPPI. 
 
Table 2.1.  Inhibition of Intracellular DPPI in RNK-16 Cells by Dipeptide Vinyl 
Sulfones. 
Inhibitors %viabilitya ID50 (µM)b 
Gly-Phe-VS-Ph 47% (toxic) NI 
Ala-Phe-VS-Ph 77% (toxic) 15 
Val-Phe-VS-Ph >90% 6 
Leu-Phe-VS-Ph 40% (toxic) NI 
Lys(Z)-Phe-VS-Ph 0% (toxic) NI 
Glu-Glu-VS-Ph >80% >250 
Thr-Glu-VS-Ph >90% 45 
Ala-Hph-VS-Ph >90% 0.1-1 
Nva-Hph-VS-Ph >90% 0.1-1 
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Ala-Lys(Fla-Adp)-VS-Ph >90% ~100 
Gly-Phe-VS-CH3 >90% 21 
Ala-Phe-VS-CH3 ND ND 
Val-Phe-VS-CH3 >90% 11 
Leu-Phe-VS-CH3 >90% 4.7 
Boc-Gly-Phe-VS-Ph 61% (toxic) 330 
aViability was assessed by trypan blue exclusion after culture of RNK-16 cells with 100 
µM or greater concentration of inhibitor for at least 20 hours. 
bID50 was determined to be the concentration of inhibitor required to inhibit cellular 
DPPI by 50% after treatment of RNK-16 cells in culture for at least 20 hours and is 
representative of at least two experiments. 
 
 
Dipeptide vinyl sulfones inhibited the intracellular DPPI of RNK-16 cells (Table 2.1)6.  
For example, Ala-Hph-VS-Ph, Nva-Hph-VS-Ph, Val-Phe-VS-Ph, and Leu-Phe-VS-CH3 
inhibited intracellular DPPI with ID50’s of micromolar or sub-micromolar range. 
 The tolerance of the enzyme S2 subsite towards charged amino acid residues has 
so far not been investigated.  In order to explore the tolerance of the active site towards 
charged amino acid residues in the P2 position of the dipeptidyl vinyl sulfone inhibitors 
four vinyl sulfone inhibitors with Arg and Glu residues at P2 were synthesized and tested 
for their potency with DPPI. 
 
CHEMISTRY 
 
 Dipeptide vinyl sulfones (Figure 2.2) are prepared by coupling of Boc-AA-OH 
with the hydrochloride salt of the amino acid vinyl sulfone21.  Deblocking of the Boc 
group or side chain protecting group of dipeptide vinyl sulfones with acid gives the 
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desired dipeptide vinyl sulfones.  The amino acid vinyl sulfone derivative 6 is prepared 
from Boc-AA-OH via formation of the N,O-dimethylhydroxamate 1, reduction to the 
aldehyde 2, coupling with sulfonylphosphonate 4 using a Horner-Wittig reaction22 and 
final removal of the Boc group with acid.  Subsequent coupling with Boc-AA2-OH and 
removal of the Boc group provided the dipeptidyl vinyl sulfone 7. 
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Figure 2.2.  General Preparation of the Dipeptidyl Vinyl Sulfone. 
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RESULTS AND DISCUSSION 
 
 A variety of inhibitors including aldehydes23,24, ketoesters, ketoamides25,26, 
nitriles27, diazomethyl ketones20,28,29, halomethyl ketones30-33, acyloxymethyl ketones34-36, 
vinyl sulfones21,37, and epoxysuccinyl derivatives19,38,39  have been synthesized for cysteine 
proteases40,41.  However, only a few synthetic inhibitors have been reported for DPPI20,27.  
Leupeptin and E-64 inhibit DPPI at high inhibitor concentration19,40.  A reversible 
inhibitor Gly-NHCH(CH2Ph)CN inhibits DPPI with a KI value of 2.7 µM and Gly-Phe-
VS-CH3 inhibits DPPI with k2/KI of 56 M-1s-1
27.  The most effective inhibitor is Gly-
Phe-CHN2 with kobs/[I] of 104 M-1s-1
20.  However the stability of the diazomethyl ketone 
functional group is limited due to its high reactivity.  Therefore new types of inhibitors 
for DPPI are needed. 
Inhibition Studies.  Peptide vinyl sulfones are mechanism-based inhibitors for 
various cysteine proteases, the inhibitory potency of these compounds depends on their 
peptide sequences and the substituent on the vinyl sulfones21,37.  The vinyl sulfones are 
quite selective toward cysteine proteases since they do not inhibit serine proteases.  
However, it has recently been reported that these compounds also react with the active 
site Thr of the catalytic β subunit of the proteasome42.  The vinyl sulfone inhibited 
cysteine protease is quite stable, enzyme activity has not regained after a few days21.  
Most of the vinyl sulfones inhibit DPPI moderately and the inhibitory potency can be 
improved by varying the dipeptide sequence and substituent on the sulfones.  The best 
inhibitors, Ala-Hph-VS-Ph and Nva-Hph-VS-Ph, were derived from the sequences of the 
best AMC substrates18.  The vinyl sulfones containing a 4-chlorophenyl or methyl group, 
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as found by Chih-Min Kam, are less potent than those with a phenyl group indicating that 
the chloride on the phenyl group may interfere with the binding to the enzyme, and the 
methyl group lacks the interaction with the enzyme.  Dipeptide vinyl sulfones with a 
large hydrophobic group such as Hph or Lys(Fla-Adp) at the P1 site inhibited DPPI more 
potently than other corresponding vinyl sulfones with a P1 Phe.  The weak inhibition of 
the Lys derivative with a blocked side chain at the P2 site is consistent with the substrate 
studies confirming that DPPI does not prefer P2 bulky residues.  The x-ray structure of 
DPPI shows that the S2 pocket is quite deep and can accommodate various hydrophobic 
residues17.  However, it also indicates that the S1 site is located on the surface of the 
protein structure, thus various residues can fit in.  Inhibition of DPPI by a series of 
dipeptide vinyl sulfones synthesized by Chih-Min Kam is shown in Table 2.2. 
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Table 2.2.  Inhibition of Bovine Spleen DPPI by Dipeptide Vinyl Sulfones. 
 
Inhibitors 
 
[I] (µM) 
 
kobs/[I] (M-1s-1) 
(k2/KI) 
Gly-Phe-VS-Ph 83 150 ± 5 
Ala-Phe-VS-Ph 17 430 ± 48 
Val-Phe-VS-Ph 8.3 1600 ± 110 
Leu-Phe-VS-Ph 8.3 1700 ± 110 
Lys(Z)-Phe-VS-Ph 420 0.22 ± 0.02 
Lys(Fla-Adp)-Phe-VS-Ph 420 0.67 ± 0.02 
Ala-Hph-VS-Ph 0.004-0.043 (2,000,000)a 
Nva-Hph-VS-Ph 0.004-0.043 (890,000)a 
Ala-Lys(Fla-Adp)-VS-Ph 0.005-0.043 (850,000)a 
Glu-Glu-VS-Ph 17 710 ± 36 
Gly-Glu-VS-Ph 17 490 ± 19 
Thr-Glu-VS-Ph 8.3 2900 ± 260 
Gly-Phe-VS-CH3 42 72 ± 4.0 
Ala-Phe-VS-CH3 42 450 ± 36 
Val-Phe-VS-CH3 8.3 340 ± 26 
Leu-Phe-VS-CH3 8.3 210 ± 18 
Val-Phe-VS-Ph-Cl 42 8.7 
Leu-Phe-VS-Ph-Cl 42 6.2 
Boc-Gly-Phe-VS-Ph 420 NIb 
Boc-Thr(OtBu)-Glu-VS-Ph 420 NIb 
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Phe-VS-Ph 420 32%c 
aThe k2/Ki value was obtained by progress curve method. 
bNo inhibition after incubation for 1 h at rt. 
cPercentage inhibition after incubation for 1 h at rt. 
 
 
  Most of these dipeptides which contain the activation sequence of granzymes 
(Gly-Glu, Glu-Glu, or Thr-Glu43) or Phe at the P1 site inhibit DPPI moderately with 
kobs/[I] values of 102-103 M-1s-1.  The best inhibitor Ala-Hph-VS-Ph, which is derived 
from the best dipeptide AMC sequence, has a k2/KI value of 2,000,000 M-1s-118.  Two 
other dipeptides with an Ala-Lys(Fla-Adp) or Nva-Hph sequence are also potent 
inhibitors for DPPI with k2/KI values of (8.5-8.9) x 105 M-1s-1.  The inhibition constants 
(k2/KI) of these three inhibitors were obtained by progress curve method instead of 
incubation method since DPPI was completely inhibited when the condition of incubation 
method was performed.  Vinyl sulfones with a bulky blocking group at the P2 site such as 
Lys(Z) or Lys(Fla-Adp) showed very poor inhibition, which is consistent with the study 
of AMC substrates.  Substitution of the phenyl group on the sulfones with a methyl or 4-
chlorophenyl group decreased the inhibitory potency.  The blocked dipeptide vinyl 
sulfones do not inhibit DPPI while the amino acid derivatives inhibit this enzyme weakly.  
Several dipeptide vinyl sulfones were also tested with other lysosomal cysteine proteases 
by Mrs. Chih-Min Kam (Table 2.3).  
The best DPPI inhibitor Ala-Hph-VS-Ph inhibited DPPI more potently than 
cathepsins B, L, and H by at least over 6600 folds.  Although Nva-Hph-VS-Ph inhibited 
DPPI potently, it also inhibited cathepsins L and H moderately.  Other dipeptide vinyl 
sulfones also inhibited DPPI more selectively.  The N-terminal blocked dipeptide vinyl 
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sulfones do not inhibit DPPI, indicating the importance of the free amino group at the N-
terminus, which is also shown in the dipeptide substrates18. 
 
 
Table 2.3.  Inhibition of Various Cysteine Proteases by Dipeptide Vinyl Sulfones. 
Inhibitors kobs/[I] (M-1s-1) 
 DPPIa Cat Bb Cat Lc Cat Hd 
Ala-Hph-VS-Ph 2,000,000e 58 304 96 
Nva-Hph-VS-Ph 890,000e 23 1420 4700 
Val-Phe-VS-Ph 1600 0.1 21 8.3 
Gly-Phe-VS-CH3 72 1.3 1.0 2.7 
Val-Phe-VS-CH3 340 0.3 21 NIf 
Leu-Phe-VS-CH3 210 NI 106 NI 
aInhibition constants were measured by incubation method in 50 mM NaAc, 30 mM 
NaCl, 1 mM EDTA, 1mM DTT, pH 5.5 buffer and at 23 ˚C.  Gly-Phe-AMC (0.091 mM) 
was used as the substrate. 
bInhibition constants were measured in 0.1 M KHPO4, 1.25 mM EDTA, 0.01% Brij, pH 
6.0 buffer and at 23 ˚C.  Z-Arg-Arg-AMC (0.4 mM) was used as the substrate. 
cInhibition constants were measured in 50 mM Mes, 2.5 mM EDTA, 1mM DTT, 0.01% 
Brij, pH 5.5 buffer and at 23 ˚C.  Z-Phe-Arg-AMC (0.005 mM) was used as the substrate. 
dInhibition constants were measured in 50 mM Pipes, 2.5 mM EDTA, 1mM DTT, 0.01% 
Brij, pH 6.8 buffer and at 23 ˚C.  Arg-AMC (0.25 mM) was used as the substrate. 
eThe k2/KI value was measured by progress curve method. 
fNo inhibition after 20 min incubation of enzyme with inhibitor in the buffer. 
 
  
  
It was well established by Chih-Min Kam, that DPPI prefers a Hph or Phe residue 
at the P1 position.  The tolerance of the S2 site towards charged residues could therefore 
be explored with dipeptidyl vinyl sulfones bearing a Hph or Phe in the P1 position and a 
Glu or Arg in the P2 position.  The kinetic data showed that DPPI tolerates the negative 
charge of the Glu side chain, but does not improve the potency (Table 2.4).  Clearly, 
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small, uncharged residues at the P2 position can be better accommodated by the S2 
pocket.  The positively charged Arg side chain has a detrimental effect on the potency.  
The complete lack of inhibition can most likely be attributed to the affinity of the 
negatively charged Asp 1 at the entry of the S2 pocket.  We assume that the inhibitor 
does not even enter the active site, but merely binds to the entry of the pocket.  
 
 
Table 2.4.  Inhibition of DPPI by Dipeptidyl Vinyl Sulfones with a Charged P1 Amino 
Acid. 
 
Inhibitors 
 
[I] (µM) 
 
kobs/[I] (M-1s-1) 
 
Glu-Hph-VS-Ph 5 7680 ± 220 
Glu-Phe-VS-Ph 156 95 ± 4 
Arg-Phe-VS-Ph 420  NIa 
Arg-Hph-VS-Ph 420 NIa 
a NI = No inhibition after incubating for 1 hour. 
 
Structure and Mechanism.  The x-ray structure of DPPI indicates that the side 
chain carboxyl group of the N-terminal Asp 1 is close to the S2 site17.  This carboxyl 
group may act as an anchor for the N-terminal amino group of dipeptide substrates or 
inhibitors.  The proposed mechanism for the inhibition of DPPI by vinyl sulfones is 
shown in Figure 2.321. 
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Figure 2.3.  DPPI Mechanism of Inhibition by Dipeptidyl Vinyl Sulfones. 
 
The thiol group of the active site Cys 234 can attack the carbon on the vinyl group 
to give a covalently linked enzyme-inhibitor derivative.  The oxygen of the sulfonyl 
group interacts by hydrogen bonding with His 381 at the active site, which enhances the 
binding between the enzyme and inhibitor.  According to Turk et al. the S2 site controls 
the binding with the two negative charges of Asp 1 at the entry of the pocket and the 
chloride ion situated at the bottom of the deep hydrophobic pocket17.  This suggests that 
positively charged P2 residues do not even enter the pocket but merely bind to the Asp 1 
at the entry of the pocket, which is in agreement with the kinetic data of Arg-Phe-VS-Ph 
as well as Arg-Hph-VS-Ph.   
Stability of Vinyl Sulfones.  The unblocked dipeptide inhibitors with a free N-
terminal amine group have a tendency to form a stable seven-membered ring structure, 
therefore these dipeptides are less stable than their corresponding blocked dipeptides.   
The vinyl sulfone functional group is stable under acidic conditions, however it will 
decompose when exposed to nucleophiles in the neutral or basic buffer.  For example, the 
unblocked dipeptide vinyl sulfones are quite stable in the pH 5.5 buffer (t1/2 > 318 min), 
where the enzymatic activities are measured, but decompose in the pH 7.5 buffer by 
buffer catalysis (t1/2 = 7-110 min) except for Ala-Lys(Fla-Adp)-VS-Ph (Table 2.6).  At 
pH 7.5, the stability of these compounds was also affected by the size of the P2 amino 
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acid, for example the unblocked dipeptide with P2 Gly or Ala have a shorter half life than 
those with Val, Nva, or Leu.  Therefore, the bulky group at P2 will hinder the cyclization 
of the amino group. 
 
Table 2.6.  Stability of Dipeptide Acyloxymethyl Ketones and Vinyl Sulfones. 
 
Inhibitor 
 
 
t1/2 (min) 
 
 
 
pH 7.5 
50 mM Hepes 
(100 mM) 
pH 7.5 
50 mM Phosphate 
(100 mM) 
pH 5.5 
50 mM 
Acetate 
Gly-Phe-CH2OCOPh 13000  2200 
Gly-Phe-VS-Ph 13 
(8.4) 
14 
(8.5) 
540 
Ala-Phe-VS-Ph 31 
(15) 
37 
(18) 
1400 
Val-Phe-VS-Ph 90 
(42) 
93 
(50) 
980 
Leu-Phe-VS-Ph 60 
(26) 
62 
(29) 
1200 
Glu-Glu-VS-Ph 36  723 
Thr-Glu-VS-Ph 60 
(33) 
59 
(24) 
1000 
Boc-Gly-Phe-VS-Ph NRa  NRb 
Gly-Phe-VS-Ph-4-Cl 7.3 7.8 480 
Leu-Phe-VS-Ph-4-Cl 19 13 510 
Boc-Gly-Phe-VS-Ph-4-Cl NRb  NRb 
Gly-Phe-VS-CH3 50 53 580 
Val-Phe-VS-CH3 103  672 
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Leu-Phe-VS-CH3 97 110 1300 
aNo reaction in 24 hours. 
bNo reaction in 2 hours. 
 
Cellular Efficacy of Vinyl Sulfones.  Inhibition of intracellular DPPI by many 
vinyl sulfones was performed by the Hudig lab using RNK-16 cells (Table 2.1).  The 
cellular efficacy of these compounds (ID50) toward DPPI not only depends on their 
inhibitory potency toward the enzyme, but also on their ability to enter the cell and their 
stability in the cell medium.  Six vinyl sulfones had an ID50 of less than 25 µM, where 
Ala-Hph-VS-Ph and Nva-Hph-VS-Ph are the most potent inhibitors. This is due to their 
high inhibitory potency toward DPPI, although Ala-Hph-VS-Ph is less stable at either pH 
7.5 or 5.5 when compared to others.  Both Glu-Glu-VS-Ph and Thr-Glu-VS-Ph have 
moderate inhibition, but they contain a charged amino acid at pH 5.5. They are not good 
inhibitors of intracellular DPPI.  
 
SUMMARY AND PERSPECTIVE 
 
Comparison of the inhibition of DPPI by various inhibitors indicates that the vinyl 
sulfones with Ala-Hph or Nva-Hph are the best inhibitors for DPPI.  These compounds 
are non-toxic to cells and also effective toward intracellular DPPI, thus they are suitable 
for functional studies of DPPI.  Gly-Phe-CHN2 is also a potent inhibitor of DPPI.  
However, due to the high reactivity of the diazomethyl ketone functional group, this 
compound is easily decomposed under the acidic conditions required for the 
measurement of cysteine protease activities.  Dipeptide acyloxymethyl ketones are 
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limited by their stability and weak inhibition toward DPPI, although these compounds are 
effective and selective toward intracellular DPPI.   
 
EXPERIMENTAL 
 
Materials and Methods.  DPPI from human spleen and rat mast cell lines were 
purified by a previous procedure13.  DPPI from bovine spleen was obtained from 
Calbiochem, San Diego, CA.  Materials were obtained from Acros, Bachem Bioscience 
Inc., or Sigma Aldrich and used without further purification.  The purity of each 
compound was confirmed by TLC, 1H NMR, MS, and elemental analysis.  Chemical 
shifts are reported in ppm relative to an internal standard (trimethylsilane).  TLC was 
performed on Sorbent Technologies (250 µm) silica gel plates.  The 1H NMR spectra 
were obtained on a Varian Gemini 300 MHz spectrometer.  Electrospray ionization 
(ESI), fast-atom-bombardment (FAB) and high-resolution mass spectrometry were 
obtained using Micromass Quattro LC and VG Analytical 70-SE instruments.  Elemental 
analysis was carried out by Atlantic Microlab Inc., Norcross, GA. 
Enzyme Assay.  Enzymatic hydrolysis rates of dipeptide AMC substrates by 
bovine spleen DPPI were measured in 50 mM NaOAc, 30 mM NaCl, pH 5.5 buffer 
containing 1 mM EDTA, 1 mM DTT and at 23 °C.  The stock solution of substrate Gly-
Phe-AMC (5 mM) was prepared in Me2SO and stored at -20 °C.  Enzymatic hydrolysis 
rates were measured fluorometrically (λex = 360 nm, λem = 460 nm) using a Tecan 
fluorescence plate reader when 10 µL of an enzyme stock solution (0.22 - 2.2 µM) was 
added to a well containing 0.2 mL of buffer and 10 µl of substrate.  Enzymatic activities 
of cathepsin B were measured in 0.1 M KHPO4, 1.25 mM EDTA, 0.01% Brij, pH 6.0 
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buffer and at 23 °C.  Z-Arg-Arg-AMC (0.4 mM) was used as the substrate.  Enzymatic 
activities of cathepsin L were measured in 50 mM Mes, 2.5 mM EDTA, 1mM DTT, 
0.01% Brij, pH 5.5 buffer and at 23 °C.  Z-Phe-Arg-AMC (0.005 mM) was used as the 
substrate.  Enzymatic activities of cathepsin H were measured in 50 mM Pipes, 2.5 mM 
EDTA, 1mM DTT, 0.01% Brij, pH 6.8 buffer and at 23 °C.  Arg-AMC (0.25 mM) was 
used as the substrate. 
 Inhibition Kinetics: Incubation method.  The inactivation reaction was initiated 
at 23 °C by addition of a 25 µL (or 10 µL) aliquot of inhibitor in Me2SO to 0.25 mL (or 
0.1 mL) of buffered solution and 25 µL (or 10 µL) of enzyme (2.2 µM).  Aliquots (10 
µL) were withdrawn at various time intervals, diluted into 0.48 mL of buffer solution and 
10 µL of 20 mM Gly-Phe-AMC (0.4 mM).  Enzymatic hydrolysis rates were measured 
fluorometrically using a Spex fluoremeter.  When using the Tecan microplate reader, 
aliquots (10 µl) were withdrawn and added to the well containing 0.2 mL of buffer 
solution and 10 µL of 5 mM Gly-Phe-AMC.  Inhibition of cathepsins B, L, and H were 
measured similarly.  First order inactivation rate constants (kobs) were obtained from 
plots of ln vt/vo vs time and had correlation coefficients greater than 0.98.  Inactivation 
rate constants were the average of duplicate experiments. 
Diethyl Phenylsulfonylmethanephosphonate (Ph-SO2-CH2-PO(OEt)2).  A 
mixture of chloromethyl phenyl sulfide (3.2 g, 20 mmole) and triethyl phosphite (3.3 g, 
20 mmole) was heated at 130 - 140 °C for 5 h22.  The resultant mixture was distilled 
under reduced pressure, and the starting materials were distilled out. The oily residue was 
diethyl phenylmercaptomethanephosphonate (yield 65%).  1H-NMR (CDCl3) 1.2-1.3 (t, 
6H, 2 x CH3), 3.1-3.2 (d, 2H, SO2-CH2), 4-4.2 (m, 4H, CH2CH3), 7.2-7.4 (m, 5H, Ph).  
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Diethyl phenylsulfonylmethanephosphonate was prepared by oxidation of diethyl 
phenylmercaptomethanephosphonate with potassium permanganate22 (55% yield).  1H-
NMR (CDCl3): 1.2-1.3 (t, 6H, 2 x CH3), 3.7-3.8 (d, 2H, SO2-CH2), 4.1-4.2 (m, 4H, 2 x 
CH2CH3), 7.5-7.7 (m, 3H, Ph), 7.9-8.0 (d, 2H, Ph).   MS m/z 293 (M + 1). 
Boc-Phe-H.  Boc-Phe-N(OCH3)CH3 was prepared from Boc-Phe-OH and N,O-
dimethylhydroxylamine hydrochloride using standard mixed anhydride coupling 
procedure (93% yield).  1H-NMR (CDCl3) δ 1.4 (s, 9H, Boc), 2.8-2.9 (m, 1H, CH2-Phe), 
3.0-3.1 (m, 1H, CH2-Phe), 3.2 (s, 3H, N-CH3), 3.6 (s, 3H, O-CH3), 4.9 (m, 1H, α-C), 5.2 
(b, 1H, NH), 7.1-7.3 (m, 5H, Ph).  MS (FAB +) m/z 309 (M + 1, 30 %), 253 (M – tBu + 1, 
100 %).  Reduction of Boc-Phe-N(OCH3)CH3 with lithium aluminum hydride according 
to a previously described method44 gave Boc-Phe-H (88% yield).  1H-NMR (CDCl3) δ 
1.4 (s, 9H, Boc), 3.1 (d, 2H, CH2-Phe), 4.4 (m, 1H, α-C), 5.0 (b, 1H, NH), 7.1-7.3 (m, 
5H, Ph), 9.6 (s, 1H, CHO).  MS (FAB+) m/z 250 (M + 1, 15 %), 150 (M – Boc + 1, 100 
%). 
 Phe-VS-Ph.HCl.  Boc-Phe-VS-Ph was prepared by reaction of Boc-Phe-H with 
diethyl phenylsulfonylmethanephosphonate in the presence of 2 N sodium methoxide22 
(85% yield).  1H-NMR (CDCl3) δ 1.3-1.4 (s, 9H, Boc), 2.9 (d, 2H, CH2-Phe), 4.4-4.5 (b, 
1H, α-H), 4.6-4.7 (b, 1H, NH), 6.3 (d, 1H, CH=CH), 6.9-7.0 (dd, 1H, CH=CH), 7.1-7.3 
(m, 5H, Ph), 7.5-7.8 (m, 5H, Ph).  MS (FAB+) m/z 388 (M + 1, 15 %), 288 (M – Boc + 1, 
100 %).  Boc-Phe-VS-Ph was deblocked with 6.7 N HCl in EtOAc to give Phe-VS-
Ph·HCl (88% yield).  1H-NMR (DMSO-d6) δ 2.9-3.0 (m, 1H, CH2-Phe), 3.1-3.2 (m, 1H, 
CH2-Phe), 4.2 (b, 1H, α-H), 6.7-6.8 (m, 2H, CH=CH), 7.1-7.3 (m, 6H, Ph), 7.6-7.8 (m, 
5H, Ph), 8.6-8.8 (b, 2H, Ph).   MS (FAB+) m/z 288 (M - Cl, 100 %). 
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Hph-VS-Ph.HCl.  Boc-Hph-VS-Ph was prepared by reaction of Boc-Hph-H with 
diethyl phenylsulfonylmethanephosphonate in the presence of 2 N sodium methoxide 
(75% yield).  1H-NMR (CDCl3) δ 1.4 (s, 9H, Boc), 1.7-2.0 (m, 2H, CH2-Hph), 2.6-2.7 (m, 
2H, CH2-Hph), 4.3-4.4 (m, 1H, α-H), 4.4-4.5 (m, 1H, α-H), 6.4 (d, 1H, CH=CH), 6.8-6.9 
(dd, 1H, CH=CH), 7.1-7.3 (m, 5H, Ph), 7.5-7.7 (m, 3H, Ph), 7.8-7.9 (d, 2H, Ph).  MS 
(FAB+) m/z 302 (M – Boc + 1, 100 %).  Boc-Hph-VS-Ph was deblocked with 6.7 N HCl 
in EtOAc to give Hph-VS-Ph·HCl (90% yield).  
Glu-Phe-VS-Ph·HCl.  Boc-Glu-Phe-VS-Ph was prepared from Boc-Glu(OtBu)-
OH and Phe-VS-Ph·HCl using the standard mixed anhydride coupling method (76 % 
yield).  1H-NMR (CDCl3)  δ 1.4 (s, 18H, Boc and t-Bu), 1.8 (m, 2H, Glu-CH2), 2.0 (m, 
2H, Glu-CH2), 2.7 (m, 2H, Phe-CH2), 4.0 (m, 1H, α-H), 4.7 (b, 1H, α-H), 5.2 (m, 1H, 
NH), 6.5 (d, 1H, CH=CH), 6.9 (dd, 1H, CH=CH), 7.1-7.3 (m, 5H, Ph), 7.5-7.7 (m, 3H, 
Ph), 7.8-7.9 (d, 2H, Ph).  MS (FAB+) m/z 572 (M + 1, 100%).  Boc-Glu-Phe-VS-Ph was 
deblocked with 6.7 N HCl in EtOAc gave Glu-Phe-VS-Ph·HCl (82 %yield).  1H-NMR 
(DMSO-d6) δ 1.8-2.0 (m, 2H, Glu-CH2), 2.1-2.2 (m, 2H, Glu-CH2), 2.9 (d, 2H, Phe-
CH2), 4.0 (m, 1H, α-H), 5.7 (m, 1H, α-H), 6.8 (d, 1H, CH=CH), 6.8-7.0 (dd, 1H, 
CH=CH), 7.1-7.3 (m, 5H, Ph), 7.5-7.8 (m, 5H, Ph), 8.1 (b, 2H, NH2), 8.9 (b, 1H, NH), 
12.2 (b, 1H, COOH).  MS (FAB+) m/z 417 (M - Cl, 100%).  HRMS calcd. for 
C21H25N2O5S: 417.14842.  Obsd. 417.14864.  Anal. calcd. for C21H25N2O5SCl·0.5H2O: 
C, 54.60, H, 5.67, N, 6.06.  Found: C, 54.30, H, 5.88, N, 6.12.  
Arg-Phe-VS-Ph·2HCl.  Boc-Arg(Boc)2-Phe-VS-Ph was prepared from Boc-
Arg(Boc)2-OH and Phe-VS-Ph·HCl using standard mixed anhydride coupling method, 
yield 100 %.  1H-NMR (CDCl3) δ 1.4-1.6 (m & s, 29H, 3 x Boc and Arg-CH2), 1.6-1.7 
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(m, 2H, Arg-CH2), 2.9-3.0 (m, 2H, Phe-CH2), 3.5 (m, 2H, Arg-CH2), 4.7 (b, 1H, α-H), 4.9 
(m, 1H, α-H), 6.5 (d, 1H, CH=CH), 6.9-7.0 (dd, 1H, CH=CH), 7.0-7.3 (m, 5H, Ph), 7.5-
7.7 (m, 3H, Ph), 7.8-7.9 (d, 2H, Ph).  MS (FAB+) m/z 744 (M + 1, 100 %).  Boc-
Arg(Boc)2-Phe-VS-Ph was deblocked with 6.7 N HCl in EtOAc gave Arg-Phe-VS-
Ph·2HCl (77% yield).  1H-NMR (DMSO-d6) δ 1.3-1.5 (m, 2H, Arg-CH2), 1.6-1.8 (m, 2H, 
Arg-CH2), 2.9 (m, 2H, Phe-CH2), 3.0-3.2 (m, 2H, Arg-CH2), 3.8 (m, 1H, α-H), 4.8 (m, 
1H, α-H), 6.7 (d, 1H, CH=CH), 6.8-7.0 (dd, 1H, CH=CH), 7.1-7.3 (m, 5H, Ph), 7.6-7.8 
(m, 3H, Ph), 7.8-7.9 (d, 2H, Ph), 8.2-8.4 (b, 4H, 2 x NH2), 9.0 (b, 3H, 3 x NH).  MS 
(FAB+) m/z 444 (M – 2 Cl + 1, 100 %).  HRMS calcd. for C22H30N5O3S: 444.20694.  
Obsd. 444.20637.  Anal. calcd. for C22H31N5O3SCl2·0.91H2O: C, 49.58, H, 6.21, N, 13.14.  
Found: C, 49.28, H, 6.20, N, 13.45.  
Glu-Hph-VS-Ph·HCl.  Boc-Glu-Hph-VS-Ph was prepared from Boc-Glu-OH 
and Hph-VS-Ph·HCl using standard mixed anhydride coupling method (100% yield).  1H-
NMR (CDCl3) δ 1.4 (s, 18H, Boc and t-Bu), 1.8 (m, 2H, Glu-CH2), 2.0 (m, 2H, Glu-CH2), 
2.2 (m, 1H, Hph-CH2), 2.4 (m, 1H, Hph-CH2), 2.6-2.7 (m, 2H, Hph-CH2), 4.0 (m, 1H, α-
H), 4.7 (b, 1H, α-H), 5.2 (m, 1H, NH), 6.5 (d, 1H, CH=CH), 6.9 (dd, 1H, CH=CH), 7.1-
7.3 (m, 5H, Ph), 7.5-7.7 (m, 3H, Ph), 7.8-7.9 (d, 2H, Ph).  MS (FAB+) m/z 588 (M + 1, 
100 %).  Boc-Glu-Hph-VS-Ph was deblocked with 6.7 N HCl in EtOAc to give Glu-Hph-
VS-Ph·HCl (86% yield).  1H-NMR (DMSO-d6) 1.7-1.8 (m, 2H, Glu-CH2), 1.9-2.1 (m, 2H, 
Glu-CH2), 2.1-2.2 (m, 2H, Hph-CH2), 2.9 (d, 2H, Hph-CH2), 4.0 (m, 1H, α-H), 5.7 (m, 
1H, α-H), 6.8 (d, 1H, CH=CH), 6.8-7.0 (dd, 1H, CH=CH), 7.1-7.3 (m, 5H, Ph), 7.5-7.8 
(m, 5H, Ph), 8.1 (b, 2H, NH2), 8.9 (b, 1H, NH), 12.2 (b, 1H, COOH).  MS (FAB
+) m/z 
431 (M - Cl, 100 %).  HRMS calcd. for C22H27N2O5S: 431.16407.  Obsd. 431.16652.  
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Anal. calcd. for C22H26N2O5S·HCl·0.4H2O: C, 55.73, H, 5.91, N, 5.90.  Found: C, 55.85, 
H, 6.12, N, 5.71.  
Arg-Hph-VS-Ph·2HCl.  Boc-Arg(Boc)2-Hph-VS-Ph was prepared from Boc-
Arg(Boc)2-OH and Hph-VS-Ph·HCl using standard mixed anhydride coupling method 
(85% yield ).  1H-NMR (CDCl3) 1.4-1.6 (m & s, 29H, 3 x Boc and Arg-CH2), 1.6-1.7 (m, 
2H, Arg-CH2), 1.8-2.0 (m, 2H, Hph-CH2), 2.6-2.8 (m, 2H, Hph-CH2), 3.9  (m, 2H, Arg-
CH2), 4.2 (m, 1H, α-H), 4.7 (b, 1H, α-H), 5.9 (b, 1H, NH), 6.4-6.8 (dd, 1H, CH=CH), 
6.9-7.0 (dd, 1H, CH=CH), 7.0-7.3 (m, 5H, Ph), 7.5-7.7 (m, 3H, Ph), 7.8-7.9 (d, 2H, Ph), 
9.2-9.4 (b, 2H, 2 x NH); Boc-Arg(Boc)2-Hph-VS-Ph was deblocked with 6.7 N HCl in 
EtOAc to give Arg-Hph-VS-Ph·2HCl (77% yield).  1H-NMR (DMSO-d6) 1.3-1.5 (m, 2H, 
Arg-CH2), 1.6-2.0 (m, 4H, 2 x Arg-CH2), 2.5-2.6 (m, 2H, Hph-CH2), 3.1-3.2 (m, 2H, Arg-
CH2), 3.9-4.0 (m, 1H, α-H), 4.4-4.6 (m, 1H, α-H), 6.8 (d, 1H, CH=CH), 6.9-7.0 (dd, 1H, 
CH=CH), 7.1-7.3 (m, 5H, Ph), 7.6-7.8 (m, 3H, Ph), 7.8-7.9 (d, 2H, Ph), 8.2-8.4 (b, 4H, 2 
x NH2), 8.8 (b, 1H, NH), 9.1 (b, 1H, NH).  MS (FAB
+) m/z 458 (M – 2 Cl, 100 %).  
HRMS calcd. for C23H32N5O3S: 458.22259.  Obsd. 458.22424.  Anal. calcd. for 
C23H31N5O3S·2HCl·1H2O: C, 50.36, H,6.43, N, 12.77.  Found: C, 50.35, H, 6.48, N, 12.79.  
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CHAPTER 3 
 
PEPTIDYL ALLYL SULFONES: A NEW CLASS OF INHIBITORS FOR  
CLAN CA PROTEASES 
 
 
INTRODUCTION 
 
Calpains.  Calpains are a class of cysteine proteases, which are activated by 
calcium.  They belong to the clan CA of cysteine proteases together with papain, DPPI, 
cruzains, and cathepsins.  Several forms of this family of enzymes are known.  So far 
eight homologs of human calpain have been identified, two of which have received 
increased attention: calpain I (or µ-calpain) and calpain II (or m-calpain).  Their activity 
in vitro is dependent on the calcium concentration (micromolar amounts for calpain I and 
millimolar amounts for calpain II)1-4.  They are present in the cytosol of mammalian cells 
and play an important role in physiological processes that control the degradation of the 
cytoskeleton as well as hormone receptors5,6.  Enhanced calpain activity however has 
been related to cell injury due to ischemic stroke7, physical damage8, and hypoxia9.  
Thus, calpain is an attractive target for the development of inhibitors, which should be 
useful for the treatment of a variety of diseases.  
Cysteine proteases are effectively inhibited by a variety of peptidic as well as 
nonpeptidic structures.  Clan CA cysteine proteases are effectively inhibited by several 
classes of peptidyl inhibitors including transition state, reversible and irreversible 
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inhibitors10.  Examples for reversible transition state inhibitors are peptide aldehydes11-14, 
α-diketones15-18, α-ketoesters19,20, α-ketoamides19,21 and α-ketoacids19.  Clan CA 
proteases are irreversibly inhibited by peptidyl diazomethyl ketones and fluoromethyl 
ketones22,23, peptidyl epoxides (E-64, E-64-c, E-64-d)24, and vinyl sulfones25 (Table 3.1).  
However the potency and specificity of the irreversible inhibitors have so far been 
limited.   
 
Table 3.1.  Irreversible Inhibitors for Calpain. 
Warhead Inhibitor kobs (M
-1s-1) or 
IC50 (µM) 
Reference
O
HOOC
 
Ep-475 7,450 
26 
O
S
O
HOOC
O O  O S O
HOOC
O O
N
H
O H
N
O
 
IC50 = 0.3 
27 
CHN2
O  Cbz-Leu-Leu-Tyr-CH=N2 230,000 
28 
F
O  Cbz-Leu-Leu-Phe-CH2F 290,000 
15 
O
Cl
 Cbz-Leu-Leu-Phe-CH2Cl 9,500 
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 E-64 Inhibitors.  Many potent inhibitors have also been inspired by mimicking 
natural inhibitors.  E-64 (N-(L-3-trans-carboxyoxiran-2-carbonyl)-L-leucyl)-amido(4-
guanido)butane) is one example for a natural irreversible inhibitor (Figure 1.3), which 
was first isolated from Asperigillus japonicus by Hanada et al in 197833.  E-64 is a 
universal inhibitor for clan CA proteases, such as papain (0.104 nM)35, cathepsin B 
(89,400 M-1s-1)34, bromelain (0.110 nM for fruit bromelain and 0.025 nM for stem 
bromelain)35, ficin (0.084 nM)35, cathepsin L (96,250 M-1s-1)36, calpain II (7,500 M-1s-1)37-
39, and cruzain (70,600 M-1s-1)40, but does not inhibit clan CD proteases such as 
caspases41, legumains42, and gingipains43, and only inhibits clostripain very slowly44.   
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Figure 3.1.  Structure of the Cysteine Protease Inhibitor E-64. 
 
 The trans-epoxy succinic acid (HOOC-(2S,3S)-EP-CO-) was found to be the 
reactive moiety.  The active site cysteine performs a nucleophilic attack on the C2 or C3 
carbon of the oxirane ring depending on the enzyme, and the epoxide opens up resulting 
in the formation of a hydroxyl group, and the enzyme is bound irreversibly.  Several E-64 
analogs, which retain the expoxy succinate moiety but vary the amino acid substituents, 
have been analyzed for inhibitory potency with calpain.  However, E-64 derivatives are 
broad spectrum inhibitors, and exclusive selectivity for calpain inhibition has not been 
achieved so far.  
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INHIBITOR DESIGN 
 
In order to develop new functional groups suitable for irreversible inhibition of 
cysteine proteases, we attempted the synthesis of peptidyl epoxy sulfones.  The design of 
the peptidyl epoxy sulfone was based on vinyl sulfones, which are a class of promising 
irreversible peptidyl inhibitors for clan CA cysteine proteases.  Vinyl sulfones contain a 
Michael acceptor functional group and react irreversibly with the active site cysteine as 
described in chapter 2.  Palmer et al have developed the vinyl sulfone warhead, and 
found that it was a potent inhibitor of calpain25.  Another widely used warhead is the 
epoxide moiety of the natural product inhibitor E-64.  Aza-peptide epoxides, for example 
are potent and selective inhibitors for clan CD cysteine proteases including caspases and 
legumain45.  This class will be further described in chapter 4.  We proposed that 
combining the reactivity of the E-64 epoxide warhead with the selectivity of the vinyl 
sulfone moiety will result in both a potent and specific new class of inhibitors for 
cysteine proteases (Figure 3.2). 
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Figure 3.2.  Hypothesis for a New Functional Group. 
 
  We focused on the clan CA cysteine proteases calpain and papain, and thus 
decided to attach this novel warhead to an optimal di- or tripeptide sequence for 
satisfactory calpain and papain inhibition.  We chose Leu-Phe, Ala-Phe, and Val-Phe 
with the N-terminal Cbz-protecting group15.     
 
RESULTS AND DISCUSSION 
 
 Our strategy for the synthesis of epoxy sulfones began with the synthesis of the 
appropriate peptidyl vinyl sulfone (Figure 3.3).  Vinyl sulfones have been previously 
synthesized and prepared by coupling the chiral amino acid aldehydes 1 and the 
corresponding sulfonyl phosphonate 2 using Wadsworth-Emmons chemistry (see chapter 
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2)25.  The stereochemistry of the vinyl sulfone is primarily E, but the presence of small 
amounts of the Z isomer cannot be excluded46.  The Boc-group was then removed using 
4N HCl in ethyl acetate.  Coupling of the salt 4 to a Cbz-protected amino acid 5 using 
standard mixed anhydride conditions furnished the dipeptidyl vinyl sulfone precursor 6.   
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Figure 3.3.  Preparation of Cbz-protected Vinyl Sulfones. 
 
In order to synthesize the epoxy sulfone, we decided to epoxidize the double bond 
moiety in the peptidyl vinyl sulfone precursor using basic peroxidizing conditions.  When 
we tried to epoxidize the vinyl sulfone using tBuLi and nBuOOH in freshly distilled THF 
at -78 °C, the formation of a new compound was observed by TLC.  The vinyl sulfone 
starting material was consumed within 20 minutes.  The new compound was purified by 
column chromatography and carefully characterized using several spectroscopic methods.  
We found that the conjugated double bond of the vinyl sulfone moiety was no longer 
present in the 1H NMR.  However according to the MS, the molecular weight of the 
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newly formed product was unchanged.  Elemental analysis also confirmed that the new 
compound was a constitutional isomer of the vinyl sulfone starting material.  The 
characteristic sulfone stretch was still present in the FT-IR spectrum.  Since the new 
compound was formed by isomerization and not oxidation, the critical reagent was the 
tBuLi base and not the oxidizing nBuOOH.  Treatment of the vinyl sulfone with nBuLi 
without the peroxide tBuOOH gave the same product.  However, the reaction was much 
more sluggish, and required several hours at room temperature.  We considered several 
possible isomeric structures for the nBuLi reaction product.  A substituted oxazoline 
formed by cyclization or an allyl sulfone (AS), with the double bond isomerized toward 
the adjacent α-carbon were two likely possibilities (Figure 3.4).   
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Figure 3.4.  Possible Constitutional Isomers of the Vinyl Sulfone Starting Material. 
 
Oxazolines have characteristic 13C NMR signals at 170 ppm for the C-2 carbon 
atom47.  Oxazolines have previously been synthesized, and we prepared the parent 
compound 11 (Figure 3.5) following the synthetic method described by Wipf et al47.  
This oxazoline could potentially acylate the active site cysteine of a cysteine protease, but 
the 1H NMR spectrum was not identical to our isomerization product.  The 13C NMR 
spectrum of our product has a new peak at 106 ppm and not one at 170 ppm for the 
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oxazoline.  In addition we observed the presence of an additional NH in the 1H NMR.  
This ruled out the formation of the oxazoline in the isomerization reaction. 
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Figure 3.5.  Preparation of the Peptidyl Oxazoline.  i) 1) NaOH, MeOH; 2) HCl; ii) 
H2N(CH2)2OH, NMM, IBCF, CH2Cl2; iii) PPh3, DEAD, THF. 
 
The allyl sulfone structure (7) was supported by all the spectroscopic data.  The 
methylene of the phenylalanine side chain shifts substantially from 2.9 ppm to 3.8 ppm in 
the 1H NMR spectrum and the shift is explained by the close proximity to the double 
bond in the newly formed isomerization product.  The distinct triplet at 4.9 ppm is 
consistent with a vinylogous proton.  Upon decoupling the vinyl proton triplet at 4.9 ppm, 
the methylene group next to the sulfone moiety at 3.83 ppm appears as a singlet, 
indicating that the protons involved are located on adjacent carbons.  It has previously 
been reported that treatment of vinyl sulfones with strong base results in the formation of 
allyl sulfones (Figure 3.6), as allyl sulfones are thermodynamically more stable than vinyl 
sulfones48,49.  The stereochemistry of the isomerized double bond was not determined, 
which leaves the E to Z ratio of the final compounds unknown.  Both E and Z or an E/Z 
mixture have been obtained upon base catalyzed isomerization of vinyl sulfones 50,51.    
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Figure 3.6.  Isomerization of Dipeptidyl Vinyl Sulfones to Allyl Sulfones. 
 
The novel, newly synthesized peptidyl allyl sulfones had the potential of being 
cysteine protease inhibitors and were tested along with the oxazoline 11 with papain, 
calpain I, and cathepsin B (Table 3.2).  This new class of compounds shows moderate 
rates of calpain and papain inactivation.  The oxazoline was also a slow inhibitor of 
calpain I.  Kinetic inhibition assays were performed using calpain I from bovine 
erythrocytes and Suc-Leu-Tyr-AMC as the fluorogenic substrate52.  Cathepsin B was 
tested using commercially available enzyme and Cbz-Arg-Arg-AMC as the substrate53.  
Papain inhibition was measured using commercially available papain and Cbz-Arg-Phe-
pNA as the substrate54.  The dipeptidyl allyl sulfones exhibit no inhibition with cathepsin 
B and limited inhibition with both calpain I and papain.  Striking is the kobs/[I] value of 
564 M-1s-1 for Cbz-Leu-Phe-AS-Ph (Isomer B) with calpain I.  This dipeptidyl allyl 
sulfone was synthesized from the dipeptidyl vinyl sulfone precursor Cbz-Leu-D-Phe-VS-
Ph.  When the double bond isomerizes the original Z stereochemistry of the vinyl sulfone 
is lost and the product has an unknown ratio of E to Z isomers at the new allyl double 
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bond.  There are several factors, which can contribute to a mixed ratio of isomers, such as 
the so-called “syn-effect”50,51 and the chelating lithium metal.  This explains the 
difference in inhibitor potency between Cbz-Leu-Phe-AS-Ph (Isomer A), which is 
derived from the vinyl sulfone precursor Cbz-Leu-L-Phe-VS-Ph, and Cbz-Leu-Phe-AS-
Ph (Isomer B).  The initial stereochemistry of the phenylalanine side chain probably plays 
a significant role in the final ratio of Z to E isomers in the allyl sulfone inhibitor.   
 
Table 3.2.  Inhibition of Various Cysteine Proteases by Dipeptidyl Allyl Sulfones. 
 
   kobs/[I] (M-1 s-1)a  
 Inhibitor Calpain Ib Papainc Cathepsin Bd 
7a Cbz-Ala-Phe-AS-Ph 3 ± 0 9 ± 0 N.I. 
7b Cbz-Val-Phe-AS-Ph 3 ± 0 6 ± 1 N.I. 
7c Cbz-Leu-Phe-AS-Ph (Isomer A)e 23 ± 4 49 ± 6 N.I. 
8 Cbz-Leu-Phe-AS-Ph (Isomer B)f 564 ± 32g 15 ± 1 N.I. 
6c Cbz-Leu-Phe-VS-Ph 550 ± 2g 10 ±  N.I. 
11 N
H N
OCbz-Leu
 
13 ± 1 N.I. N.I. 
akobs is the pseudo first order rate constant obtained from plots of ln vt/v0 vs time unless 
indicated otherwise.  bCalpain I assay conditions:  Irreversible kinetic assays were 
performed by the incubation method with calpain I from porcine erythrocytes.  
Enzymatic activities of calpain I were measured at 23 °C in 50 mM Hepes buffer (pH 
7.5) containing 10 mM cysteine and 5 mM CaCl2.  cPapain assay conditions:  Incubation 
kinetics were measured using an enzyme stock solution for the papain assays, which was 
freshly prepared from 330 µL of enzyme storage solution (1.19 mg/ml) diluted with 645 
µL papain buffer (50 mM Hepes, and 2.5 mM EDTA at pH 7.5) and 25 µL of DTT (0.1 
M).  dCathepsin B assay conditions:  Enzymatic activities of cathepsin B were measured 
by the incubation method in 0.1 M KHPO4, 1.25 mM EDTA, 0.01% Brij, pH 6.0 buffer 
and at 23 °C.  eAllyl sulfone is derived from the L-isomer of phenylalanine.  fAllyl 
sulfone is derived from the D-isomer of phenylalanine.  gkobs is obtained by the progress 
curve method and corrected for substrate, as the inhibitor concentration is too low to be 
measured by the incubation method. 
 
 49
Mechanism of Inhibition.  One mechanism for the inhibition reaction could 
involve re-isomerisation of the peptidyl allyl sulfone to the vinyl sulfone.  This 
isomerization could be catalyzed by the active site histidine and would be reflected by a 
higher inhibition rate (kobs/[I]) for the parent vinyl sulfone inhibitor.  However, as the 
parent vinyl sulfone Cbz-Leu-Phe-VS-Ph (kobs/[I] = 10 M-1s-1) was five times less potent 
with papain than the corresponding allyl sulfone Cbz-Leu-Phe-AS-Ph (Isomer A) (kobs/[I] 
= 49 M-1s-1), we conclude that the mechanism of inhibition does not involve re-
isomerisation of the allyl sulfone to the vinyl sulfone with a subsequent attack of the 
cysteine thiol on the Michael acceptor double bond.  With calpain I it is possible, that the 
isomerization mechanism is occurring, since the vinyl sulfone is a much more effective 
inhibitor of calpain. 
Two other mechanisms can be envisaged for enzyme inhibition by allyl sulfones 
(Figure 3.7).  The active site cysteine could directly displace phenyl sulfinic acid in an 
SN2 reaction (pathway b) or could attack the allylic double bond with loss of phenyl 
sulfinic acid (pathway a).  Both pathways result in alkylation of the active site cysteine 
residue.  It has previously been reported that allyl sulfones when reacted with 
nucleophiles undergo a tosyl elimination or displacement process, in which the allyl 
sulfone moiety undergoes alkylation at either the α- or γ-carbon49,55,56.  An alternative 
possibility for enzyme inactivation follows a mechanism-based pathway, which is 
initiated by removal of the amide nitrogen proton by a base or the active site histidine, 
followed by the elimination of phenyl sulfinic acid and the formation of the imine 9.  The 
active site cysteine then reacts with 9 in a Michael addition, which also irreversibly 
alkylates the enzyme.  Several PLP-dependent enzymes are irreversibly inhibited by 
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mechanism-based inactivators, where the pathway also follows displacement and β-
elimination reactions.  A vinylic imine forms as an intermediate before undergoing attack 
by a nucleophile in the active site of the enzyme57.   
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Figure 3.7.  Proposed Enzyme Mechanisms of Inhibition. 
 
CONCLUSIONS 
 
In summary we report, that in an effort to synthesize epoxy sulfone inhibitors 
using basic oxidative conditions we unexpectedly produced dipeptidyl allyl sulfones, a 
new class of inhibitors, by isomerization of the double bond.  This new class of inhibitors 
contains a novel cysteine protease warhead and shows moderate rates of calpain and 
papain inactivation.  Since it has been reported in the literature that inhibitors, which 
target calpain, are also potent inhibitors of cruzain and cathepsin L and cathepsin S, the 
allyl sulfones will also be tested with those particular enzymes.  Additionally, it would be 
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of interest to extend the allyl sulfone warhead to other cysteine proteases and investigate 
the effect of the stereochemistry of the double bond on the potency of the inhibitor.  It 
would also be of interest to determine the mechanism of inhibition since allyl sulfones are 
likely mechanism-based inhibitors. 
 
EXPERIMENTAL 
 
Materials and Methods.  Materials were obtained from Acros, Bachem 
Bioscience Inc., or Sigma Aldrich and used without further purification.  The purity of 
each compound was confirmed by TLC, 1H NMR, MS, and elemental analysis.  
Chemical shifts are reported in ppm relative to an internal standard (trimethylsilane).  
TLC was performed on Sorbent Technologies (250 µm) silica gel plates.  The 1H NMR 
spectra were obtained on a Varian Mercury 400 MHz spectrometer.  Electrospray 
ionization (ESI), fast-atom-bombardment (FAB) and high-resolution mass spectrometry 
were obtained using Micromass Quattro LC and VG Analytical 70-SE instruments.  
Elemental analysis was carried out by Atlantic Microlab Inc., Norcross, GA. 
Papain and Cathepsin B Assays.  The incubation method was used to measure 
the irreversible inhibition of papain and cathepsin B.  With cathepsin B, 30 µL of a stock 
inhibitor solution was added to 300 µL of a 0.1 M potassium phosphate buffer containing 
1.25 mM EDTA, 0.01% Brij 35 at pH 6.0, followed by the addition of 30 µL of a freshly 
prepared cathepsin B solution (approximate concentration 6.98 x 10-3 µg/µL) in the same 
potassium phosphate buffer containing 1 mM DTT (freshly prepared).  Aliquots (50 µL) 
from the inhibition mixture were withdrawn at various time intervals and added to 200 
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µL of a 0.1 M potassium phosphate buffer containing 1.25 mM EDTA, 0.01% Brij 35 at 
pH 6.0, and the substrate Cbz-Arg-Arg-AMC (499 µM).  The release of 7-amino-4-
methylcoumarin was monitored (λex = 360 nm, λem = 465 nm) using a Tecan Spectra 
Fluor microplate reader.  Pseudo first-order inactivation rate constants were obtained 
from plots of ln vt/vo versus time. 
The incubation method method was also used for papain.  The inhibition 
incubation buffer for papain was 50 mM Hepes buffer at pH 7.5, containing 2.5 mM DTT 
and 2.5 mM EDTA.  The assay used the substrate Cbz-Phe-Arg-pNA (53.7 µM) in the 
same buffer.  The approximate concentration of papain added to the incubation buffer 
was 0.29 mg/mL.  The release of p-nitroanilide was monitored at 405 nm with a 
Molecular Devices Thermomax microplate reader.   
Calpain Assays.  Calpain I was purchased from Calbiochem (La Jolla, CA) in a 
solution of 30% glycerol at a concentration of 6.96 µM and stored at -20 ˚C prior to use. 
The calpain I assay was conducted with 235 µl of a solution of 50 mM Hepes, 0.5 M 
CaCl2, 0.5 M cysteine, at pH 7.5 (calpain I buffer), 6.5 µl of Suc-Leu-Tyr-AMC substrate 
solution in DMSO, and 4.2 µl of the enzyme solution (6.96 µM) at 23 ˚C.  The enzymatic 
activity was monitored by following the change in fluorescence for 10 min at 465 nm.   
The k2 values were obtained by non-linear regression analysis and corrected for substrate 
(1 + [S]/Km = 1.274). 
Diethyl Phenylsulfonylmethanephosphonate (2, PhSO2CH2PO(OEt)2).  A 
mixture of chloromethyl phenyl sulfide (3.2 g, 20 mmole) and triethyl phosphite (3.3 g, 
20 mmole) was heated at 130 - 140 °C for 5 h.  The resultant mixture was distilled under 
reduced pressure, and the starting materials were distilled out.  The oily residue was 
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diethyl phenylmercaptomethanephosphonate, yield 3.4 g (65%).  1H-NMR (CDCl3) δ 
1.2-1.3 (t, 6H, 2 x CH3), 3.1-3.2 (d, 2H, S-CH2), 4.0-4.2 (m, 4H, 2 x CH2), 7.2-7.4 (m, 
5H, Ph).  Diethyl phenylsulfonylmethanephosphonate was prepared by oxidation of 
diethyl phenylmercaptomethanephosphonate with potassium permanganate, yield 55%.   
1H-NMR (CDCl3) δ 1.2-1.3 (t, 6H, 2 x CH3), 3.7-3.8 (d, 2H, SO2-CH2), 4.1-4.2 (m, 4H, 2 
x CH2), 7.5-7.7 (m, 3H, Ph), 7.9-8.0 (d, 2H, Ph).  MS m/z 293 (M + 1). 
2-(tert-Butoxycarbonylamino)-3-phenylpropionaldehyde (1, Boc-Phe-H).  
Boc-Phe-N(OCH3)CH3 was prepared from Boc-Phe-OH and N,O-
dimethylhydroxylamine hydrochloride using standard mixed anhydride coupling 
procedure, yield 93%. 1H-NMR (CDCl3) δ 1.4 (s, 9H, Boc), 2.8-2.9 (m, 1H, CH2-Phe), 
3.0-3.1 (m, 1H, CH2-Phe), 3.2 (s, 3H, N-CH3), 3.6 (s, 3H, O-CH3), 4.9 (m, 1H, α-H), 5.2 
(b, 1H, NH), 7.1-7.3 (m, 5H, Ph).  MS (FAB+) m/z 309 (M + 1, 30%), 253 (M – tBu + 1, 
100%).  Reduction of Boc-Phe-N(OCH3)CH3 with lithium aluminum hydride according 
to a previously described method gave Boc-Phe-H, yield 88%.  1H-NMR (CDCl3) δ 1.4 
(s, 9H, Boc), 3.1 (d, 2H, CH2-Phe), 4.4 (m, 1H, α-H), 5.0 (b, 1H, NH), 7.1-7.3 (m, 5H, 
Ph), 9.6 (s, 1H, CHO).  MS (FAB+) m/z 250 (M + 1, 15%), 150 (M – Boc + 1, 100%). 
Phenyl-(3S)-3-amino-4-phenylbut-1-enyl Sulfone Hydrochloride (4, Phe-VS-
Ph.HCl).  Boc-Phe-VS-Ph was prepared by reaction of Boc-Phe-H with diethyl 
phenylsulfonylmethanephosphonate in the presence of 2 N sodium methoxide, yield 85%.  
1H-NMR (CDCl3) δ 1.3-1.4 (s, 9H, Boc), 2.9 (d, 2H, CH2-Phe), 4.4-4.5 (b, 1H, α-H), 4.6-
4.7 (b, 1H, NH), 6.3 (d, 1H, CH=), 6.9-7.0 (dd, 1H, CH=), 7.1-7.3 (m, 5H, Ph), 7.5-7.8 
(m, 5H, SO2-Ph).  MS (FAB+) m/z 388 (M + 1, 15%), 288 (M – Boc + 1, 100%).  Boc-
Phe-VS-Ph was deblocked with 6.7 N HCl in EtOAc to give Phe-VS-Ph.HCl, yield 88%.  
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1H-NMR (DMSO-d6) δ 2.9-3.0 (m, 1H, CH2-Phe), 3.1-3.2 (m, 1H, CH2-Phe), 4.2 (b, 1H, 
α-H), 6.7-6.8 (m, 2H, CH=), 7.1-7.3 (m, 6H, CH= and Ph), 7.6-7.8 (m, 5H, SO2-Ph), 8.6-
8.8 (b, 2H, NH2).  MS (FAB+) m/z 288 (M - Cl, 100%). 
Phenyl-(3R)-3-amino-4-phenylbut-1-enyl Sulfone Hydrochloride (D-Phe-VS-
Ph.HCl).  Boc-D-Phe-VS-Ph was prepared by reaction of Boc-D-Phe-H with diethyl 
phenylsulfonylmethanephosphonate in the presence of 2 N sodium methoxide, yield 85%.  
1H-NMR (CDCl3) δ 1.3-1.4 (s, 9H, Boc), 2.9 (d, 2H, CH2-Phe), 4.4-4.5 (b, 1H, α-H), 4.6-
4.7 (b, 1H, NH), 6.3 (d, 1H, CH=), 6.9-7.0 (dd, 1H, CH=), 7.1-7.3 (m, 5H, Ph), 7.5-7.8 
(m, 5H, SO2-Ph).  MS (FAB+) m/z 388 (M + 1, 15%), 288 (M – Boc + 1, 100%).  Boc-D-
Phe-VS-Ph was deblocked with 6.7 N HCl in EtOAc to give D-Phe-VS-Ph.HCl, yield 
88%.  1H-NMR (DMSO-d6) δ 2.9-3.0 (m, 1H, CH2-Phe), 3.1-3.2 (m, 1H), 4.2 (b, 1H, α-
H), 6.7-6.8 (m, 2H, CH=), 7.1-7.3 (m, 6H, CH= and Ph), 7.6-7.8 (m, 5H, SO2-Ph), 8.6-
8.8 (b, 2H, NH2).  MS (FAB+) m/z 288 (M - Cl, 100%). 
Phenyl-(3S)-3-(N-carbobenzyloxyleucyl)amino-4-phenylbut-1-enyl Sulfone 
(6c, Cbz-Leu-Phe-VS-Ph).  Cbz-Leu-Phe-VS-Ph was prepared from Cbz-Leu-OH and 
Phe-VS-Ph·HCl using standard mixed anhydride coupling method, yield 82%.  1H-NMR 
(CDCl3) δ 0.8-0.9 (2d, 6H, 2 x Leu-CH3), 1.4-1.6 (m, 2H, Leu-CH2), 2.06 (m, 1H, Leu-
CH), 2.9-3.0 (m, 2H, CH2-Phe), 3.9-4.0 (m, 1H, α-H), 4.8-4.9 (b, 1H, NH), 4.9-5.0 (m, 
1H, α-H), 5.1 (m, 2H, Cbz) 6.3-6.4 (d & b, 2H, NH and CH=), 6.9-7.0 (dd, 1H, CH=), 
7.1-7.4 (m, 10H, 2 x Ph), 7.5-7.7 (m, 5H, SO2-Ph).  MS (ESI) m/z 535. 
Phenyl-3-(N-carbobenzyloxyleucyl)amino-4-phenylbut-2-enyl Sulfone (7c, 
Cbz-Leu-Phe-AS-Ph).  Butyllithium (3.63 ml, 6.17 mmol, 1.7 M in pentane) was added 
dropwise to a solution of tert-butylhydroperoxide (2.55 ml, 8.42 mmol, 3.3 M in toluene) 
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in freshly distilled THF (80 ml) at –78 ˚C under argon.  A solution of Cbz-Leu-Phe-VS-
Ph (3.00 g, 5.61 mmol) in dry THF (30 ml) was added dropwise.  The reaction was 
continued to stir at -20 ˚C for 45 minutes (TLC Hex/EtOAc 1:1).  The reaction was 
quenched with saturated aqueous ammonium chloride (50 ml) and allowed to warm to 
room temperature.  The organic layer was separated, and the aqueous layer was extracted 
with ethyl acetate (3 x 30 ml).  The extracts were then washed with aqueous sodium 
sulfite (10 %, 3 x 20 ml).  The combined organic layers were dried (MgSO4) and 
evaporated to give Cbz-Leu-Phe-AS-Ph as a white powder, yield 63 %.  1H-NMR 
(CDCl3) δ 0.8-0.9 (2d, 6H, 2 x Leu-CH3), 1.4-1.6 (m, 2H, Leu-CH2), 3.8 (s, 2H, CH2-
Phe), 3.9 (d, 2H, CH2-SO2), 4.1 (m, 1H, α-H), 4.8 (t, 1H, CH=), 4.9-5.0 (b, 1H, NH), 5.1 
(m, 2H, Cbz), 7.1-7.4 (m, 10H, 2 x Ph), 7.5-7.7 (m, 5H, SO2-Ph), 8.4 (b, 1H, NH).  13C 
NMR (400 MHz, CDCl3) δ 172.1, 156.3, 144.4, 140.8, 135.7, 134.2, 133.6, 131.2, 129.5, 
129.4 x 2, 129.3, 128.8 x 2, 128.7, 128.6, 128.4, 128.3, 127.8, 127.3, 126.9, 106.3, 67.6, 
56.0, 55.6, 41.7, 40.4, 22.1, 21.0, 18.4.  MS (FAB+) m/z 535 (M + 1, 100 %).  Anal. 
Calcd. for C30H34N2O5S: C, 67.39, H, 6.56, N, 5.43.  Found: C, 67.41, H, 6.56, N, 5.43.  
Phenyl-(3R)-3-(N-carbobenzyloxyleucyl)amino-4-phenylbut-1-enyl Sulfone 
(6c, Cbz-Leu-D-Phe-VS-Ph).  Cbz-Leu-D-Phe-VS-Ph was prepared from Cbz-Leu-OH 
and D-Phe-VS-Ph·HCl using standard mixed anhydride coupling method, yield 81%.  1H-
NMR (CDCl3) δ 0.8-0.9 (2d, 6H, 2 x Leu-CH3), 1.4-1.6 (m, 2H, Leu-CH2), 2.06 (m, 1H, 
Leu-CH), 2.9-3.0 (m, 2H, CH2-Phe), 3.9-4.0 (m, 1H, α-H), 4.8-4.9 (b, 1H, α-H), 4.9-5.0 
(m, 1H, NH), 5.1 (m, 2H, Cbz), 6.3-6.4 (d & b, 2H, NH and CH=), 6.9-7.0 (dd, 1H, 
CH=), 7.1-7.4 (m, 10H, 2 x Ph), 7.5-7.7 (m, 5H, SO2-Ph).  MS (ESI) m/z 535. 
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Phenyl-3-(N-carbobenzyloxyleucyl)amino-4-phenylbut-2-enyl Sulfone (7c, 
Cbz-Leu-Phe-AS-Ph) (Isomer B).  Cbz-Leu-D-Phe-VS-Ph was treated with 
butyllithium and tert-butylhydroperoxide in freshly distilled THF as described with Cbz-
Leu-Phe-VS-Ph above to give Cbz-Leu-Phe-AS-Ph (Isomer B) as a white powder, yield 
15 %.  1H-NMR (CDCl3) δ 0.8-0.9 (2d, 6H, 2 x Leu-CH3), 1.4-1.6 (m, 2H, Leu-CH2), 
2.06 (m, 1H, Leu-CH), 3.8 (s, 2H, CH2-Phe), 3.9 (d, 2H, CH2-SO2), 4.1 (m, 1H, α-H), 4.8 
(t, 1H, CH=), 4.9-5.0 (b, 1H, NH), 5.1 (m, 2H, Cbz), 7.1-7.4 (m, 10H, 2 x Ph), 7.5-7.7 
(m, 5H, SO2-Ph); 8.4 (b, 1H, NH). MS (ESI) m/z 535 (M + 1, 100 %).  Anal. calcd. for 
C30H34N2O5S: C, 67.39, H, 6.56, N, 5.43.  Found: C, 67.12, H, 6.61, N, 5.33.  
Phenyl-(3S)-3-(N-carbobenzyloxyvalyl)amino-4-phenylbut-1-enyl Sulfone 
(6b, Cbz-Val-Phe-VS-Ph).  Cbz-Val-Phe-VS-Ph was prepared from Cbz-Val-OH and 
Phe-VS-Ph·HCl using standard mixed anhydride coupling method, yield 98%.  1H-NMR 
(CDCl3) δ 0.70-0.84 (2d, 6H, Val-CH3), 2.06 (m, 1H, Val-CH), 2.91 (m, 2H, CH2-Phe), 
3.82 (m, 1H, α-H), 4.80-4.90 (m, 1H, α-H), 5.10 (s, 2H, Cbz), 5.96 (d, 1H, NH) 6.34 (d, 
1H, CH=), 6.9-7.0 (dd, 1H, CH=), 7.1-7.4 (m, 10H, 2 x Ph), 7.5-7.7 (m, 5H, SO2-Ph).  
MS (ESI) m/z 521 (M + 1, 100 %). 
Phenyl-3-(N-carbobenzyloxyvalyl)amino-4-phenylbut-2-enyl Sulfone (7b, 
Cbz-Val-Phe-AS-Ph).  Cbz-Val-Phe-VS-Ph was treated with butyllithium and tert-
butylhydroperoxide in freshly distilled THF as described with Cbz-Leu-Phe-VS-Ph above 
to give Cbz-Val-Phe-AS-Ph as a white powder, yield 21 %.  1H-NMR (CDCl3) δ 0.70-
0.85 (2d, 6H, Val-CH3), 2.1 (m, 1H, Val-CH), 3.80 (d, 2H, CH2-Phe), 3.95 (m, 3H, CH2-
SO2 and α-H), 4.90 (t, 1H, CH=), 5.12 (m, 3H, NH and Cbz), 7.1-7.4 (m, 10H, 2 x Ph), 
7.55 (t, 2H, SO2-Ph), 7.65 (t, 1H, SO2-Ph), 7.91 (d, 2H, SO2-Ph), 8.42 (b, 1H, NH).  13C 
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NMR (300 MHz, CDCl3) δ 172.1, 156.3, 144.4, 140.8, 135.7, 134.2, 133.6, 131.2, 129.5, 
129.4 x 2, 129.3, 128.8 x 2, 128.7, 128.6, 128.4, 128.3, 127.8, 127.3, 126.9, 106.3, 67.6, 
56.0, 55.6, 41.7, 22.0, 21.0, 18.4.  MS (FAB+) m/z 521 (M + 1, 100 %).  Anal. calcd. for 
C29H32N2O5S·1/10 H2O: C, 66.67, H, 6.21, N, 5.36.  Found: C, 66.31, H, 6.23, N, 5.26.  
Phenyl-(3S)-3-(N-carbobenzyloxyalanyl)amino-4-phenylbut-1-enyl Sulfone 
(6a, Cbz-Ala-Phe-VS-Ph).  Cbz-Ala-Phe-VS-Ph was prepared from Cbz-Ala-OH and 
Phe-VS-Ph·HCl using standard mixed anhydride coupling method, yield 88%.  1H-NMR 
(CDCl3) δ 1.25 (d, 3H, Ala-CH3), 2.91 (dq, 2H, CH2-Phe), 4.10 (m, 1H, α-H), 4.80-4.90 
(m, 1H, α-H), 5.10 (s, 2H, Cbz), 6.34 (b, 1H, NH), 6.39 (d, 1H, CH=), 6.90-6.98 (dd, 1H, 
CH=), 7.10-7.39 (m, 10H, 2 x Ph), 7.55 (t, 2H, SO2-Ph), 7.65 (t, 1H, SO2-Ph), 7.91 (d, 
2H, SO2-Ph).  13C NMR (400 MHz, CDCl3) δ 172.1, 156.3, 144.4, 140.8, 135.7, 134.2, 
133.6, 131.2, 129.5, 129.4 x 3, 129.3, 128.8 x 2, 128.7, 128.6, 128.4, 128.3, 127.8, 127.3, 
126.9, 67.6, 51.7, 51.6, 40.2, 19.4. 
Phenyl-3-(N-carbobenzyloxyalanyl)amino-4-phenylbut-2-enyl Sulfone (7a, 
Cbz-Ala-Phe-AS-Ph).  Cbz-Ala-Phe-VS-Ph was treated with butyllithium and tert-
butylhydroperoxide in freshly distilled THF as described with Cbz-Leu-Phe-VS-Ph above 
to give Cbz-Ala-Phe-AS-Ph as a white powder, yield 93 %.  1H-NMR (CDCl3) δ 1.21 (d, 
3H, Ala-CH3), 3.80 (m, 4H, CH2-Phe and CH2-SO2), 4.12 (q, 1H, α-H), 4.88 (t, 1H, 
CH=), 5.11 (m, 3H, NH and Cbz), 7.30 (m, 10H, 2 x Ph), 7.50 (t, 2H, SO2-Ph), 7.64 (t, 
1H, SO2-Ph), 7.83 (d, 2H, SO2-Ph), 8.40 (b, 1H, NH).  13C NMR (400 MHz, CDCl3) δ 
172.1, 156.3, 144.4, 140.8, 135.7, 134.2, 133.6, 131.2, 129.5, 129.4 x 2, 129.3, 128.8 x 2, 
128.7, 128.6, 128.4, 128.3, 127.8, 127.3, 126.9, 107.2, 67.6, 51.7, 51.6, 40.2, 19.4.  MS 
(FAB+) m/z 493 (M + 1, 100 %).  HRMS calcd. for C27H29N2O5S: 493.17972.  Obsd. 
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493.17663.  Anal. calcd. for C27H28N2O5S: C, 65.83, H, 5.73, N, 5.69.  Found: C, 65.73, 
H, 5.82, N, 5.68.  
N-Benzyloxycarbonylleucylalanine Methyl Ester (Cbz-Leu-Ala-OMe).  Cbz-
Leu-Ala-OMe was prepared from Cbz-Leu-OH and Ala-OMe using standard mixed 
anhydride coupling, yield 93 %.  1H-NMR (CDCl3) δ 0.90 (d, 6H, Leu-CH3), 1.41 (d, 3H, 
Ala-CH3), 1.58 (m, 1H, Leu-CH), 1.62 (m, 2H, Leu-CH2), 3.88 (s, 3H, OCH3), 4.21 (m, 
1H, α-H), 4.59 (m, 1H, α-H), 5.11 (s, 2H, Cbz), 5.23 (b, 1H, NH), 6.45 (b, 1H, NH), 7.31 
(m, 5H, Ph).  
N-Benzyloxycarbonylleucylalanine (Cbz-Leu-Ala-OH).  Cbz-Leu-Ala-OMe 
(4.23 g, 12.2 mmol) was suspended in methanol at room temperature.  Aqueous sodium 
hydroxide (14.69 ml, 1N, 14.69 mmol) was added.  The reaction was stirred for 1 hour 
(TLC Hex/EtOAc 1:1).  The reaction was cooled to 0 ºC and acidified with 1N HCl (pH 
2).  The mixture was extracted with ethyl acetate (3 x 50 ml).  The organic layer was 
washed with water (3 x 20 ml) and brine (3 x 20 ml) and dried (MgSO4).  The solvent 
was evaporated to give Cbz-Leu-Ala-OH as a white powder, yield 85 %.  1H-NMR 
(CDCl3) δ 0.90 (d, 6H, Leu-CH3), 1.41 (d, 3H, Ala-CH3), 1.59 (m, 1H, Leu-CH), 1.63 
(m, 2H, Leu-CH2), 4.30 (m, 1H, α-H), 4.59 (m, 1H, α-H), 5.11 (s, 2H, Cbz), 5.60 (b, 1H, 
NH), 6.97 (b, 1H, NH), 7.31 (m, 5H, Ph). 
N-(N-Benzyloxycarbonylleucylalanyl)-N-2-ethanolamine (Cbz-Leu-Ala-
NH(CH2)2OH).  Cbz-Leu-Ala-OH was coupled to ethyl hydroxyl amine using standard 
mixed anhydride coupling to give crude Cbz-Leu-Ala-NH(CH2)2OH, which was 
recrystallized from cold ethyl acetate to give a white powder, yield 63 %.  1H-NMR 
(CDCl3) δ 0.90 (d, 6H, Leu-CH3), 1.41 (d, 3H, Ala-CH3), 1.58 (m, 1H, Leu-CH), 1.62 
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(m, 2H, Leu-CH2), 2.92 (b, 1H, OH), 3.38 (m, 1H, NHCH2), 3.41 (m, 1H, NHCH2), 3.69 
(d, 2H, CH2OH), 4.13 (m, 1H, α-H), 4.43 (m, 1H, α-H), 5.11 (s, 2H, Cbz), 5.19 (b, 1H, 
NH), 6.45 (b, 1H, NH), 6.79 (b, 1H, NH), 7.31 (m, 5H, Ph).  
N-(N-Benzyloxycarbonylleucyl)-N-2-(4,5-dihydrooxazol-2-yl)ethylamine (11, 
Cbz-Leu-Ala-oxazoline).  Cbz-Leu-Ala-NH(CH2)2OH (1.15 g, 3.02 mmol) was 
dissolved in THF (20 ml).  Triphenyl phosphine (1.19 g, 4.54 mmol) was added followed 
by dropwise addition of diisopropylazadicarboxylate (0.92 g, 4.54 mmol).  The reaction 
was stirred for 2 hours at room temperature.  The solvent was evaporated, and the crude 
oil was subjected to column chromatography (silica, MeOH/ CH2Cl2 7 %) to give Cbz-
Leu-Ala-oxazoline as a white powder, yield 75 %.  1H-NMR (CDCl3) δ 0.90 (d, 6H, Leu-
CH3), 1.41 (d, 3H, Ala-CH3), 1.58 (m, 1H, Leu-CH), 1.69 (m, 2H, Leu-CH2), 3.83 (t, 2H, 
NCH2), 4.19 (m, 1H, α-H), 4.36 (t, 2H, OCH2), 4.62 (m, 1H, α-H), 5.11 (s, 2H, Cbz), 
5.19 (b, 1H, NH), 6.62 (b, 1H, NH), 7.36 (m, 5H, Ph).  MS (FAB+) m/z 362 (M + 1, 100 
%). HRMS calcd. for C19H28N3O4: 362.20813.  Obsd. 362.20798.  Anal. calcd. for 
C19H27N3O4·1/4 H2O: C, 62.36, H, 7.57, N, 11.48.  Found: C, 62.22, H, 7.55, N, 11.64. 
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CHAPTER 4 
 
DESIGN, SYNTHESIS, AND EVALUATION OF POTENT AND SELECTIVE  
INHIBITORS FOR S. MANSONI LEGUMAIN 
(ASPARAGINYL ENDOPEPTIDASE) 
 
INTRODUCTION 
 
 Schistosomias is after malaria the most prevalent parasitic disease and infects 
more than 250 million people in tropical regions.  There are three distinct parasitic 
species, that are responsible for schistosomias: Schistosoma japonicum, Schistosoma 
haematobium and Schistosoma mansoni.  Schistosoma mansoni, which is found in 54 
countries in Africa, Asia, and South America, is the schistosome species that causes 
intestinal schistosomias (WHO).  The individuals infected with S. mansoni suffer from 
liver fibrosis and portal hypertension.  The drug of choice praziquantel has up to date 
been effective in treating the disease.  However recent evidence for an emerging 
resistance of the parasite to praziquantel has been reported1-5.   
To complete its life-cycle the schistosome parasite requires two separate hosts, a 
fresh water snail and a mammal or human as the primary host (Figure 4.1).  Schistosoma 
mansoni resides in the veins of the mesenteries of its mammalian host, where the female 
ingests 330 000 red blood cells per hour6 as a source for amino acids7.  The red blood 
cells are lysed by hemolysin in the esophagus of the parasite8,9.  The parasite employs 
cysteine and aspartic proteases in a catalytic cascade of hemoglobin degradation10-12.  The 
first cysteine proteases to be identified were Sm31 and Sm3213-15.  Other proteases, which 
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have so far been identified, include cathepsin L16, cathepsin D17, and cathepsin C18.  
Sm31 exhibits clan CA characteristics and has therefore been designated schistosome 
cathepsin B.  It has been studied predominantly over other proteases expressed by adult 
schistosomes.  Sm32 is an asparaginyl endopeptidase homologous to a family of cysteine 
proteases called legumains, and therefore also known as schistosome legumain19.    
 
 
Figure 4.1.  Schistosome Life-Cycle20. 
 
 Legumains (EC.3.4.22.34) form a family (C13) of clan CD proteases.  Other 
members of the clan CD proteases include caspases, gingipains, and clostripains.  They 
are related by a shared catalytic-site motif and a common scaffold within their catalytic 
domains21.  They were first identified in leguminous plants22,23, and later in mammalian 
cells24.  In mammalian cells legumain has been linked to osteoclast formation and bone 
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resorption25, and the processing of bacterial antigens26 and the potential autoantigen, 
myelin basic protein, in the major histocompatability (MHC) class II system27.  In S. 
mansoni the legumain protease is dissimilar to the other proteinases and may process gut-
associated clan CA zymogens to their active forms, thus facilitating the digestion of 
ingested host serum proteins28,29.  S. mansoni legumain is not inhibited by the clan CA 
cysteine protease inhibitor E-64 or the diazomethane inhibitor Cbz-Phe-Ala-CHN2.   
Irreversible protease inhibitors would have great potential for the short-term therapeutic 
administration against parasitic infections28.  So far there has been no success in the 
determination of a crystal structure of the asparaginyl endopeptidase.  Therefore potent 
and selective irreversible inhibitors would not only contribute therapeutic properties, but 
also help determine the structural and enzymatic specificities of the legumain active site.  
Like all clan CD proteases, the substrate specificity of legumain is controlled by the 
interactions of the S1 subsite.  Legumains selectively hydrolyze substrates with an 
asparaginyl residue in the P1 position.  Mathieu et al have mapped the substrate 
specificity for the P2 and P3 amino acid residues30, and found that Sm32 is less selective 
with respect to the P2 and P3 positions, but prefers Ala or Thr.  The synthetic substrate 
Cbz-Ala-Ala-Asn-AMC was effectively cleaved by S. mansoni legumain and human 
legumain with KM’s of 90 and 80 µM respectively.  This peptide sequence provides a 
basis for the design of potential inhibitors.  
 The synthetic inhibitors reported so far include peptidyl aza-Asn 
halomethylketones (Cbz-Ala-Ala-AAsn-CH2Cl, kobs/[I] = 139,000 M-1s-1, Cbz = 
benzyloxycarbonyl), peptidyl Michael acceptors derived from Asn (kobs/[I] up to 766 M-
1s-1)31, and peptidyl acyloxymethylketones up to 109,000 M-1s-1 tested with mammalian 
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legumain32 (Figure 4.2).  Aspartyl peptidyl fluoromethyl ketones designed specifically for 
caspase inhibition have found to be moderate inhibitors of legumain33.   
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Figure 4.2.  Previously Reported Legumain Inhibitors; a) Peptidyl Michael acceptor 
inhibitor (kobs/[I] = 776 M-1s-1)31, b) Aza-peptidyl chloromethyl ketone (kobs/[I] = 139,088 
M-1s-1)31, c) Acyloxymethylketone inhibitor (kobs/[I] = 109,000 M-1s-1)32. 
 
In an effort to design and synthesize more specific and selective legumain 
inhibitors, we created two new classes of inhibitors.  Initially, we based our design on the 
previously reported aza-peptide epoxides, a novel class of cysteine protease inhibitors 
specific for clan CD proteases developed by our laboratory34.  We extended this design 
towards aza-peptide epoxides, a new class of inhibitors specific for legumain.  We have 
also replaced the epoxide moiety with the double bond, to create a second new class of 
inhibitors, the aza-peptide Michael acceptors, which are even more potent than the 
epoxide inhibitors. 
 69
 
4.1.  AZA-PEPTIDE EPOXIDES: POTENT AND SELECTIVE  
INHIBITORS OF SCHISTOSOMA MANSONI LEGUMAIN 
 
INHIBITOR DESIGN 
 
Aza-peptide epoxides (Figure 4.1.1) were designed to closely resemble an 
extended peptide legumain substrate (1) with the placement of the carbonyl group of the 
epoxide moiety in the inhibitor (2) in a location identical to that of the carbonyl of the 
scissile peptide bond in a legumain substrate.  This design allowed the peptide chain of 
the inhibitor to exactly match that of a good substrate up to the scissile peptide carbonyl 
group.  Conversion of the α-carbon of an amino acid residue into a nitrogen results in the 
formation of an aza-amino acid residue, which allows the ready synthesis of a variety of 
epoxide derivatives.  In our design of aza-peptide epoxides for legumains, we have used 
the epoxysuccinyl group from E-64 and attached it to an aza-Asn residue (AAsn) to place 
the epoxy moiety on the P' site of the inhibitor structure.  We abbreviate the epoxide as 
EP and aza-asparagine as AAsn, thus the above inhibitor is designated Cbz-Ala-Ala-
AAsn-EP-R'.  In contrast, in E-64 derivatives, the epoxide is usually attached to the N-
terminus of a peptide or amino acid35.  Aza-peptide epoxides (2) have the advantage of 
being easily extended in the P' direction, allowing interactions with the S' subsites of 
legumain. 
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Figure 4.1.1.  Design of Aza-Peptide Epoxide Inhibitors. 
 
CHEMISTRY 
 
Methods for synthesizing the various epoxide moities for the new inhibitors are 
shown in Figure 4.1.3.  Enantiomerically pure diethyl epoxysuccinate esters (3, 2S,3S and 
2R,3R) were synthesized by Zhao Zhao Li from diethyl D-(-) and L-(+)-tartrate, 
following the general method developed by Mori and Iwasawa (Figure 4.1.2)36,37.   
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Figure 4.1.2.  Synthesis of Enantiomerically Pure Epoxysuccinate Esters. 
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The trans-oxirane-2,3-dicarboxylic acid diethyl ester (3, trans) was synthesized 
using a general procedure for the stereocontrolled epoxidation of α,β-unsaturated 
carbonyl compounds, which was similar to the method developed by Meth-Cohn38.  The 
cis-oxirane-2,3-dicarboxylic acid diethyl ester was synthesized using the same procedure 
with diethyl maleate as the starting material.  Selective hydrolysis using KOH in ethanol 
by a procedure similar to that described previously39,40  yielded the monoethyl 
epoxysuccinates (5).  Complete hydrolysis of both esters was accomplished by using 2 eq 
of NaOH in methanol, to give the oxirane-2,3-dicarboxylic acid (4, trans, 2R,3R, and 
2S,3S).  Additional oxirane-2-carboxylic acid monoester derivatives (6b, c) were 
obtained by adding 1 eq of benzyl alcohol or phenethyl alcohol to 4 using DMAP as a 
base and EDC as the coupling reagent.  Amide derivatives of oxirane-2,3-dicarboxylic 
acid (6d-h) were obtained by coupling the corresponding amine or amino acid (R2NH 
where R can be H, CH3, nBu, CH2Ph, CH2CH2Ph, CH(CH3)CONHCH2Ph) to 5 using 
EDC and HOBt, followed by hydrolysis of the ethyl ester using 1.2 eq of KOH in 
ethanol41.  The trans-3-phenethyloxirane-2-carboxylic acid (6i) was synthesized by 
Özlem Doğan Ekici coupling 3-phenylpropionaldehyde (7) with malonic acid to form the 
α,β-unsaturated acid, which can be further transformed into an ethyl ester (8).  The 
double bond was epoxidized using t-butyl hydroperoxide and t-butyl lithium38, and then 
the ethyl ester was hydrolyzed using KOH.  Using a similar method, trans-3-(4-
chlorophenyl)oxirane-2-carboxylic acid (6j) was synthesized by epoxidizing 3-(4-
chlorophenyl)acrylic acid methyl ester, followed by the deblocking of the methyl ester.   
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We chose the Cbz-Ala-Ala-AAsn sequence for legumain inhibitors since Cbz-Ala-Ala-
Asn-NHMec (NHMec = 7-(4-methyl)coumarylamide) is an optimal substrate sequence42.  
We have previously reported a general synthetic method for the preparation of aza-
peptide epoxides (Figure 4.1.4)34.  The peptidyl hydrazide Cbz-Ala-Ala-NHNH2 (9) was 
prepared from Cbz-Ala-Ala-OMe by reaction with excess hydrazine in methanol.  The 
aza-asparagine side chain was introduced by alkylation of Cbz-Ala-Ala-NHNH2 with 
ethyl bromoacetate and NMM in DMF.  The ethyl ester was then converted to the amide 
(10) by ammonolysis with NaCN as a catalyst using the method described by Hogberg et 
al43.  The substituted hydrazide (10) was then coupled to various oxirane derivatives (6a-
j) using EDC and HOBt to give the desired aza-peptide epoxides (11a-j).  
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Figure 4.1.4. Synthesis of Aza-Peptide Epoxide Inhibitors. 
 
 
RESULTS AND DISCUSSION 
 
The synthetic aza-Asn inhibitors (11a-j) were tested against S. mansoni legumain 
by Conor Caffrey in the laboratory of Jim McKerrow at the University of California, San 
Francisco.  The IC50 values for inhibition of S. mansoni legumain varied from 45 to 288 
nM and kobs/[I] values (~104 M-1s-1) were obtained for selected inhibitors by the progress 
curve method (Table 4.1.1).
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Legumains were inhibited by aza-peptide epoxides with a variety of substituents 
on the prime side of the epoxide such as esters (COOR), alkyl and aryl groups 
(CH2CH2Ph or Ph-4-Cl), monosubstituted or disubstituted amides (CONR2), and 
disubstituted amides.  The epoxide stereochemistry affected the reaction rate, and the 
order of reactivity is S,S > R,R > trans > cis.  The more potent form of E-64 also 
possesses S,S stereochemistry at the epoxide moiety, while the R,R isomer is less reactive 
toward cysteine proteases.  Interestingly, the placement of esters or disubstituted amides 
on the epoxide moiety gave more potent inhibitors than the placement of alkyl groups or 
monosubstituted amides on the epoxide moiety.  The ethyl ester on the epoxide (S,S 
isomer of 11a, kobs/[I] = 43,000 M-1s-1) was more potent than the benzyl ester (S,S isomer 
of 11b, kobs/[I] = 26,700 M-1s-1) with pig kidney legumain (Data obtained for Karen 
James’ compounds by Alan Barrett’s lab), but both esters were almost equally potent 
with S. mansoni legumain (11a kobs/[I] = 17,400 M-1s-1, IC50 = 53 nM and 11b, kobs/[I] = 
15,300 M-1s-1, IC50 = 47 nM).  The most potent inhibitor of S. mansoni legumain was the 
phenethyl ester Cbz-Ala-Ala-AAsn-(2S,3S)-EP-COOCH2CH2Ph (11c, IC50 = 45 nM). 
Surprisingly, neither the pig kidney nor the S. mansoni legumain was inhibited by 
the monosubstituted amides Cbz-Ala-Ala-AAsn-(2S,3S)-EP-CONHCH2Ph (11d) and 
Cbz-Ala-Ala-AAsn-(2S,3S)-EP-CONHCH2CH2Ph (11e) nor the amino acid derivative 
Cbz-Ala-Ala-AAsn-(2R,3R)-EP-CO-Ala-NHCH2Ph (11f).  The only difference between 
the benzyl amide and the benzyl ester is that an NH replaces the oxygen of the carboxylic 
acid.  The lack of inhibition by the benzyl amide could be explained by the formation of 
different hydrogen bonds within the active site as a result of the NH replacing the 
oxygen.  Interestingly, the disubstituted amides Cbz-Ala-Ala-AAsn-(2S,3S)-EP-
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CON(nBu)2 (11g, IC50 = 68 nM) and Cbz-Ala-Ala-AAsn-(2S,3S)-EP-CON(CH3)CH2Ph 
(11h, IC50 = 63 nM) were quite potent inhibitors of S. mansoni legumain.  We speculate 
that this is a result of the lack of a hydrogen bond.  Interestingly, aza-peptide epoxides 
with a P1 aza-Asp and mono- and disubstituted amides or amino acids on the epoxide 
moiety work extremely well with the caspases (unpublished results).  Caspase specific 
inhibitors with a P1 aza-Asp and an ester functional group on the epoxide moiety have 
either no reactivity toward legumain or very small rates (15 - 86 M-1s-1 with various 
tetrapeptide inhibitors).  No mono- or disubstituted amide with a P1 aza-Asp has been 
tested with legumain so far.  However it would appear that these potent caspase inhibitors 
should have little or no inhibitory potency toward legumain.  The alkyl epoxide moieties 
11i (CH2CH2Ph) and 11j (Ph-4-Cl) were the poorest S. mansoni legumain inhibitors (IC50 
values > 70 nM).  We speculate that for maximum potency, the enzyme needs the 
carbonyl next to the epoxide moiety (possibly for hydrogen bonding or to activate the 
epoxide due to its electronegativity).   
The aza-peptide epoxides had previously been investigated for their stability 
(unpublished results).  It was found that the caspase-6 specific inhibitor Cbz-Leu-Glu-
Thr-AAsp-(S,S)-EP-COOCH2Ph is equally potent with caspase-6 when incubated with 
buffer containing DTT as when incubated with buffer lacking DTT.  The stability of 
epoxysuccinyl peptide inhibitors under physiological conditions toward simple thiols has 
been reported in the literature39.  E-64 is not alkylated by 100 mM cysteine nor does is 
inactivate lactate dehydrogenase, a non-proteolytic thiol-dependent enzyme44.  Our 
laboratory has also synthesized aza-peptide epoxides specific for dipeptidyl peptidase I 
(DPPI), which is specific for a free N-terminus.  The free N-terminus however cyclizes 
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with the warhead.  This was also observed with the dipeptidyl vinyl sulfones (see Chapter 
2).  The aza-peptide epoxides with a half-life of 350 min at pH 7 and 7.5 are more stable 
than the dipeptidyl vinyl sulfones.  For example, Nva-AHph-EP-COOEt was 7 and 9-fold 
more stable than Nva-Hph-VS-Ph at pH 7 and 7.5, respectively (unpublished results). 
Aza-peptide epoxides are specific clan CD cysteine protease inhibitors and do not 
inhibit clan CA cysteine proteases, serine proteases, or aspartyl proteases.  The aza-Asn 
inhibitors are selective for mammalian and S. mansoni legumains, since Cbz-Ala-Ala-
AAsn-(2S,3S)-EP-COOEt 11a showed essentially no cross reactivity with other enzymes 
in clan CD such as caspases (kobs/[I] = < 1 M-1s-1 with caspases-3, -6 and –8).  Aza-
peptide epoxides also displayed little to no inhibition of the clan CA cysteine proteases 
papain and cathepsin B and no inhibition of the serine protease α-chymotrypsin34.  The 
inhibitor Cbz-Ala-Ala-AAsn-(2S,3S)-EP-COOEt (11a) did not inhibit the serine protease 
granzyme B nor the aspartyl proteases porcine pepsin, human cathepsin D, plasmepsin 2 
from P. falciparum, HIV-1 protease, and the secreted aspartic proteinase 2 (SAP-2) from 
Candida albicans (unpublished results).  
 
SUMMARY 
 
In summary, we have shown that aza-peptide epoxides can be constructed to 
selectively and potently inhibit S. mansoni legumain.  Aza-peptide epoxides are a new 
class of cysteine protease inhibitors specific for the clan CD cysteine proteases, as they 
show little to no inhibition of clan CA cysteine proteases, serine proteases, or aspartyl 
proteases.  The aza-peptide epoxides designed for legumains show little to no cross-
reactivity with other clan CD proteases such as capsases.  Currently, we are trying to 
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refine the P' portion of the inhibitors to obtain greater specificity and are testing this class 
of inhibitors with other clan CD enzymes. 
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4.2.  AZA-PEPTIDE MICHAEL ACCEPTORS: POTENT AND SELECTIVE 
INHIBITORS OF SCHISTOSOMA MANSONI LEGUMAIN 
 
INHIBITOR DESIGN 
 
In the past Michael acceptors have been employed as warheads against several 
cysteine proteases45-47.  Among the most effective inhibitors are vinyl sulfones48 and α,β-
unsaturated carbonyl derivatives  against various cysteine proteases49,50.  The original 
strategy reported in the literature was to replace the carbonyl group of a good substrate 
with a moiety, that would trap the enzymatic nucleophile (Ser-OH or Cys-OH) without 
altering the structural features required for enzyme recognition and binding45.  The 
fumarate derivative of the epoxy succinate E-64c, which is one of the first Michael 
acceptor inhibitors reported, extends the α,β-unsaturated carbonyl by an additional 
carbonyl in the β-position 44.  This modification allows the preservation of the scissile 
carbonyl for possible structural recognition and binding requirements within the enzyme 
active site.  Both the fumarate analog of E-64c and the epoxide parent compound do not 
inhibit clan CD proteases, but are very effective with clan CA proteases.  The E-64c 
epoxide warhead itself, however, can be incorporated into inhibitors specific for clans 
other than clan CA.  This has been described in chapter 4.1 with the design and synthesis 
of the aza-peptide epoxides specific for the clan CD Schistosoma mansoni asparaginyl 
endopeptidase legumain.  The fumarate derivative of  E-64c (trans-HOOC-CH=CHCO-
Leu-NH(CH2)2CH(CH3)2) inhibits cathepsin B (kapp = 625 M-1s-1), cathepsin H (kapp = 11 
M-1s-1), and cathepsin L (kapp = 2272 M-1s-1) irreversibly.  The α,β-unsaturated carboxyl 
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moiety undergoes a Michael addition by the active site nucleophile, and thus the inhibitor 
irreversibly binds to the enzyme.  Since the aza-peptide epoxides described in chapter 4.1 
proved to be potent and selective inhibitors for S. mansoni legumain, we in parallel 
modified this particular design by replacing the epoxide moiety with a double bond to 
form a Michael acceptor (Figure 4.2.1).  Herein we report the design, synthesis, and 
evaluation of aza-peptide Michael acceptors as potent and specific inhibitors for S. 
mansoni legumain, and provide evidence for the mechanism of inhibition.   
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Figure 4.2.1.  Aza-Peptidyl Michael Acceptor Design Derived from Aza-Peptidyl 
Epoxides. 
 
  In addition we synthesized a biotinylated derivative of one of the better Michael 
acceptor inhibitors.  Biotin has been used in the past as an affinity label for protease 
activity.  By attaching a biotin label onto a selective inhibitor, it is possible to locate in 
situ activity of the target enzyme within an organism.  A biotinylated Michael acceptor 
inhibitor specific for S. mansoni legumain would therefore be a useful tool in detecting 
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legumain activity within the parasite or possible precursors of legumain or other 
legumain-like proteases. 
 
CHEMISTRY 
 
The synthesis of the aza-peptide fumarate analogues is based on the design of the 
aza-peptide epoxide inhibitors.  The general strategy is to mimic an extended peptide 
substrate while keeping the synthesis facile.  Replacing the α-carbon of the P1 
asparaginyl residue with a nitrogen allows practical extension into the P' direction by 
coupling to the desired fumarate derivatives or commercially available acrylic acid 
analogues.  The fumarate carbonyl is now in the exact place as the scissile peptide 
carbonyl of the peptidase substrate, and the P' site of the inhibitor can be easily modified 
to explore the tolerance of the S' subsite interactions between the enzyme and the 
inhibitor.  
A series of amide fumarate derivatives (13a - x) were prepared starting with 
monoethyl fumarate and the corresponding primary or secondary amines by standard 
mixed anhydride coupling using NMM and iBCF followed by deprotection of the ethyl 
ester in methanol using aqueous NaOH (Figure 4.2.2).  The various disubstituted 
aromatic amines were synthesized by Tiffany Stark and Amy Campbell by reductive 
amination starting with aromatic aldehyde precursors and an aromatic primary amine.  
The benzyl ester fumarate derivative was formed from monoethyl fumarate and benzyl 
alcohol using NMM and DCC as the coupling reagent.  The choice of the trans 
stereochemistry was based on the epoxide inhibitors described in chapter 4.1.  The cis 
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epoxysuccinates showed very little potency and therefore the design of the fumarate 
analogues did not take the cis stereochemistry into consideration. 
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Figure 4.2.2.  Preparation of Fumarate Precursors. 
 
The peptidyl hydrazides were prepared according to our previously reported 
method for the synthesis of aza-peptide epoxides in chapter 4.1.  The optimal substrate 
sequence Cbz-Ala-Ala-Asn-AMC for legumain determined by Mathieu et al provided the 
basis for the peptide sequence of the inhibitors30.  The peptidyl hydrazide 3 was formed 
starting with Cbz-Ala-Ala-OMe using excess hydrazine in methanol. The asparaginyl 
side chain was synthesized via alkylation of the hydrazide with ethyl bromoacetate and 
NMM.  The alkylation of the primary nitrogen over the hydrazide nitrogen immediately 
next to the carbonyl is based on the more nucleophilic character of the primary nitrogen.  
Subsequent conversion of the ethyl ester to the amide (9) was accomplished by 
ammonolysis with catalytic amounts of NaCN according to the procedure described by 
Hogberg et al43.  The peptide precursor was then coupled to the substituted fumarate 
amides  (13a – x), fumarate esters, or commercially available acrylic acids using HOBt 
and EDC to complete the synthesis of the various aza-peptide fumarate or acrylic acid 
derivatives (15a – f) (Figure 4.2.3). 
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 For the design of the biotinylated derivative (Figure 4.2.4), we chose to attach the 
biotin moiety on the non-prime side of the inhibitor in place of the Cbz protecting group, 
in order not to interfere with the active site binding interactions.  We assumed that the 
alkyl spacer in the biotin moiety created a sufficient distance between the structural 
features of the warhead that are essential for inhibition.  We chose the ethyl ester 15a 
(Cbz-Ala-Ala-AAsn-CH=CHCOOEt) as the most suitable inhibitor to be derivatized, as 
it is the most potent, and as the monoethyl fumarate precursor is commercially available.  
For the synthesis of the biotinylated inhibitor we chose to replace the Cbz protecting 
group with the Boc protecting group, since Cbz deprotection requires catalytic 
hydrogenation, which could affect the double bond of the fumarate moiety.  The Boc 
group can be removed with TFA using dilute conditions.  The Boc-protected aza-peptide 
Michael acceptor was synthesized in analogous fashion to the Cbz-protected compounds.  
The coupling of biotin to the free N-terminus of the Michael acceptor inhibitor provided 
initial difficulties, as the carboxylic acid moiety was not reactive enough for coupling 
with HOBt/EDC.  The mixed anhydride coupling method failed in both methylene 
chloride as well as THF, as biotin is extremely insoluble in most organic solvents.  We 
initially decided to activate the carboxylic acid moiety of biotin by converting it to the 
acid chloride.  This functionality however turned out to be too reactive.  The biotin N-
hydroxysuccinimide has previously been successfully coupled to the N-terminus of 
peptidyl inhibitors51,52.  Coupling of biotin N-hydroxysuccinimide 17 to the TFA salt of 
Ala-Ala-AAsn-CH=CHCOOEt (20) in the presence of triethylamine gave the 
biotinylated aza-peptidyl fumarate ethyl ester 21 in good yield.
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RESULTS AND DISCUSSION 
 
Synthetic Design.  The design of the aza-peptide has been employed with 
inhibitors of legumain before31,34.  Replacing the chiral α-carbon with a nitrogen changes 
the orientation of the scissile peptide bond.  The aza-peptide functionality is planar and 
therefore restricts the conformation and rotational freedom of the original peptide bond.  
Niestroj et al have previously reported the synthesis of aza-asparaginyl chloromethyl 
ketones31.  A concern that arose during their synthetic strategy was the intramolecular 
cyclization of the asparagine’s side chain with the warhead.  However the rigidity of the 
aza-peptide backbone prevents the intramolecular cyclization and renders the inhibitor 
stable after deprotection of the side chain.  During the course of our synthetic progress, 
the asparagine side chain remained unprotected and no cyclization was observed.   
 The aza-peptide design is also highly practical for the introduction of a variety of 
substituents on the P1' position.  Fumarates and acrylates can be derivatized prior to 
coupling to the peptide precursor.  This will allow us to perform an extensive SAR study 
to explore the tolerance of the enzyme’s S' subsite.   
 There are two possible routes to incorporate the aza moiety in the peptide 
backbone.  The hydrazide can be prepared prior to alkylation with the asparagine side 
chain by conversion of the peptide methyl ester to the peptidyl hydrazide.  A second 
approach is to directly add an amino acid side chain analog bearing the hydrazine moiety.  
One has to consider the reactivity of the hydrazine moiety.  Depending on the hydrazine 
substituent the reactivity of one hydrazine nitrogen over the other changes.  An electron 
withdrawing substituent, such as esters or amides, places a higher nucleophilic character 
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on the primary hydrazine carbon.  An electron donating substituent deposits the reactivity 
on the secondary nitrogen53,54.  For these reasons, we chose to convert the peptide methyl 
ester into the hydrazide prior to introduction of the side chain, since this would allow us 
to extend our design onto aza-peptidyl analogs other than the aza-asparagine moiety.  We 
are also currently investigating the use of the aza-peptidyl functionality with ornithine, 
lysine, and aspartate analogs.  The alternate strategy is only limited to a small number of 
amino acid analogs.   
Legumain Inhibition.  The compounds were tested for their inhibitory potency 
towards S. mansoni legumain.  The IC50 values are reported in Table 4.2.1.  The results 
are overall comparable to the general trend of the epoxide inhibitors described in chapter 
4.1.  
 
Table 4.2.1.  S. mansoni Legumain Inhibition with Aza-Peptide Michael Acceptors. 
 
Compound 
O
O
N
H O
H
N
N
H
O
N
O
R
O
NH2
 
IC50 (nM) 
15a -COOEt1 31 ± 25 
15b -COOBzl 38 
14a -CONEt2 N.I. 
14b -CON(nBu)2 550 
14c -CO-Pip 1,000 
14d -CONHPh 700 
14e -CONHBzl 1,000 
14f -COBzl-4-F 800 
14g -CONHCH2CH2Ph 600 
14h -CON(CH3)Ph 60 
14i -CON(CH3)Bzl 55 
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14j -CON(CH3)CH2-1-Napth 35 
14k -CON(CH3)CH2CH2Ph 600 
14l -CON(Bzl)Ph 70 
14m -CON(Bzl)2 45 
14n -CON(Bzl-4-OMe)Bzl 90 
14o -CON(Bzl-4-F)Bzl 60 
14p -CON(CH2-2-furyl)2 900 
14q -CON(Bzl)-2-CH2-Napth 70 
14r -CON(Bzl)-1-CH2-Napth 62 
14s -CO-tetrahydroquinoline 70 
14t -CO-tetrahydroisoquinoline 200 
14u -CO-indoline 70 
14v -CO-isoindoline 300 
14w -CO-(4-Ph-pyridine) 750 
14x -CO-MePhe-N(CH3)CH2CH2Ph 750 
15c -COPh N.I. 
15d -CH=CH-CH3 N.I. 
15e -2-furyl >2,000 
15f -3-Py >2,000 
N.I. = No inhibition after 20 minutes of incubation. 
1prepared by Karen James. 
 
 
The fumarate benzyl and ethyl esters (15a, 15b) are one of the most potent 
inhibitors.  The monosubstituted amides (14e, f, g) and the acrylate derivatives (15d, e, f) 
show little to no inhibition, which leads us to conclude that the hydrogen bonding 
network between the inhibitor and the active site is optimal with the carbonyl next to the 
double bond and without the H-bond donating monosubstituted amide.  The benzoyl 
acrylate Cbz-Ala-Ala-AAsn-CH=CHCOPh (15c) fulfills both of the aforementioned 
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requirements, but surprisingly does not inhibit legumain.  We found that the aromatic 
fumarate extensions give lower IC50’s than the alkyl derivatives (NEt2, N(nBu)2, Pip).  
We speculate that increased Π-stacking of the aromatic residues in one of the enzyme 
pockets improves the binding of the inhibitor.  The aromatic difuryl derivative 14p 
unexpectedly only inhibits with an IC50 of 900 nM.   
The positioning and orientation of the phenyl or naphthyl rings plays an important 
role.  The N-methyl phenyl analog (14h) is less potent (IC50 = 60 nM) compared to the 
N-methyl benzyl analog (14i, IC50 = 55 nM).  However extending the alkyl spacer by one 
additional methylene group to the N-methyl phenethyl analog (14k) decreases the 
inhibition dramatically (IC50 = 600 nM).   The extended aromaticity of the N-methyl-1-
methyl naphthyl (14j) derivative compared to the N-methyl benzyl amide produced an 
even lower IC50 (35 nM).   The dibenzyl amide shows the lowest IC50 of the aromatic 
disubstituted amides (14m, IC50 = 45 nM).  The substitution of one of the benzyl rings 
with an electron donating methoxy (14n) or an electron withdrawing fluorine (14o) only 
reduces the potency.  The next step was to combine the effects of the naphthyl group with 
the benzyl substituent.  But neither the N-benzyl-2-methylnaphthyl (14q) nor the N-
benzyl-1-methylnaphthyl analog (14r) improves the IC50 of the dibenzylamide.  The 
orientation and flexibility of the benzyl group is restricted in the quinoline (14s), 
isoquinoline (14t), indoline (14u), and isoindoline (14v) analogs.  Both quinoline and 
indoline exhibit good potency (IC50 = 70 nM), but lower in comparison to the benzyl 
amide.  The aromatic ring is much less flexible in the indoline and quinoline bicyclic 
system.  The orientation of the aromatic ring in the isoindoline and isoquinoline 
compounds is different from their parent compounds due to the different location of the 
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nitrogen.  The altered orientation of the aromatic ring significantly lowers their potency.  
Both the 4-phenyl tetrahydropyridine (14w) and the amino acid derivative (14x) could 
not improve the effectiveness of the warhead.  The esters are generally more potent than 
the amide analogs, however the difficulty of their preparation also limits the variety of 
possible compounds.  The biotinylated inhibitor Biotin-Ala-Ala-AAsn-CH=CHCOOEt 
(21) exhibited the greatest potency with legumain (IC50 = 10 nM).    
Stability Studies.  The increased reactivity of the ester derivatives, however, is 
not only limited to enzyme inhibition.  In addition we observed that the esters are reactive 
with thioalkylating agents such as DTT (Table 4.2.2).  Upon incubation of various 
Michael acceptor inhibitors with DTT in legumain assay buffer we observed the 
disappearance of the Michael acceptor double bond over time.  The very potent Cbz-Ala-
Ala-AAsn-CH=CHCOOEt (IC50 = 31 nM) was found to have a half-life of 3.7 minutes 
with a first-order rate constant of 3.10 x 10-3 s-1, when reacted with excess DTT in 
legumain assay buffer at room temperature at pH 6.8.  Amide substituted Michael 
acceptors react with DTT at a slower rate.  Half-lives of 20 min and 17 min and a first 
order rate constant of 5.78 x 10-4 s-1 and 6.73 x 10-4 s-1 were determined for Cbz-Ala-Ala-
AAsn-CH=CHCON(Me)Bzl and Cbz-Ala-Ala-AAsn-CH=CHCON(Bzl)2 respectively. 
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Table 4.2.2. Degradation of Various Inhibitors in the Presence of DTT. 
 pH 5.8 pH  6.8 
Inhibitor kobs (M-1s-1) t1/2 (min) kobs (M-1s-1) t1/2 (min) 
R-CH=CHCOOEt 6.06 x 10-4 19 3.10 x 10-3 3.7 
R-CH=CHCOOBzl   4.60 x 10-3 2.5 
R-CH=CHCON(Me)Bzl 3.07 x 10-5 376 5.78 x 10-4 20 
R-CH=CHCON(Bzl)2   6.73 x 10-4 17 
R-CH=CHCH=CHCH3 stable  stable  
 
In general acrylates are more reactive toward nucleophilic attack than acrylamides 
due to differences in electron withdrawing properties.  Freidig et al have discovered 
similar results regarding the reactivity of the non-peptidyl parent compounds, ethyl 
acrylate and acrylamide, with the thioalkylating glutathione.  Their study concludes that 
ethyl acrylate reacts with glutathione 85 times faster than acrylamide with second order 
rate constants of 0.66 M-1s-1 and 7.8 x 10-3 M-1s-1 55.  Our reactivity experiments with 
peptidyl acrylamides and acrylates and DTT result in a kacrylate/kacrylamide reactivity ratio 
between 5 and 6.  Alkyl substituted acrylates show no reaction with DTT.   
We observed that the reactivity of the Michael acceptor with DTT also depends 
on the pH of the buffer solution.   The pka of the DTT thiol is 9.2.  A higher pH results in 
a higher concentration of deprotonated DTT thiol in solution, and promotes the 
nucleophilic attack on the double bond.  Lowering the pH in the degradation assay 
decreases the rate of reactivity dramatically.  The ethyl ester, for example, has a half-life 
of 3.7 minutes in the reaction with DTT at pH 6.8.  Lowering the pH to 5.8 increases the 
half-life to 19 minutes.  The effect of pH on the stability of the amide derivatives is much 
more pronounced.  The half-life of Cbz-Ala-Ala-AAsn-CH=CHCON(Me)Bzl increases 
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from 20 minutes to 376 minutes when lowering the pH.  In a previous study with caspase 
specific tetrapeptidyl aza-aspartyl Michael acceptors, we found that the half-life of the 
caspase specific ethyl ester analog in the reaction with DTT was 10 minutes at pH 7.2.  
At the same pH the N-methyl benzyl amide had a half-life of 116 minutes.  We suspect 
that the length of the peptide of the inhibitor and the size of the steric bulk of the side 
chain have an effect on the rate of degradation.  Therefore the reactivity of the individual 
inhibitor with DTT at the pH of the enzyme inhibition assay has to be taken into 
consideration when evaluating the potency of the inhibitor.  
We are certain that the degradation of the legumain Michael acceptor inhibitors 
upon DTT addition involves thioalkylation of the Michael acceptor double bond by the 
reactive DTT thiol, since the gradual disappearance of the double bond can be monitored 
spectroscopically.  Initially it was unclear, which carbon of the double bond was 
alkylated.  There are two possible sites of attack, the C2 or C3 carbon of the double bond, 
to give two alkylated regioisomers (Figure 4.2.5).   
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Figure 4.2.5.  Mechanism of Thioalkylation of Aza-Peptidyl Michael Acceptor Inhibitors 
with DTT. 
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The order of reactivity of the various Michael acceptors with respect to different 
P1' substituents, where esters > amides > alkyls, indicates that the thioalkylation occurs at 
the C2 position of the double bond.  In search of further support for the regioselective 
thioalkylation of our inhibitors by DTT, we used ChemDraw to predict the difference of 
the two possible products in the 1H NMR spectrum.  The estimated chemical shift for a 
C2 thioalkylation places the proton of the new thioether linkage at 4.11 ppm.  A C3 
thioalkylation would result in an estimated chemical shift of 3.59 ppm.  Since other 
protons in the structure of DTT would interfere with the peaks of interest in our 
experimental 1H NMR spectrum, we chose benzyl mercaptan as a thioalkylating agent 
instead of DTT.  We followed the reaction of Cbz-Ala-Ala-AAsn-CH=CHCOOEt with 
benzyl mercaptan in DMSO by 1H NMR for several hours, and observed the expected 
gradual disappearance of the vinyl proton at 6.59 ppm together with a simultaneous 
increase of a new signal at 4.05 ppm.  Unfortunately the new signal coincides with the α-
H of the peptide backbone of the inhibitor, which scrambles the multiplicity of the new 
peak.  However, the chemical shift of the new signal closely corresponds to the shift 
predicted by ChemDraw for a C2 thioalkylation, and thus supports our hypothesis. 
Mechanism of Inhibition.  Cysteine proteases are generally inhibited by Michael 
acceptors in a nucleophilic attack of the side chain thiol of the catalytic cysteine residue 
within the active site on the β-carbon of the Michael acceptor double bond.  A covalent 
bond forms and the inhibitor is irreversibly bound to the enzyme.  In our particular 
structure, the nucleophilic attack of the active site cysteine thiol is theoretically possible 
on either carbon of the double bond.  In our recent study with the related aza-peptidyl 
epoxide compounds, the X-ray crystal structures of caspase-1 (like legumain, a clan CD 
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protease) inhibited by PhPr-Val-Ala-AAsp-EP-COOCH2Ph and PhPr-Val-Ala-AAsp-EP-
CH2CH2Ph (Ron Rubin, Parke-Davis now Pfizer, unpublished results) revealed that the 
attack of the cysteine thiol occurred at the C3 carbon of the epoxide moiety.  However, 
one cannot draw similar conclusions for the aza-peptidyl Michael acceptors.   
The aforementioned reactivity of the inhibitor with DTT gives insights into the 
enzymatic mechanism.  As the mechanism of legumain inhibition also occurs by 
nucleophilic attack of the active site cysteine thiol on the Michael acceptor similar to the 
thiol attack of DTT, we envision mechanistic parallels.  We predict that the enzymatic 
thioalkylation by the active site cysteine attacks the Michael acceptor double bond at the 
C2 carbon as concluded by the reactivity studies with DTT described above.  
Furthermore, the 1H NMR gives spectroscopic evidence for a C2 thioalkylation of the 
inhibitor by the reagent benzyl mercaptan.  The decline of inhibitory potency in the series 
of esters, amides and alkyls provides additional support for our hypothesis, as the 
reactivity of the enzyme with the inhibitor exhibits the same trend as the reactivity of the 
inhibitor in the degradation assay with DTT. 
Clan CD Specificity.  A selection of representative inhibitors was tested with the 
clan CD proteases caspase 3, 6, and 8, clostripain and gingipain K.   Caspases are highly 
specific for Asp in the P1 position of the substrate and prefer tri- and tetrapeptides over 
di-peptides.  The difference in the amino acid sequence of the substrate further divides 
the specificity of the individual caspases.  Clostripains and gingipains prefer dipeptides 
with an Orn or Lys P1 amino acid residue.  This P1 specificity unique to each member of 
the clan CD cysteine proteases allows the design of inhibitors that will only target a 
desired family within the clan CD proteases.  It is therefore not surprising that all 
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legumain inhibitors show no inhibition with caspase 3, 6, and 8, clostripain, and only 
limited inhibition with gingipain (Cbz-Ala-Ala-AAsn-CH=CHCOOEt and Cbz-Ala-Ala-
AAsn-CH=CHCON(Me)-2-CH2-Napth, kobs/[I] < 6 M-1s-1).   
Specificity with Other Cysteine Proteases.  The inhibitors were tested with the 
clan CA proteases calpain I, papain, and cathepsin B and showed little to no inhibition 
after 30 minutes of incubation.  Papain was only inhibited by Cbz-Ala-Ala-AAsn-
CH=CHCONHCH2CH2Ph (11.5 M-1s-1), which surprisingly is not a very potent inhibitor 
of legumain.  The ethyl ester derivative exhibited very limited inhibition with cathepsin B 
(< 1 M-1 s-1).  Limited inhibition was also observed with Cbz-Ala-Ala-AAsn-
CH=CHCON(Bzl)2 against calpain I (< 1 M-1s-1).  The specificity of the clan CA 
proteases is generally governed by the nature of the P2 amino acid residue of the peptide 
substrate.  We believe that the lack of inhibition of clan CA cysteine proteases arises 
from the rigid nature of the aza-peptide moiety, which most likely prevents effective 
binding of the warhead near the enzyme’s catalytic residues.  For the same rigidity 
caused by the aza-peptide moiety, the aza-peptide epoxide inhibitors for legumain 
reported in chapter 4.1 and caspases  also show lack of inhibition with clan CA proteases.  
 
SUMMARY 
 
 Aza-peptidyl Michael acceptors are a new class of inhibitors for Schistosoma 
mansoni legumain.  The inhibitors are very potent and highly selective within both the 
clan CD and clan CA cysteine proteases.  In our SAR study of the P1' specificity, we 
discovered that legumain prefers aromatic residues, and that the orientation and extension 
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of the residue into the S1' subsite plays an important role.  Additionally the strength of 
the electron withdrawing group on the P1' position of the double bond controls the 
potency of the inhibitor.  We have found that the inhibitor’s warhead reacts with 
thioalkylating agents, such as DTT, and that the progress of this reaction is dependent on 
the pH and the electron withdrawing nature of the P1' substituent.  We conclude from the 
difference in reactivity with thioalkylating agents and from the difference in the IC50 
values of the inhibition assay with legumain, and our 1H NMR study that the mechanism 
of inhibition occurs by attack of the active site cysteine on the carbon immediately next 
to the scissile bond.  This insight provides us with new possibilities in the design of more 
potent inhibitors.  Derivatizing this particular carbon with an electron-withdrawing group, 
as for example a halogen, could promote the effectiveness of our inhibitors.  A second 
task is to increase the stability of the Michael acceptor warhead with regards to its 
reactivity with thioalkylating agents by strategically introducing a steric bulk on the 
double bond without affecting the overall potency of the warhead.  
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CONCLUSIONS AND PERSPECTIVES 
 
Table 4.2.3. Summary of Aza-Peptide Epoxides and Aza-Peptide Michael Acceptors. 
Aza-Peptide Epoxides Aza-Peptide Michael Acceptors 
     
Cbz-Ala-Ala
N
H
N
O
R
O
NH2
O
Enz-Cys-SH
2
3
 
 
        
Cbz-Ala-Ala
N
H
N
O
R
O
NH2
Enz-Cys-SH
2
3
 
 
• A new class of inhibitors. 
• Specific for legumain. 
• Stereochemistry specificity:  S,S > R,R 
> trans > cis. 
• P′ specificity:  
            Esters and disubstituted amides. 
• A new class of inhibitors. 
• Specific for legumain. 
• More reactive than epoxides. 
• P′ specificity: aromatic residues. 
• Reactivity with DTT gives   
 insights into the enzyme mechanism. 
 
 
 Comparing aza-peptide epoxide inhibitors to aza-peptide Michael acceptor 
inhibitors, we found that Michael acceptors are more potent inhibitors of S. mansoni 
legumain.  In addition, there is strong evidence for a difference in the site of attack by the 
active site cysteine thiol.  The site of attack on the epoxide inhibitors occurs at the C3 
carbon according to the crystal structure of the tetrapeptidyl aza-peptide epoxide bound to 
caspase, whereas there is strong evidence for a C2 thioalkylation for the Michael 
acceptors.  The increased potency of the Michael acceptors suggests that a transition state 
oxyanion is not essential for effective binding of the inhibitor.  Instead the overall 
reactivity of the warhead primarily contributes to enzyme inhibition.  Therefore, the 
design of future classes of inhibitors or the modification of the presently known inhibitors 
should focus on the electronic properties of the warhead.  More powerful electron 
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withdrawing substituents on the prime side of the epoxide or Michael acceptor warhead 
could improve the current results.  A possible future derivative with a halogen at the C2 
position of the warhead is shown in figure 4.2.6. 
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H O
H
N
N
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O
OEt
CONH2
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Figure 4.2.6.  Proposed Future Modification of the Aza-Peptide Michael Acceptor. 
 
 Both the epoxide and the Michael acceptor inhibitors presented in this thesis have 
great potential to be used as drugs.  They are both selective and very potent.  Since the 
medicinal value of peptide inhibitors is generally quite poor due to the high molecular 
weight and the susceptibility of the amide bonds to enzymatic processing in the due 
course of metabolism, the peptide backbone of the inhibitor requires some modification 
to reduce the peptidic character.  The cross reactivity of the Michael acceptors with 
thioalkylating agents, such as DTT or glutathione, presents a second issue that needs to 
be addressed in the future development of this new class of inhibitors as medicinal 
agents.   However, the groundwork for a promising new class of anti-parasitic agents has 
been laid to replace the presently used drugs, which are becoming more and more 
ineffective due to the growing resistance of the schistosome parasite.  
 
 
 100
EXPERIMENTAL 
 
Materials and Methods.  Materials were obtained from Acros, Bachem 
Bioscience Inc., or Sigma Aldrich and used without further purification.  The purity of 
each compound was confirmed by TLC, 1H NMR, MS, and elemental analysis.  
Chemical shifts are reported in ppm relative to an internal standard (trimethylsilane).  
TLC was performed on Sorbent Technologies (250 µm) silica gel plates.  The 1H NMR 
spectra were obtained on a Varian Mercury 400 MHz spectrometer.  Electrospray 
ionization (ESI), fast-atom-bombardment (FAB) and high-resolution mass spectrometry 
were obtained using Micromass Quattro LC and VG Analytical 70-SE instruments.  
Elemental analysis was carried out by Atlantic Microlab Inc., Norcross, GA. 
Papain and Cathepsin B Assays.  The incubation method was used to measure 
the irreversible inhibition of papain and cathepsin B.  With cathepsin B, 30 µL of a stock 
inhibitor solution was added to 300 µL of 0.1 M potassium phosphate buffer containing 
1.25 mM EDTA, 0.01% Brij 35 at pH 6.0, followed by the addition of 30 µL of a freshly 
prepared cathepsin B solution (approximate concentration 6.98 x 10-3 µg/µL) in the same 
potassium phosphate buffer containing 1 mM DTT (freshly prepared).  Aliquots (50 µL) 
from the inhibition mixture were withdrawn at various time intervals and added to 200 
µL of a 0.1 M potassium phosphate buffer containing 1.25 mM EDTA, 0.01% Brij 35 at 
pH 6.0, and the substrate Cbz-Arg-Arg-AMC (499 µM).  The release of 7-amino-4-
methylcoumarin was monitored (λex = 360 nm, λem = 465 nm) using a Tecan Spectra 
Fluor microplate reader.  Pseudo first-order inactivation rate constants were obtained 
from plots of ln vt/vo versus time. 
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The incubation method method was also used for papain.  The inhibition 
incubation buffer for papain was 50 mM Hepes buffer at pH 7.5, containing 2.5 mM DTT 
and 2.5 mM EDTA.  The assay used the substrate Cbz-Phe-Arg-pNA (53.7 µM) in the 
same buffer.  The approximate concentration of papain added to the incubation buffer 
was 0.29 mg/mL.  The release of p-nitroanilide was monitored at 405 nm with a 
Molecular Devices Thermomax microplate reader.   
Caspase 3, -6, and –8 Assays.  All caspase assays were performed by Özlem 
Doğan Ekici in our laboratory.  Assays using the fluorogenic substrate Ac-DEVD-AMC 
(λex = 360 nm, λem = 465 nm) were carried out on a Tecan Spectra Fluor microplate 
reader at 37 oC.  Inhibition rates were determined by the progress curve method.  The 
concentration of the caspase-3 stock solution was 2 nM in the assay buffer.  Assay buffer 
consists of a 1:1 mixture of 40 mM Pipes, 200 mM NaCl, 0.2% (w/v) CHAPS, and 
sucrose 20% (w/v) to 20 mM DTT solution in H2O at pH 7.2.  The concentration of the 
substrate stock solution was 2 mM in DMSO.  The enzyme was pre-activated for 10 min 
at 37 oC in the assay buffer. The standard 100 µL reaction was started by adding 40 µL of 
assay buffer, 5 µL of various amounts of inhibitor (stock solution concentrations varied 
from 5 x 10-3 M to 4.84 x 10-7 M in DMSO), and 5 µL of substrate in DMSO (100 µM 
final concentration) at 37 oC.  Enzyme stock solution (50 µL of 2 nM, final concentration: 
1 nM) was added to the mixture after 1 min and reading started immediately for 20 min at 
37 oC.  Inhibition experiments were repeated in duplicate and standard deviations were 
determined.   
Caspase-6 kinetic assays were performed using the same conditions and the same 
substrate (Ac-DEVD-AMC, 2 mM stock solution in DMSO). The enzyme stock solution 
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was 10 nM (final concentration in the well: 5 nM) in the assay buffer.  The inhibitor stock 
solution concentrations varied from 5 x 10-3 M to 2.42 x 10-6 M in DMSO.   
Caspase-8 kinetic assays were performed using the same conditions and the same 
substrate (Ac-DEVD-AMC, 2mM stock solution in DMSO).  The enzyme stock solution 
was 100 nM (final concentration in the well: 50 nM) in the assay buffer.  The inhibitor 
stock solution concentrations varied from 5 x 10-3 M to 2.42 x 10-6 M in DMSO.  
G. Salvesen determined the KM values for Ac-DEVD-AMC with caspase-3 (KM = 
9.7 µM), caspase-6 (KM = 236.35 µM), and caspase-8 (KM = 6.79 µM).  The k2 values are 
11.309-fold higher than the apparent rate for caspase-3 because of the 100 mM [S] and 
KM = 9.7 µM.  The k2 values are 1.4231-fold higher than the apparent rate for caspase-6 
because of the 100 mM [S] and KM = 236.35 µM.  The k2 values are 15.7275-fold higher 
than the apparent rate for caspase-8 because of the 100 mM [S] and KM = 6.79 µM.   
Gingipain K and Clostripain Assays.  The clostripain and gingipain assays were 
performed by Brian Rukamp in our laboratory.  Clostripain was purchased from Sigma 
Chemical Co. (St. Louis, MO) as a solid which was dissolved in an activation solution of 
8 mM DTT at a concentration of 5.962 µM and stored at -20 °C prior to use.  The 
inhibition of clostripain began with the addition of 25 µl of stock inhibitor solution 
(concentration varies by inhibitor) in DMSO to a solution of 250 µl of 20 mM Tris/HCl, 
10 mM CaCl2, 0.005% Brij 35, 2 mM DTT buffer at pH 7.6 (clostripain buffer) and 5 µl 
of the stock enzyme solution.  Aliquots (25 µl) of this incubation mixture were taken at 
various time points and added to a solution containing 100 µl of the clostripain buffer and 
5 µl of Z-Phe-Arg-AMC substrate solution (0.139 mM) in DMSO.  The enzymatic 
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activity was monitored by following the change in fluorescence at 465 nm.  The all data 
obtained was processed by pseudo-first order kinetics. 
Gingipain K stock solution was obtained from Jan Potempa's lab (University of 
Georgia, Athens, GA) in a buffer containing 20 mM Bis-Tris, 150 mM NaCl, 5 mM 
CaCl2, 0.02% NaN3, at pH 8.0 at a concentration of 9 µM, which was stored at -20 °C 
prior to use.  Before using the enzyme, an aliquot (1 µl) of the stock enzyme was diluted 
to a concentration of 4.61 nM in 1.951 ml of a solution of 0.2 M Tris/HCl, 0.1 M NaCl, 5 
mM CaCl2, 2 mM DTT at pH 8.0 (gingipain K buffer) and kept at 0 °C.  This solution 
was used only for one day, as freezing the enzyme at this concentration destroyed all 
activity.  The inhibition of gingipain K began with the addition of 25 µl of stock inhibitor 
solution (concentration varies by inhibitor) in DMSO to 244 µl of the diluted enzyme 
solution (4.61 nM) in gingipain K buffer warmed to rt.  Aliquots (20 µl) of this were 
taken at various time points and added to a solution containing 100 µl of the gingipain K 
buffer and 5 µl of Suc-Ala-Phe-Lys-AMC · TFA as the substrate (0.910 mM stock) in 
DMSO.  The enzymatic activity was monitored by following the change in fluorescence 
at 465 nm.  The data for gingipain K was processed by pseudo-first order kinetics. 
Legumain Assays.  The legumain assays were performed by Conor Caffrey and 
Elizabeth Hansell at Jim McKerrow’s laboratory at UCSF.  The zymogen form of 
schistosome legumain SmAE was expressed in Pichia56.  The lyophilized enzyme (50-
100 mg) was reconstituted in 1.5 mL 0.5 M sodium acetate, pH 4.5 containing 4 mM 
DTT, and left to stand at 37 °C for 3-4 hours to allow for auto-activation of the zymogen.  
In a black 96-well microtiter plate, 50 µL of activated enzyme was added to an equal 
volume of 0.1 M citrate-phosphate buffer pH 6.8 containing 4 mM DTT.  The inhibitors, 
 104
added as 1 µL aliquots (serial water dilutions of DMSO stock solutions, 2 to 0.00002 µM 
(final)), were preincubated with the protease at room temperature for 20 min.  After 
incubation, 100 uL of the same buffer containing 20 µM substrate (Cbz-Ala-Ala-Asn-
AMC) was added to the wells and the reaction monitored for 20 minutes.  A plot of the 
RFU/min versus the inhibitor concentration (µM) permitted calculation of an IC50 value. 
Pichia cell culture medium containing recombinant S. mansoni pro-legumain was 
incubated overnight at room temperature in 0.3 M sodium acetate, pH 4.5, 2 mM DTT to 
allow autoactivation of the endogenous zymogen.  Inhibitor (1 µl) at 6 concentrations (to 
yield 0 to 1 µM [final]) was spotted into a 96-well black microtiter plate.  To this was 
added 180 µl 0.1 M citrate-phosphate buffer, pH 6.8, containing 2 mM DTT and 20 µM 
Cbz-AAN-AMC substrate.  Activated legumain (20 µl) was added to the mix and the 
progress of inhibition followed every 2 seconds for 30 minutes at 25 °C (Molecular 
Devices Flex Station fluorometer in the injection mode; ex 355/em 460).  The kinact/Ki 
values were determined using non-linear regression analysis (GraphPad Prism 3.X) and 
corrected for substrate (1+S/KM: 1 + 20/60 = 1.33).   
Stability Studies of Aza-peptidyl Michael Acceptors.  An aliquot (15 µL)  
of 10 mM aza-peptidyl Michael acceptors in DMSO was added to legumain buffer (385 
µL, pH 5.8 or 6.8) containing DTT (3.4 mM) and the reaction of the double bond of the 
inhibitor with DTT was monitored spectrophotometrically at 250 nm over time.  The kobs 
was obtained from pseudo first-order rate plots of ln (At/A0) versus time and the half-
lives were derived from t1/2 = ln 2/kobs.  
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General Procedure for Mixed Anhydride Coupling. 
N-Benzyloxycarbonylalanylalanyl Methyl Ester  (Cbz-Ala-Ala-OMe).   N-
Methylmorpholine (2 mmol) was added to Cbz-Ala-OH in CH2Cl2 at -15 ºC followed by 
isobutyl chloroformate.  N-Methylmorpholine (2 mmol) was added to a cooled solution (-
15 ºC) of HCl·H-Ala-OMe (2 mmol) in CH2Cl2.  This solution was added to the Cbz-Ala-
OH mixture, which had been stirring at -15 ºC.  The mixture was continued to stir at -15 
ºC for 30 minutes, then warmed to room temperature and continued to stir over night.  
The amount of solvent was doubled, then washed with citric acid (10 %, 3 x 50 ml), 
saturated NaHCO3 (3 x 50 ml), and brine (3 x 50 ml), and finally dried (MgSO4).  The 
solvent was evaporated to give Cbz-Ala-Ala-OMe as a pure white solid in good yield (90 
%).  1H NMR (CDCl3): 1.18 (t, 9H, CH3), 3.5 (s, 3H, OCH3), 4.1 (m, 1H, α-H), 4.2 (m, 
1H, α-H), 5.03 (m, 2H, Cbz), 5.18 (m, 1H, NH), 7.22-7.40 (m, 5H, Ph), 7.9 (m, 1H, NH). 
N-Benzyloxycarbonylalanylalanyl Hydrazide (Cbz-Ala-Ala-NHNH2) (3) was 
synthesized from Cbz-Ala-Ala-OMe by hydrazinolysis.  Anhydrous hydrazine (10 eq) 
was added to a solution of Cbz-Ala-Ala-OMe (1 eq) in MeOH at room temperature, and 
the resulting mixture was then stirred at room temperature for 16 hours.  Excess 
hydrazine and solvent were removed by evaporation.  The resulting residue was washed 
with ethanol and ether to give Cbz-Ala-Ala-NHNH2 as a white solid (57% yield).  1H 
NMR (DMSO-d6): 1.1-1.3 (d, CH3), 4.0-4.1 (m, 1H, α-H), 4.1-4.3 (m, 2H, α-H and NH), 
5.05 (s, 2H, Cbz), 7.3-7.4 (m, 5H, Ph), 7.5 (d, 1H, NH), 7.9 (d, 1H, NH), 9.05 (s, 1H, 
NH). 
N1-(N-Benzyloxycarbonylalanylalanyl)-N2-ethoxycarbonylmethylhydrazine 
(Cbz-Ala-Ala-NHNHCH2COOEt).  Ethyl bromoacetate (1.1 eq) was added dropwise to 
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a stirred solution of Cbz-Ala-Ala-NHNH2 (1 eq) and NMM (1.1 eq) in DMF that was 
cooled to -10 °C.  The resulting solution was stirred for 30 min at -10 °C, after which the 
mixture was allowed to react at room temperature for 36 hours.  The DMF was 
evaporated, and the residue was purified on a silica gel column using 1:9 MeOH:CH2Cl2 
as the eluting solvent system to give the ethyl ester as a white solid (yield 36%).  1H 
NMR (DMSO-d6): 1.18 (t, 9H, CH3), 3.5 (d, 2H, NCH2COOEt), 4.0-4.15 (m, 3H, α-H 
and OCH2CH3), 4.2 (m, 1H, α-H), 5.03 (m, 2H, Cbz), 5.18 (m, 1H, NH), 7.22-7.40 (m, 
5H, Ph), 7.4-7.5 (d, 1H, NH), 7.9 (m, 1H, NH), 9.35 (m, 1H, NH).  MS (FAB) m/z 395 
[(M + 1)+]. 
N1-(N-Benzyloxycarbonylalanylalanyl)-N2-carbamoylmethylhydrazine (Cbz-
Ala-Ala-NHNHCH2CONH2) (4).  The ethyl ester Cbz-Ala-Ala-NHNHCH2COOEt (1 
eq) was dissolved in a 9 M solution (100 eq) of NH3 in methanol and a small amount of 
DMF, and allowed to stir on an ice bath.  To this solution was added catalytic NaCN (0.1 
eq).  The flask was closed with a rubber septum and allowed to stir at 0 °C for three days.  
The solvent was evaporated and the product was precipitated with 1:9 MeOH:CH2Cl2 and 
methanol to yield a white solid (68% yield).  1H NMR (DMSO-d6): 1.18 (d, 6H, CH3), 
3.2 (d, 2H, NCH2CONH2), 4.0-4.12 (m, 1H, α-H), 4.2 (m, 1H, α-H), 5.03 (m, 2H, Cbz), 
5.22 (m, 1H, NH), 7.18 (d, 1H, NH), 7.3-7.5 (m, 6H, Ph and NH), 8.0 (m, 1H, NH), 9.38 
(m, 1H, NH).  MS (FAB) m/z 366 [(M + 1)+].  HRMS (FAB) Calcd. for C16H24N5O5: 
366.17774.  Observed m/z 366.17665. 
General Procedure: HOBt/EDC Coupling Method.  To a stirred solution of the 
peptidyl hydrazide precursor (1 eq) (9) and the epoxysuccinate, fumarate and acrylic acid 
precursor (2 eq) (13a – x and 15a – f), HOBt (2 eq) and EDC (2 eq) was added.  The 
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mixture was allowed to react for 16 h at room temperature.  The DMF was evaporated, 
and the residue was redissolved in EtOAc.  The organic layer was washed with 2% citric 
acid, saturated NaHCO3, saturated NaCl, dried over MgSO4, and concentrated.  
Chromatography on a silica gel column using 10% MeOH/CH2Cl2 as the eluent afforded 
the aza-peptidyl fumarate, epoxysuccinates or acrylate derivatives.  MS and 1H NMR 
(CDCl3 or DMSO-d6) were consistent with the proposed structures. 
(2S,3S)-3-(N2-(N-Benzyloxycarbonylalanylalanyl)-N1-
carbamoylmethylhydrazinocarbonyl)oxirane-2-carboxylic Acid Phenethyl Ester 
(11c, Cbz-Ala-Ala-AAsn-(2S,3S)-EP-COOCH2CH2Ph).  This compound was obtained 
using the HOBt/EDC coupling method and purified by column chromatography on silica 
gel using 10% MeOH/CH2Cl2 as the eluent and then recrystallized from EtOAc/ hexane 
to give a white powder (9% yield).  1H-NMR ((CD3)2CO): 1.34 (m, 6H, 2 x Ala-CH3), 
2.87 (s, 2H, NCH2CO), 2.98 (t, 2H, CH2-Ph),  3.48 (s, 1H, EP), 4.04 (m, 1H, α-H), 4.17 
(m, 1H, α-H), 4.28-4.43 (m, 3H, CH2-CH2-Ph and EP), 5.10 (m, 2H, Cbz), 6.57 (s, 1H, 
NH), 6.65 (s, 1H, NH), 7.19-7.38 (m, 10H, 2 x Ph), 7.77 (s, 1H, NH), 9.89 (s, 1H, NH). 
MS (ESI) m/z 584 [(M + 1)+].  HRMS (ESI) calculated for C28H34N5O9 : 584.233.  
Observed m/z 584.235653.  Anal. Calcd. for  C28H33N5O9·0.1H2O·0.5EtOAc: C, 57.18; 
H, 6.06; N, 11.11.  Found: C, 56.96; H, 5.88; N, 11.08.  
 (2S,3S)-3-(N2-(N-Benzyloxycarbonylalanylalanyl)-N1-
carbamoylmethylhydrazinocarbonyl)oxirane-2-carboxylic Acid N,N-Dibutyl-amide 
(11g, Cbz-Ala-Ala-AAsn-(2S,3S)-EP-CON(nBu)2).  This compound was obtained using 
the HOBt/EDC coupling method and purified by column chromatography on silica gel 
using 1:9 MeOH/CH2Cl2 as the eluent and then recrystallized from EtOAc/ hexane to 
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give a white powder (26% yield).  1H-NMR (DMSO-d6): 0.84-0.90 (m, 6H, 2 x N-CH2-
CH2-CH2-CH3), 1.17-1.27 (m, 10H, 2 x Ala-CH3 and 2 x N-CH2-CH2-CH2-CH3), 1.41 (t, 
2H, N-CH2-CH2-CH2-CH3), 1.51 (t, 2H, N-CH2-CH2-CH2-CH3), 3.20-3.32 (m, 7H, 
NCH2CO and CH2-N-CH2 and EP), 3.63 (s, 1H, EP), 4.04 (m, 1H, α-H), 4.26 (m, 1H, α-
H ), 4.99 (m, 2H, Cbz), 7.21 (s, 1H, NH), 7.33 (m, 5H, Ph), 7.49 (s, 1H, NH), 8.15 (d, 
1H, NH), 10.62 (s, 1H, NH).  MS (ESI) m/z 591 [(M + 1)+].  HRMS (ESI) calculated for 
C28H43N6O8 : 591.3059.  Observed m/z 591.314238.  Anal. Calcd. for  C28H42N6O8·1H2O: 
C, 55.25; H, 7.29; N, 13.81.  Found: C, 55.32; H, 7.10; N, 13.80.  
 (2S,3S)-3-(N2-(N-Benzyloxycarbonylalanylalanyl)-N1-
carbamoylmethylhydrazinocarbonyl)oxirane-2-carboxylic Acid N,N-
Methylbenzylamide (11h, Cbz-Ala-Ala-AAsn-(2S,3S)-EP-CON(Me)-Bzl).  This 
compound was obtained using the HOBt/EDC coupling method and purified by column 
chromatography on silica gel using 10% MeOH/CH2Cl2 as the eluent and then 
recrystallized from EtOAc/hexane to give a white powder (10% yield).  1H-NMR 
(DMSO-d6): 1.11-1.27 (m, 6H, 2 x Ala-CH3), 2.95 (d, 3H, N-CH3), 3.20-3.32 (d, 3H, 
NCH2CO and EP), 3.34 (s, 1H, EP), 4.04-4.61 (m, 4H, 2 x α-H, CH2-Ph), 5.02 (m, 2H, 
Cbz), 7.21 (s, 1H, NH), 7.33 (m, 5H, Ph), 7.42 (d, 1H, NH), 8.20 (d, 1H, NH), 10.73 (s, 
1H, NH).  MS (ESI) m/z 583 [(M + 1)+].  HRMS (ESI) calculated for C28H35N6O8 : 
583.2567.  Observed m/z 583.251638.  Anal. Calcd. for  C28H34N6O8·1.3H2O: C, 55.49; 
H, 6.09; N, 13.87.  Found: C, 55.45; H, 5.89; N, 13.85. 
 trans-3-(N2-(N-Benzyloxycarbonylalanylalanyl)-N1-
carbamoylmethylhydrazinocarbonyl)oxirane-2-phenethyl (11i, Cbz-Ala-Ala-AAsn-
trans-EP-CH2-CH2-Ph).  This compound was obtained using the HOBt/EDC coupling 
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method and purified by column chromatography on silica gel using 1:9 MeOH/CH2Cl2 as 
the eluent and then recrystallized from EtOAc/ hexane to give a white powder (40% 
yield).  1H-NMR (DMSO-d6): 1.15-1.17 (d, 3H, CH3), 1.23-1.25 (d, 3H, CH3), 1.67 (m, 
2H, CH2-CH2-Ph), 2.65 (m, 2H, CH2-CH2-Ph), 2.86 (m, 1H, EP), 3.28-3.31 (d, 2H, 
NCH2CO), 3.63 (s, 1H, EP), 4.01 (m, 1H, α-H), 4.24 (m, 1H, α-H ), 4.99 (m, 2H, Cbz), 
7.13 (s, 1H, NH), 7.17-7.41 (m, 10H, 2 x Ph), 7.48 (s, 1H, NH), 8.17 (d, 1H, NH), 10.67 
(s, 1H, NH).  MS (ESI) m/z 540 [(M + 1)+].  HRMS (ESI) calculated for C27H34N5O7 : 
540.2392.  Observed m/z 540.2458.  Anal. Calcd. for C27H33N5O7·0.2H2O: C, 59.70; H, 
6.20; N, 12.89.  Found: C, 59.46; H, 6.15; N, 12.76.  
4-Chlorophenyl-trans-oxirane Carboxylic Acid (HOOC-EP-Ph-Cl).  The 
starting 4-chloro-trans-cinnamic acid (1 eq) was cooled to –20 °C in dry methanol.  
Thionyl chloride (3 eq) was added dropwise to the cooled solution over one hour.  The 
mixture was stirred at –15 °C for an additional 30 minutes and subsequently stirred at 
room temperature over night.  Evaporation of the volatiles yielded the methyl ester 
MeOOC-CH=CH-Ph-Cl as a white solid (89% yield).  Without further purification the 
methyl ester was subjected to epoxidation.  An anhydrous solution of t-butyl 
hydroperoxide in toluene (3.3 M, 1.5 eq) was added to freshly distilled THF at -78 °C 
under argon.  A solution of butyllithium in pentane (1.7 M, 1.1 eq) was added drop wise.  
The mixture was stirred at -78 °C for 5 minutes when a solution of MeOOC-CH=CH-Ph-
Cl (1 eq) in tetrahydrofuran was added drop wise.  The reaction was stirred at -78 °C for 
30 minutes then at room temperature for 16 hours.  Solid sodium sulfite was added and 
the mixture was continued to stir for 20 minutes, then diluted with ether and filtered over 
celite.  The solvent was evaporated, and the crude residue was subjected to column 
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chromatography on silica gel using 3:1 hexane/EtOAc as the eluent.  1H-NMR (CDCl3): 
3.47 (d, 1H, EP), 3.83 (s, 3H, CH3), 4.08 (d, 1H, EP), 7.21 (d, 2H, Ph), 7.33 (d, 2H, Ph).  
Standard deblocking of the methyl ester with sodium hydroxide (1 N) followed by acidic 
workup (1 N HCl) produced the 3-(4-chlorophenyl) glycidic acid.  1H-NMR (DMSO-d6): 
3.65 (s, 1H, EP), 4.14 (s, 1H, EP), 7.37 (d, 2H, Ph), 7.43 (d, 2H, Ph).  
trans-3-(N2-(N-Benzyloxycarbonylalanylalanyl)-N1-
carbamoylmethylhydrazinocarbonyl)oxirane-2-(4-chlorophenyl) (11j, Cbz-Ala-Ala-
AAsn-trans-EP-Ph-Cl).  This compound was obtained using the HOBt/EDC coupling 
method and purified by column chromatography on silica gel using 1:9 MeOH/CH2Cl2 as 
the eluent and then recrystallized from EtOAc/CH2Cl2 to give a white powder (50% 
yield).  1H-NMR (DMSO-d6): 1.02-1.03 (d, 3H, CH3), 1.14-1.18 (d, 3H, CH3), 3.29-3.31 
(d, 2H, NCH2CO), 3.94-4.16 (m, 4H, epoxy and 2 x α-H), 4.99 (m, 2H, Cbz), 7.20 (s, 
1H, NH), 7.32 (m, 9H, Ph and Ph-Cl), 8.07-8.09 (d, 1H, NH), 10.64 (s, 1H, NH).  HRMS 
(ESI) calculated for C25H29N5O7Cl : 546.1758.  Observed m/z 546.175551.  Anal. Calcd. 
for  C25H28N5O7Cl·0.2H2O: C, 54.63; H, 5.21; N, 12.74.  Found: C, 54.65; H, 5.25; N, 
12.47. 
General Procedure: Mixed Anhydride Coupling Method.  Coupling of the 
amine precursors to the fumarates was accomplished using the mixed anhydride coupling 
method.  To a solution of the fumarate (1 eq) in CH2Cl2 at -20 °C was added N-
methylmorpholine (NMM, 1 eq) followed by isobutyl chloroformate (IBCF, 1 eq).  After 
the reaction mixture was allowed to stir for 30 min, the amine (1 eq) was added to the 
mixture.  Hydrochloride salts of the amine were pretreated with NMM (1 eq) at –20 °C in 
CH2Cl2 prior to addition.  After 30 min the reaction was continued to stir for 4 hours at 
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room temperature.  The DMF was evaporated and the residue was washed and purified 
using the same procedure as described above for the EDC/HOBt coupling method.  MS 
and 1H NMR (DMSO-d6 or CDCl3) were consistent with the proposed structures.  
trans-3-Benzyloxycarbonylacrylic Acid or Monobenzyl Fumarate 
(HOOCCH=CHCOOBzl).  Equimolar amounts of fumaric acid and benzyl alcohol were 
dissolved in anhydrous DMF.  NMM (1 eq) was added at 0 ºC followed by EDC after 15 
minutes.  The reaction was stirred over night at room temperature.  DMF was evaporated 
and the crude residue was redissolved in EtOAc.  The product was extracted with 
saturated aqueous NaHCO3.  The aqueous layer was then acidified with 1N HCl to pH 2.  
The product was extracted with EtOAc, and the organic layer was washed with water and 
dried (MgSO4).  The solvent was evaporated and the crude residue was subjected to 
column chromatography (MeOH/CH2Cl2) to give a white powder (51% yield).  1H-NMR 
(DMSO-d6): 5.21 (s, 2H, CH=CH-COOCH2Ph), 6.73 (s, 2H, CH=CH-COOCH2Ph), 
7.29-7.43 (m, 5H, Ph).  MS (ESI) m/z 207 [(M + 1)+]. 
N2-(N-Benzyloxycarbonylalanylalanyl)-N1-trans-(3-
benzyloxycarbonylacryloyl)-N1-carbamoylmethylhydrazine  (15b, Z-Ala-Ala-AAsn-
CH=CHCOOBzl).  This compound was obtained using the HOBt/EDC coupling method 
and purified by column chromatography on silica gel using 10% MeOH/CH2Cl2 as the 
eluent and then recrystallized from EtOAc/hexane to give a white powder (20% yield).  
1H-NMR ((CD3)2CO): 1.37 (m, 6H, 2 x Ala-CH3), 2.88 (s, 2H, NCH2CO), 4.21-4.24 (m, 
1H, α-H), 4.50 (m, 1H, α-H), 5.10 (m, 2H, Cbz), 5.24 (s, 2H, O-CH2-Ph), 6.58-6.33 (m, 
2H, NH and CH=CH), 6.74-6.88 (d, 1H, CH=CH), 7.31-7.44 (m, 11H, 2 x Ph and NH), 
7.76 (s, 1H, NH), 8.16 (d, 1H, NH), 9.89 (s, 1H, NH).  MS (ESI) m/z 554 [(M + 1)+].  
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HRMS (ESI) calculated for C27H32N5O8 : 554.2219. Observed m/z 554.225088.    Anal. 
Calcd. for  C27H31N5O8·0.2H2O: C, 58.20; H, 5.68; N, 12.57.  Found: C, 58.16; H, 5.60; 
N, 12.47. 
trans-3-Diethylcarbamoylacrylic Acid Ethyl Ester (EtOOCCH=CHCONEt2)  
was obtained by mixed anhydride coupling of equimolar amounts of monoethyl fumarate 
and diethylamine.  The crude product was recrystallized from hexane/EtOAc to give a 
white powder (95% yield).  1H-NMR (CDCl3): 1.17-1.21 (t, 3H, N-CH2CH3), 1.22-1.24 
(t, 3H, N-CH2CH3), 1.32 (t, 3H, CH3CH2O ), 3.40-3.47 (m, 4H, 2 x N-CH2), 4.24-4.26 (q, 
2H, CH3CH2O), 6.78-6.82 (d, 1H, J = 14.8 Hz, CH=CHCON), 7.31-7.35 (d, 1H, J = 14.8 
Hz, CH=CHCON).  
trans-3-Diethylcarbamoylacrylic Acid (13a, HOOCCH=CHCONEt2). 
EtOOCCH=CHCONEt2 was hydrolyzed in MeOH using NaOH (1M aqueous, 1.1 eq) 
under standard deblocking conditions to give a white crystalline solid (53% yield). 
N2-(N-Benzyloxycarbonylalanylalanyl)-N1-carbamoylmethyl-N1-trans-(3-
diethylcarbamoylacryloyl)hydrazine  (14a, Z-Ala-Ala-AAsn-CH=CHCONEt2).  This 
compound was obtained using the HOBt/EDC coupling method and purified by column 
chromatography on silica gel using 10% MeOH/CH2Cl2 as the eluent and then 
recrystallized from EtOAc/hexane to give a white powder (11% yield).  1H-NMR 
(DMSO-d6): 1.02-1.05 (t, 3H, NCH2CH3), 1.08-1.11 (t, 3H, NCH2CH3), 1.17-1.19 (d, 2H, 
Ala-CH3), 1.24-1.26 (d, 2H, Ala-CH3), 3.20-3.32 (d, 6H, NCH2CO and 2 x N-CH2), 4.02-
4.07 (m, 1H, α-H), 4.27-4.31 (m, 1H, α-H), 4.99 (m, 2H, Cbz), 7.00-7.04 (d, 1H, 
CH=CHCON), 7.18 (s, 1H, NH), 7.33 (m, 6H, Ph and CH=CHCON), 7.39 (d, 1H, NH), 
8.20 (d, 1H, NH), 10.68 (s, 1H, NH).  MS (ESI) m/z 519 [(M + 1)+].  HRMS (ESI) 
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calculated for C24H35N6O7 : 519.2608.  Observed m/z 519.2657.  Anal. Calcd. for  
C24H34N6O7·0.7H2O: C, 54.27; H, 6.72; N, 15.82.  Found: C, 54.25; H, 6.69; N, 15.87.  
trans-3-Dibutylcarbamoylacrylic Acid Ethyl Ester 
(EtOOCCH=CHCON(nBu)2)  was obtained by mixed anhydride coupling of equimolar 
amounts of monoethyl fumarate and dibutylamine.  The crude product was recrystallized 
from hexane/EtOAc to give a white powder (95% yield).  1H-NMR (CDCl3): 0.95 (m, 
6H, 2 x nBu-CH3), 1.32 (m, 7H, 2 x CH2CH2CH2CH3 and CH3CH2O ), 1.51-1.59 (m, 4H, 
2 x CH2CH2CH2CH3), 3.33 (t, 2H, N-CH2), 3.39 (t, 2H, N-CH2), 4.24 (q, 2H, CH3CH2O), 
6.76-6.81 (d, 1H, J = 15.6 Hz, CH=CHCON), 7.33-7.36 (d, 1H, J = 15.2 Hz, 
CH=CHCON).  
trans-3-Dibutylcarbamoylacrylic Acid (13b, HOOCCH=CHCON(nBu)2). 
EtOOCCH=CHCON(nBu)2 was hydrolyzed in MeOH using NaOH (1M aqueous, 1.1 eq) 
under standard deblocking conditions to give a clear, colorless syrup (80% yield).  1H-
NMR (CDCl3): 0.95 (m, 6H, 2 x nBu-CH3), 1.30-1.37 (m, 4H, 2 x CH2CH2CH2CH3), 
1.53-1.59 (m, 4H, 2 x CH2CH2CH2CH3), 3.33 (t, 2H, N-CH2), 3.39 (t, 2H, N-CH2), 6.79-
6.83 (d, 1H, J = 15.6 Hz, CH=CHCON), 7.33-7.36 (d, 1H, J = 15.2 Hz, CH=CHCON). 
N2-(N-Benzyloxycarbonylalanylalanyl)- N1-carbamoylmethyl-N1-trans-(3-
dibutylcarbamoylacryloyl)hydrazine (14b, Z-Ala-Ala-AAsn-CH=CHCON(nBu)2). 
This compound was obtained using the HOBt/EDC coupling method and purified by 
column chromatography on silica gel using 10% MeOH/CH2Cl2 as the eluent and then 
recrystallized from EtOAc/hexane to give a white powder (15% yield).  1H-NMR 
(DMSO-d6): 0.95 (m, 6H, 2 x nBu-CH3), 1.11-1.27 (m, 6H, 2 x Ala-CH3), 1.30-1.37 (m, 
4H, 2 x CH2CH2CH2CH3), 1.53-1.59 (m, 4H, 2 x CH2CH2CH2CH3), 3.20-3.32 (d, 6H, 
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NCH2CO and 2 x N-CH2), 4.00-4.01 (m, 1H, α-H), 4.25-4.30 (m, 1H, α-H), 4.99 (m, 2H, 
Cbz), 7.00-7.04 (d, 1H, CH=CHCON), 7.21 (s, 1H, NH), 7.33 (m, 6H, Ph and 
CH=CHCON), 7.42 (d, 1H, NH), 8.20 (d, 1H, NH), 10.73 (s, 1H, NH).  MS (FAB) m/z 
575 [(M + 1)+].  HRMS (FAB) calculated for C28H43N6O7 : 575.32052.  Observed m/z 
575.31932.  Anal. Calcd. for  C28H42N6O7·0.8H2O: C, 57.16; H, 7.35; N, 14.28.  Found: 
C, 57.18; H, 7.35; N, 14.28.  
trans-3-(1-Piperidyloxo)acrylic Acid Ethyl Ester (EtOOCCH=CHCO-Pip) 
was obtained by mixed anhydride coupling of equimolar amounts of monoethyl fumarate 
and piperidine to give a clear syrup (99% yield).  
trans-3-(1-Piperidyloxo)acrylic Acid (13c, HOOCCH=CHCO-Pip).   
EtOOCCH=CHCO-Pip was hydrolyzed in MeOH using NaOH (1M aqueous, 1.1 eq) 
under standard deblocking conditions to give a clear, colorless syrup which was 
recrystallized over night from hexane/EtOAc to give a white powder (27% yield).  1H-
NMR (DMSO-d6): 1.46-1.60 (m, 6H, 3 x piperidine CH2), 3.45-3.49 (m, 4H, CH2-N-
CH2), 6.41-6.44 (d, 1H, J = 15.2 Hz, CH=CHCON), 7.33-7.37 (d, 1H, J = 15.2 Hz, 
CH=CHCON). 
N2-(N-Benzyloxycarbonylalanylalanyl)-N1-carbamoylmethyl-N1-trans-(3-(1-
piperidyloxo)acryloyl)hydrazine  (14c, Z-Ala-Ala-AAsn-CH=CHCO-Pip).  This 
compound was obtained using the HOBt/EDC coupling method and purified by column 
chromatography on silica gel using 10% MeOH/CH2Cl2 as the eluent and recrystallized 
from hexane/EtOAc to give a white powder (10% yield).  1H-NMR ((CD3)CO): 1.28 (m, 
2H, piperidine-CH2), 1.37 (d, 3H, Ala-CH3), 1.41 (d, 3H, Ala-CH3), 1.52-1.67 (m, 4H, 2 
x piperidine-CH2), 2.80 (s, 2H, NCH2CO), 3.55 (m, 4H, CH2-N-CH2), 4.24 (m, 1H, α-H), 
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4.50 (m, 1H, α-H), 5.10 (m, 2H, Cbz), 7.11-7.15 (d, 1H, J = 14.8 Hz, CH=CHCON), 
7.30-7.44 (m, 7H, CH=CHCON and Ph and NH), 7.77 (s, 1H, NH), 9.82 (s, 1H, NH).  
MS (ESI) m/z 531 [(M + 1)+].  HRMS (ESI) calculated for C25H35N6O7 : 531.2532.  
Observed m/z 531.256723.  Anal. Calcd. for C25H34N6O7·0.7H2O: C, 55.32; H, 6.50; N, 
15.48.  Found: C, 55.26; H, 6.43; N, 15.28.  
trans-3-Phenylcarbamoylacrylic Acid Ethyl Ester (EtOOCCH=CHCONHPh) 
was obtained by mixed anhydride coupling of equimolar amounts of monoethyl fumarate 
and aniline to give a white solid (59% yield).  1H-NMR (CDCl3): 1.34 (t, 3H, CH3CH2), 
4.29 (q, 2H, CH3CH2), 6.93-6.97 (d, 1H, J = 15.2 Hz, CH=CHCON), 7.10-7.14 (d, 1H, J 
= 15.2 Hz, CH=CHCON), 7.15 (t, 1H, Ph), 7.34 (t, 2H, Ph), 7.61 (d, 2H, Ph), 7.85 (s, 1H, 
NH). 
trans-3-Phenylcarbamoylacrylic Acid (13d, HOOCCH=CHCONHPh).  
EtOOCCH=CHCONHPh  was hydrolyzed in MeOH using NaOH (1M aqueous, 1.1 eq) 
under standard deblocking conditions to give a white solid (81% yield).  1H-NMR 
(DMSO-d6): 6.61-6.65 (d, 1H, J = 15.2 Hz, CH=CHCON), 7.02-7.14 (m, 1H, 
CH=CHCON), 7.14-7.31 (m, 2H, Ph), 7.32 (t, 2H, Ph), 7.66 (d, 2H, Ph), 10.47 (s, 1H, 
NH). 
N2-(N-Benzyloxycarbonylalanylalanyl)-N1-carbamoylmethyl-N1-trans-(3-
phenylcarbamoylacryloyl)hydrazine (14d, Z-Ala-Ala-AAsn-CH=CHCONHPh).  
This compound was obtained using the HOBt/EDC coupling method with minimal 
NaHCO3 washing during the workup.  The product was isolated as a yellow solid without 
chromatography by recrystallization from 10% MeOH/CH2Cl2 (21% yield).  1H-NMR 
(DMSO-d6): 1.18-1.27 (m, 6H, 2 x Ala-CH3), 3.20-3.32 (d, 2H, NCH2CO), 4.04-4.08 (m, 
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1H, α-H), 4.28-4.31 (m, 1H, α-H), 4.99 (m, 2H, Cbz), 7.05-7.42 (m, 11H, 2 x Ph, NH 
CH=CHCON and CH=CHCON), 7.63-7.65 (d, 2H, Ph), 7.52 (s, 1H, NH), 8.15 (d, 1H, 
NH), 10.42 (s, 1H, NH), 10.72 (s, 1H, NH).  MS (ESI) m/z 539 [(M + 1)+].  HRMS (ESI) 
calculated for C26H31N6O7 : 539.2208.  Observed m/z 539.2254.  Anal. Calcd. for  
C26H30N6O7: C, 57.98; H, 5.61; N, 15.60.  Found: C, 57.73; H, 5.58; N, 15.72.  
trans-3-Benzylcarbamoylacrylic Acid Ethyl Ester 
(EtOOCCH=CHCONHBzl) was obtained by mixed anhydride coupling of equimolar 
amounts of monoethyl fumarate and benzylamine to give a white powder (72% yield).  
trans-3-Benzylcarbamoylacrylic Acid (13e, HOOCCH=CHCONHBzl).  
EtOOCCH=CHCONHBzl was hydrolyzed in MeOH using NaOH (1M aqueous, 1.1 eq) 
under standard deblocking conditions to give a white solid (81% yield).  1H-NMR 
(DMSO-d6): 4.37 (d, 2H, N-CH2-Ph), 6.52-6.56 (d, 1H, J = 15.2 Hz, CH=CHCON), 
6.94-6.98 (d, 1H, J = 15.6 Hz, CH=CHCON), 7.14-7.31 (m, 5H, Ph), 8.97 (t, 1H, NH). 
N2-(N-Benzyloxycarbonylalanylalanyl)-N1-carbamoylmethyl-N1-trans-(3-
benzylcarbamoylacryloyl)hydrazine (14e, Z-Ala-Ala-AAsn-CH=CHCONHBzl).  
This compound was obtained using the HOBt/EDC coupling method with minimal 
washing during the workup and purified by recrystallization from ice cold EtOAc without 
column chromatography (18% yield).  1H-NMR (DMSO-d6): 1.17-1.26 (m, 6H, 2 x Ala-
CH3), 3.30-3.32 (d, 2H, NCH2CO), 4.02-4.07 (m, 1H, α-H), 4.27-4.32 (m, 1H, α-H), 
4.35-4.36 (d, 2H, CH2Ph), 4.99 (m, 2H, Cbz), 6.89-6.92 (d, 1H, J = 14.2 Hz, 
CH=CHCON), 7.06-7.10 (d, 1H, J = 14.8 Hz, CH=CHCON), 7.16-7.41 (m, 11H, 2 x Ph 
and NH), 7.42 (d, 1H, NH), 8.16 (d, 1H, NH), 8.94 (t, 1H, NH), 10.72 (s, 1H, NH).  MS 
(ESI) m/z 553 [(M + 1)+].  HRMS (ESI) calculated for C27H33N6O7 : 553.2397.  Observed 
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m/z 553.2411.   Anal. Calcd. for  C27H32N6O7·0.3H2O: C, 58.12; H, 5.89; N, 15.06.  
Found: C, 58.07; H, 5.81; N, 15.03.  
trans-3-(4-Fluorobenzylcarbamoyl)acrylic Acid Ethyl Ester 
(EtOOCCH=CHCONH-Bzl-4-F) was obtained by mixed anhydride coupling of 
equimolar amounts of monoethyl fumarate and 4-fluoro benzylamine to give a pink solid 
(66% yield).  1H-NMR (CDCl3):  1.32 (t, 3H, CH2CH3), 4.21 (q, 2H, CH2CH3), 4.47 (d, 
2H, N-CH2-Ph), 6.52-6.56 (d, 1H, J = 15.2 Hz, CH=CHCON), 6.94-6.98 (d, 1H, J = 15.6 
Hz, CH=CHCON), 6.99-7.04 (m, 2H, Ph), 7.20-7.27 (m, 2H, Ph). 
  trans-3-(4-Fluorobenzylcarbamoyl)acrylic Acid (13f, HOOCCH=CHCONH-
Bzl-4-F).  EtOOCCH=CHCONH-Bzl-4-F was hydrolyzed in MeOH using NaOH (1M 
aqueous, 1.1 eq) under standard deblocking conditions to give a clear, colorless syrup 
(45% yield).  1H-NMR (DMSO-d6): 4.34-4.35 (d, 2H, N-CH2-Ph), 6.52-6.55 (d, 1H, J = 
15.2 Hz, CH=CHCON), 6.93-6.94 (d, 1H, J = 15.6 Hz, CH=CHCON), 7.14-7.16 (t, 2H, 
Ph), 7.27-7.31 (t, 2H, Ph), 8.99 (t, 1H, NH). 
N2-(N-Benzyloxycarbonylalanylalanyl)-N1-carbamoylmethyl-N1-trans-(3-(4-
fluorobenzyl)carbamoylacryloyl)hydrazine (14f, Z-Ala-Ala-AAsn-CH=CHCONH-
Bzl-4-F).  This compound was obtained using the HOBt/EDC coupling method and 
purified by column chromatography using 10% MeOH/CH2Cl2 as the eluent to give a 
pink powder (8% yield).  1H-NMR (DMSO-d6): 1.17-1.26 (m, 6H, 2 x Ala-CH3), 3.30-
3.32 (d, 2H, NCH2CO), 4.02-4.07 (m, 1H, α-H), 4.27-4.35 (m, 3H, α-H and CH2PhF), 
4.99 (m, 2H, Cbz), 6.88-6.92 (d, 1H, J = 16 Hz, CH=CHCON), 7.06-7.32 (m, 11H, 
CH=CHCON and NH and 2 x Ph), 7.43 (d, 1H, NH), 7.53 (s, 1H, NH), 8.19 (d, 1H, NH), 
8.97 (t, 1H, NH), 10.72 (s, 1H, NH).  MS (ESI) m/z 571 [(M + 1)+].  HRMS (ESI) 
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calculated for C27H32N6O7F : 571.2323.  Observed m/z 571.231651.  Anal. Calcd. for  
C27H31N6O7F: C, 56.84; H, 5.48; N, 14.73.  Found: C, 56.73; H, 5.58; N, 14.68.  
trans-3-Phenethylcarbamoylacrylic Acid Ethyl Ester 
(EtOOCCH=CHCONHCH2CH2Ph) was obtained by mixed anhydride coupling of 
equimolar amounts of monoethyl fumarate and phenethylamine to give a clear colorless 
syrup (78% yield).  
trans-3-Phenethylcarbamoylacrylic Acid (13g, 
HOOCCH=CHCONHCH2CH2Ph).  EtOOCCH=CHCONHCH2CH2Ph was hydrolyzed 
in MeOH using NaOH (1M aqueous, 1.1 eq) under standard deblocking conditions to 
give a clear, colorless syrup (81% yield).  1H-NMR (DMSO-d6): 3.54 (t, 2H, N-CH2-
CH2-Ph), 3.61 (t, 2H, N-CH2-CH2-Ph) 6.43-6.47 (d, 1H, J = 15.2 Hz, CH=CHCON), 
6.98-7.02 (d, 1H, J = 15.6 Hz, CH=CHCON), 7.14-7.31 (m, 5H, Ph). 
N2-(N-Benzyloxycarbonylalanylalanyl)-N1-carbamoylmethyl-N1-trans-(3-
phenethylcarbamoylacryloyl)hydrazine (14g, Z-Ala-Ala-AAsn-
CH=CHCONHCH2CH2Ph).  This compound was obtained using the HOBt/EDC 
coupling method with minimal washing during the workup and purified by column 
chromatography on silica gel using 10% MeOH/CH2Cl2 as the eluent and then washed 
with EtOAc to give a white powder (12% yield).  1H-NMR (DMSO-d6): 1.18-1.27 (m, 
6H, 2 x Ala-CH3), 2.74 (m, 2H, N-CH2CH2Ph), 3.20-3.32 (d, 2H, NCH2CO), 3.52-3.58 
(m, 2H, N-CH2CH2Ph), 4.04-4.08 (m, 1H, α-H), 4.28-4.31 (m, 1H, α-H), 4.99 (m, 2H, 
Cbz), 6.86-6.89 (d, 1H, J = 14.4 Hz, CH=CHCON), 7.04-7.08 (d, 1H, J = 14.8 Hz, 
CH=CHCON), 7.16-7.41 (m, 11H, 2 x Ph and NH), 7.50 (d, 1H, NH), 8.16 (d, 1H, NH), 
8.53 (s, 1H, NH), 10.72 (s, 1H, NH).  MS (ESI) m/z 567 [(M + 1)+].  HRMS (ESI) 
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calculated for C28H35N6O7 : 567.2596.  Observed m/z 567.256723.  Anal. Calcd. for  
C28H34N6O7·0.3H2O·0.2hexane: C, 59.52; H, 6.40; N, 14.26.  Found: C, 59.71; H, 6.18; 
N, 13.99.  
trans-N-Methylphenylcarbamoylacrylic Acid Ethyl Ester 
(EtOOCCH=CHCON(CH3)Ph) was obtained by mixed anhydride coupling of 
equimolar amounts of monoethyl fumarate and N-methyl aniline to give a white solid 
(99% yield). 1H-NMR (CDCl3): 1.25 (t, 3H, CH3CH2), 3.39 (s, 3H, N-CH3), 4.17 (q, 2H, 
CH3CH2), 6.93-6.97 (d, 1H, J = 15.2 Hz, CH=CHCON), 7.10-7.14 (d, 1H, J = 15.2 Hz, 
CH=CHCON), 7.15 (t, 1H, Ph), 7.34 (t, 2H, Ph), 7.61 (d, 2H, Ph). 
trans-N-Methylphenylcarbamoylacrylic Acid (13h, 
HOOCCH=CHCON(CH3)Ph).  EtOOCCH=CHCON(CH3)Ph  was hydrolyzed in 
MeOH using NaOH (1M aqueous, 1.1 eq) under standard deblocking conditions to give a 
white solid (29% yield).  1H-NMR (DMSO-d6): 3.14 (s, 3H, N-CH3), 6.50-6.54 (d, 1H, J 
= 15.2 Hz, CH=CHCON), 6.60-6.64 (d, 1H, J = 15.2 Hz, CH=CHCON), 7.32 (t, 2H, 
Ph), 7.40 (d, 1H, Ph), 7.47 (d, 1H, Ph). 
N2-(N-Benzyloxycarbonylalanylalanyl)-N1-carbamoylmethyl-N1-trans-(3-
(methylphenylcarbamoyl)acryloyl)hydrazine (14h, Z-Ala-Ala-AAsn-
CH=CHCON(CH3)Ph).  This compound was obtained using the HOBt/EDC coupling 
method.  The product was isolated by chromatography with 10% MeOH/CH2Cl2 as the 
eluent and recrystallized from hexane/EtOAc to give a white powder (34% yield).  1H-
NMR (DMSO-d6): 1.18-1.27 (m, 6H, 2 x Ala-CH3), 3.20-3.32 (m, 5H, NCH2CO and N-
CH3), 4.02-4.07 (m, 1H, α-H), 4.30 (m, 1H, α-H), 4.99 (m, 2H, Cbz), 6.56 (d, 1H, 
CH=CHCON), 7.06-7.10 (d, 1H, CH=CHCON ), 7.14 (s, 1H, NH), 7.29-7.46 (m, 11H, 2 
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x Ph, NH), 8.14 (d, 1H, NH), 10.65 (s, 1H, NH).  MS (ESI) m/z 553 [(M + 1)+].  HRMS 
(ESI) calculated for C27H33N6O7 : 553.2356.  Observed m/z 553.2411.  Anal. Calcd. for  
C27H32N6O7: C, 58.69; H, 5.84; N, 15.21.  Found: C, 58.43; H, 5.90; N, 15.20.  
trans-3-Benzylmethylcarbamoylacrylic Acid Ethyl Ester 
(EtOOCCH=CHCON(CH3)Bzl) was obtained by mixed anhydride coupling of 
equimolar amounts of monoethyl fumarate and N-methyl benzylamine to give a clear, 
pink syrup (76% yield).  
trans-3-Benzylmethylcarbamoylacrylic Acid (13i, 
HOOCCH=CHCON(CH3)Bzl).  EtOOCCH=CHCON(CH3)Bzl  was hydrolyzed in 
MeOH using NaOH (1M aqueous, 1.1 eq) under standard deblocking conditions to give a 
clear, colorless syrup (77% yield).  1H-NMR (CDCl3): 3.03 (s, 3H, N-CH3), 4.62-4.67 (d, 
2H, N-CH2-Ph), 6.83-6.87 (d, 1H, J = 16 Hz, CH=CHCON), 7.15-7.17 (d, 1H, J = 8 Hz, 
CH=CHCON), 7.25-7.50 (m, 5H, Ph). 
N2-(N-Benzyloxycarbonylalanylalanyl)-N1-carbamoylmethyl-N1-trans-(3-
benzylmethylcarbamoylacryloyl)hydrazine (14i, Z-Ala-Ala-AAsn-
CH=CHCON(CH3)Bzl).  This compound was synthesized using the HOBt/EDC 
coupling method and purified by column chromatography on silica gel using 10% 
MeOH/CH2Cl2 as the eluent and then recrystallized from EtOAc/hexane to give a white 
powder (54% yield).  1H-NMR (DMSO-d6): 1.18-1.27 (m, 6H, 2 x Ala-CH3), 2.89 (s, 3H, 
N-CH3), 3.20-3.32 (d, 2H, NCH2CO), 4.04-4.08 (m, 1H, α-H), 4.28-4.31 (m, 1H, α-H), 
4.57 (m, 2H, N-CH2-Ph), 4.99 (m, 2H, Cbz), 7.05-7.41 (m, 13H, CH=CHCON and 
CH=CHCON and 2 x Ph and NH), 7.49 (d, 1H, NH), 8.16 (d, 1H, NH), 10.72 (s, 1H, 
NH).  MS (ESI) m/z 567 [(M + 1)+].  HRMS (ESI) calculated for C28H35N6O7 : 567.2604.  
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Observed m/z 567.256723.  Anal. Calcd. for  C28H34N6O7·0.9H2O: C, 57.70; H, 6.19; N, 
14.42.  Found: C, 57.91; H, 6.25; N, 14.27.  
trans-3-(Methyl-1-naphthylmethylcarbamoyl)acrylic Acid Ethyl Ester 
(EtOOCCH=CHCON(CH3)CH2-1-Napth) was obtained by mixed anhydride coupling 
of equimolar amounts of monoethyl fumarate and N-methyl-1-naphthyl methylamine 
hydrochloride to give a clear, colorless syrup (99% yield).   1H-NMR (CDCl3): 1.31 (t, 
3H, CH3CH2), 3.03 (s, 3H, N-CH3) 4.29 (q, 2H, CH3CH2), 5.30 (s, 2H, N-CH2-naphthyl), 
6.92 (d, 1H, J = 15.2 Hz, CH=CHCON), 7.10-7.52 (m, 5H, naphthyl and CH=CHCON), 
7.81-7.91 (m, 2H, naphthyl), 7.85 (d, 1H, naphthyl). 
trans-3-(Methyl-1-naphthylmethylcarbamoyl)acrylic Acid (13j, 
HOOCCH=CHCON(CH3)CH2-1-Napth).  EtOOCCH=CHCON(CH3)CH2-1-Napth  
was hydrolyzed in MeOH using NaOH (1M aqueous, 1.1 eq) under standard deblocking 
conditions to give a white solid after recrystallization from cold EtOAc (13% yield). 1H-
NMR (DMSO-d6): 3.01 (s, 3H, CH3), 5.01 (s, 2H, CH2), 6.61-6.65 (d, 1H, J = 15.2 Hz, 
CH=CHCON), 7.17-7.21 (d, 1H, CH=CHCON), 7.37-7.60 (m, 4H, naphthyl), 7.85-8.01 
(m, 3H, naphthyl). 
N2-(N-Benzyloxycarbonylalanylalanyl)-N1-carbamoylmethyl-N1-trans-(3-
(methyl-1-naphthylmethylcarbamoyl)acryloyl)hydrazine (14j, Z-Ala-Ala-AAsn-
CH=CHCON(CH3)CH2-1-Napth).  This compound was obtained using the HOBt/EDC 
coupling method and purified by column chromatography on silica gel using 10% 
MeOH/CH2Cl2 as the eluent and then recrystallized from EtOAc/hexane to give a yellow 
powder (31% yield).  1H-NMR (DMSO-d6): 1.18-1.27 (m, 6H, 2 x Ala-CH3), 3.10 (s, 3H, 
N-CH3), 3.20-3.32 (d, 2H, NCH2CO), 4.04-4.08 (m, 1H, α-H), 4.28-4.31 (m, 1H, α-H), 
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4.99 (m, 4H, Cbz and N-CH2-naphthyl), 7.07-7.61 (m, 12H, naphthyl and Ph 
CH=CHCON and CH=CHCON and NH), 7.85-8.10 (m, 3H, naphthyl), 8.15 (d, 1H, NH), 
10.42 (s, 1H, NH), 10.72 (s, 1H, NH).  MS (ESI) m/z 617 [(M + 1)+].  HRMS (ESI) 
calculated for C32H37N6O7 : 617.265.  Observed m/z 617.2724.  Anal. Calcd. for  
C32H36N6O7·0.5H2O: C, 61.43; H, 5.96; N, 13.43.  Found: C, 61.48; H, 6.03; N, 13.25. 
trans-3-(Methylphenethylcarbamoyl)acrylic Acid Ethyl Ester 
(EtOOCCH=CHCON(CH3)CH2CH2Ph) was obtained by mixed anhydride coupling of 
equimolar amounts of monoethyl fumarate and N-methyl phenethylamine to give a clear 
colorless syrup (64% yield).  
trans-3-(Methylphenethylcarbamoyl)acrylic Acid (13k, 
HOOCCH=CHCON(CH3)CH2CH2Ph).  EtOOCCH=CHCON(CH3)CH2CH2Ph  was 
hydrolyzed in MeOH using NaOH (1M aqueous, 1.1 eq) under standard deblocking 
conditions to give a clear, colorless syrup (81% yield).  1H-NMR (DMSO-d6): 2.82 (s, 
3H, N-CH3), 3.54 (t, 2H, N-CH2-CH2-Ph), 3.61 (t, 2H, N-CH2-CH2-Ph), 6.43-6.47 (d, 1H, 
J = 15.2 Hz, CH=CHCON), 6.98-6.7.02 (d, 1H, J = 15.6 Hz, CH=CHCON), 7.14-7.31 
(m, 5H, Ph). 
N2-(N-Benzyloxycarbonylalanylalanyl)-N1-carbamoylmethyl-N1-trans-(3-
(Methylphenethylcarbamoyl)acryloyl)hydrazine (14k, Z-Ala-Ala-AAsn-
CH=CHCON(CH3)CH2CH2Ph).  This compound was obtained using the HOBt/EDC 
coupling method and purified by column chromatography on silica gel using 10% 
MeOH/CH2Cl2 as the eluent and then recrystallized from EtOAc/hexane to give a white 
powder (28% yield).  1H-NMR (DMSO-d6): 1.18-1.27 (m, 6H, 2 x Ala-CH3), 2.74-2.82 
(m, 2H, N-CH2CH2Ph), 2.86 (s, 3H, N-CH3), 3.20-3.32 (d, 2H, NCH2CO), 3.52-3.58 (m, 
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2H, N-CH2CH2Ph), 4.04-4.08 (m, 1H, α-H), 4.28-4.31 (m, 1H, α-H), 4.99 (m, 2H, Cbz), 
6.86-6.89 (d, 1H, J = 14.4 Hz, CH=CHCON), 7.04-7.08 (d, 1H, J = 14.8 Hz, 
CH=CHCON), 7.16-7.41 (m, 11H, 2 x Ph and NH), 7.50 (d, 1H, NH), 8.16 (d, 1H, NH), 
10.72 (s, 1H, NH).  MS (ESI) m/z 581 [(M + 1)+].  HRMS (ESI) calculated for 
C29H37N6O7 : 581.2717.  Observed m/z 581.272373.  Anal. Calcd. for  
C29H36N6O7·0.6H2O·0.1hexane: C, 59.25; H, 6.48; N, 14.01.  Found: C, 59.27; H, 6.50; 
N, 13.82.  
trans-3-Phenylbenzylcarbamoylacrylic Acid Ethyl Ester 
(EtOOCCH=CHCON(Bzl)Ph) was obtained by mixed anhydride coupling of equimolar 
amounts of monoethyl fumarate and phenyl benzylamine to give an orange oil (87% 
yield).  
trans-3-Phenylbenzylcarbamoylacrylic Acid (13l, 
HOOCCH=CHCON(Bzl)Ph).  EtOOCCH=CHCON(Bzl)Ph was hydrolyzed in MeOH 
using NaOH (1M aqueous, 1.1 eq) under standard deblocking conditions to give a clear, 
colorless syrup (74% yield).  1H-NMR (DMSO-d6): 4.97 (s, 2H, N-CH2-Ph), 6.61-6.62 
(d, 1H, CH=CHCON), 7.15-7.43 (m, 11H, CH=CHCON and 2 x Ph). 
N2-(N-Benzyloxycarbonylalanylalanyl)-N1-carbamoylmethyl-N1-trans-(3-
phenylbenzylcarbamoylacryloyl)hydrazine  (14l, Z-Ala-Ala-AAsn-
CH=CHCON(Bzl)Ph).  This compound was obtained using the HOBt/EDC coupling 
method and purified by column chromatography on silica gel using 10% MeOH/CH2Cl2 
as the eluent to give a white powder (14% yield).  1H-NMR (DMSO-d6): 1.20-1.21 (d, 
3H, Ala-CH3), 1.26 (d, 3H, Ala-CH3), 3.31 (s, 2H, NCH2CO), 4.04-4.08 (m, 1H, α-H), 
4.28-4.31 (m, 1H, α-H), 4.96-4.99 (d, 4H, N-CH2-Ph and Cbz), 6.57-6.61 (d, 1H, J = 
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15.2 Hz, CH=CHCON), 7.14-7.45 (m, 18H, CH=CHCON and 3 x Ph and 2 x NH), 8.16 
(d, 1H, NH), 10.71 (s, 1H, NH).  MS (ESI) m/z 629 [(M + 1)+].  HRMS (ESI) calculated 
for C33H37N6O7 : 629.2691.  Observed m/z 629.272373.  Anal. Calcd. for  
C33H36N6O7·0.09H20·0.17hexane: C, 62.15; H, 6.05; N, 12.83.  Found: C, 62.15; H, 5.96; 
N, 12.66. 
trans-3-Dibenzylcarbamoylacrylic Acid Ethyl Ester 
(EtOOCCH=CHCON(Bzl)2) was obtained by mixed anhydride coupling of equimolar 
amounts of monoethyl fumarate and dibenzylamine to give a clear, pink syrup (87% 
yield).  
trans-3-Dibenzylcarbamoylacrylic Acid (13m, HOOCCH=CHCON(Bzl)2). 
EtOOCCH=CHCON(Bzl)2 was hydrolyzed in MeOH using NaOH (1M aqueous, 1.1 eq) 
under standard deblocking conditions to give a clear, colorless syrup which was 
recrystallized over night from hexane/EtOAc (30% yield).  1H-NMR (DMSO-d6): 4.57 (s, 
2H, N-CH2-Ph), 4.65 (s, 2H, N-CH2-Ph), 6.59-6.63 (d, 1H, J = 15.2 Hz, CH=CHCON), 
7.15-7.17 (d, 1H, J = 8 Hz, CH=CHCON), 7.25-7.50 (m, 10H, 2 x Ph). 
N2-(N-Benzyloxycarbonylalanylalanyl)- N1-carbamoylmethyl-N1-trans-(3-
dibenzylcarbamoylacryloyl)hydrazine  (14m, Z-Ala-Ala-AAsn-CH=CHCON(Bzl)2).  
This compound was obtained using the HOBt/EDC coupling method and purified by 
column chromatography on silica gel using 10% MeOH/CH2Cl2 as the eluent to give a 
white powder (34% yield).  1H-NMR (DMSO-d6): 1.19 (d, 3H, Ala-CH3), 1.26 (d, 3H, 
Ala-CH3), 3.31 (s, 2H, NCH2CO), 4.04-4.08 (m, 1H, α-H), 4.28-4.31 (m, 1H, α-H), 4.56 
(s, 2H, N-CH2-Ph), 4.63 (s, 2H, N-CH2-Ph), 5.00 (m, 2H, Cbz), 7.13-7.41 (m, 17H, 
CH=CHCON and CH=CHCON and 3 x Ph and NH), 7.48 (s, 1H, NH), 8.14 (d, 1H, NH), 
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10.71 (s, 1H, NH).  MS (ESI) m/z 643 [(M + 1)+].  HRMS (ESI) calculated for 
C34H39N6O7 : 643.2843.  Observed m/z 643.288023.  Anal. Calcd. for  C34H38N6O7: C, 
63.54; H, 5.96; N, 13.08.  Found: C, 63.75; H, 6.02; N, 12.81.  
trans-3-(Benzyl-4-methoxybenzylcarbamoyl)acrylic Acid Ethyl Ester 
(EtOOCCH=CHCON(Bzl-4-OMe)Bzl) was obtained by mixed anhydride coupling of 
equimolar amounts of monoethyl fumarate and 4-methoxy benzyl benzylamine to give a 
clear colorless syrup (91% yield).  
trans-3-(Benzyl-4-methoxybenzylcarbamoyl)acrylic Acid (13n, 
HOOCCH=CHCON(Bzl-4-OMe)Bzl).  EtOOCCH=CHCON(Bzl-4-OMe)Bzl  was 
hydrolyzed in MeOH using NaOH (1M aqueous, 1.1 eq) under standard deblocking 
conditions to give a clear, colorless syrup (44% yield).  1H-NMR (DMSO-d6): 3.73 (s, 
3H, OCH3), 4.50-4.54 (d, 2H, N-CH2-Ph), 4.56-4.61 (d, 2H, N-CH2-Ph), 6.59-6.63 (d, 
1H, J = 15.2 Hz, CH=CHCON), 6.86-6.92 (2 x d, 2H, Ph), 7.07-7.09 (d, 1H, J = 8 Hz, 
CH=CHCON), 7.14-7.39 (m, 7H, 2 x Ph). 
N2-(N-Benzyloxycarbonylalanylalanyl)-N1-trans-(3-benzyl-(4-
methoxybenzyl)carbamoyl)acryloyl-N1-carbamoylmethylhydrazine  (14n, Z-Ala-
Ala-AAsn-CH=CHCON(Bzl-4-OMe)Bzl).  This compound was obtained using the 
HOBt/EDC coupling method and purified by recrystallization from 10% MeOH/CH2Cl2 
to give a yellow powder (9% yield).  1H-NMR (DMSO-d6): 1.19-1.20 (d, 3H, Ala-CH3), 
1.26-1.28 (d, 3H, Ala-CH3), 3.32 (s, 2H, NCH2CO), 3.72 (s, 3H, OCH3), 4.04-4.09 (m, 
1H, α-H), 4.28-4.32 (m, 1H, α-H), 4.48-4.54 (d, 2H, N-CH2-Ph), 4.54-4.59 (d, 2H, N-
CH2-Ph), 5.00 (m, 2H, Cbz), 6.84-6.91 (2 x d, 2H, Ph), 7.06-7.08 (d, 1H, J = 8.8 Hz, 
CH=CHCON), 7.12-7.42 (m, 14H, CH=CHCON and 3 x Ph and NH), 7.50 (s, 1H, NH), 
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8.16-8.17 (d, 1H, NH), 10.71 (s, 1H, NH).  MS (ESI) m/z 673 [(M + 1)+].  HRMS (ESI) 
calculated for C35H41N6O8 : 673.3001.  Observed m/z 673.298588.  Anal. Calcd. for  
C35H40N6O8·0.5CH2Cl2: C, 59.61; H, 5.78; N, 11.75.  Found: C, 59.76; H, 5.71; N, 11.54.  
trans-3-Benzyl(4-fluorobenzyl)carbamoylacrylic Acid Ethyl Ester 
(EtOOCCH=CHCON(Bzl-4-F)Bzl) was obtained by mixed anhydride coupling of 
equimolar amounts of monoethyl fumarate and 4-fluorobenzyl benzylamine to give a 
clear, colorless syrup (95% yield).  
trans-3-Benzyl(4-fluorobenzyl)carbamoylacrylic Acid (13o, 
HOOCCH=CHCON(Bzl-4-F)Bzl).  EtOOCCH=CHCON(Bzl-4-F)Bzl  was hydrolyzed 
in MeOH using NaOH (1M aqueous, 1.1 eq) under standard deblocking conditions to 
give a clear, colorless syrup (44% yield).  1H-NMR (DMSO-d6): 4.50-4.54 (d, 2H, N-
CH2-Ph), 4.56-4.61 (d, 2H, N-CH2-Ph), 6.59-6.63 (d, 1H, J = 15.2 Hz, CH=CHCON), 
6.99-7.44 (m, 11H, CH=CHCON and CH=CHCON and 2 x Ph). 
N2-(N-Benzyloxycarbonylalanylalanyl)-N1-trans-(3-benzyl(4-
fluorobenzyl)carbamoylacryloyl)-N1-carbamoylmethylhydrazine  (14o, Z-Ala-Ala-
AAsn-CH=CH-CON(Bzl-4-F)Bzl).  This compound was obtained using the HOBt/EDC 
coupling method and purified by column chromatography using 10% MeOH/CH2Cl2 as 
the eluent.  Recrystallization with hexane/EtOAc gave a white powder (11% yield).  1H-
NMR (DMSO-d6): 1.19-1.20 (d, 3H, Ala-CH3), 1.26-1.28 (d, 3H, Ala-CH3), 3.32 (s, 2H, 
NCH2CO), 4.05-4.09 (m, 1H, α-H), 4.28-4.32 (m, 1H, α-H), 4.35 (s, 2H, CH2Ph), 4.62-
4.64 (d, 2H, N-CH2-Ph), 5.00 (m, 2H, Cbz), 7.09-7.34 (m, 17H, CH=CHCON and 
CH=CHCON and 3 x Ph and NH), 7.40-7.42 (d, 1H, NH), 7.50 (s, 1H, NH), 8.15-8.16 (d, 
1H, NH), 10.71 (s, 1H, NH).  MS (ESI) m/z 661 [(M + 1)+].  HRMS (ESI) calculated for 
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C34H38N6O7F : 661.2781.  Observed m/z 661.278601.  Anal. Calcd. for  
C34H37N6O7F·0.35H2O: C, 61.22; H, 5.70; N, 12.60. Found: C, 61.16; H, 5.71; N, 12.60. 
trans-3-(Bis-(2-furylmethyl)carbamoyl)acrylic Acid Ethyl Ester 
(EtOOCCH=CHCON(CH2-2-furyl)2) was obtained by mixed anhydride coupling of 
equimolar amounts of monoethyl fumarate and bis-2-furanmethyl amine to give a brown 
syrup (83% yield).  1H-NMR (CDCl3): 1.26 (t, 3H, CH3CH2), 2.94 (d, 1H, J = 3.2 Hz, 
furyl), 3.47 (t, 1H, furyl), 3.64 (d, 1H, N-CH2), 3.97 (d, 1H, N-CH2), 4.12 (q, 2H, 
CH3CH2), 4.36 (d, 1H, N-CH2), 4.71 (d, 1H, N-CH2), 5.25 (d, 1H, furyl), 6.26-6.33 (m, 
3H, furyl), 6.51-6.53 (d, 1H, J = 15.2 Hz, CH=CHCON), 7.37 (s, 1H, CH=CHCON). 
trans-3-(Bis-(2-furylmethyl)carbamoyl)acrylic Acid (13p, 
HOOCCH=CHCON(CH2-2-furyl)2).  EtOOCCH=CHCON(CH2-2-furyl)2 was 
hydrolyzed in MeOH using NaOH (1M aqueous, 1.1 eq) under standard deblocking 
conditions to give a brown solid (91% yield). 1H-NMR (DMSO-d6): 2.73 (d, 1H, J = 3.6 
Hz, furyl), 3.13 (t, 1H, furyl), 3.49 (d, 1H, N-CH2), 4.03 (d, 1H, N-CH2), 4.35-4.49 (dd, 
2H, N-CH2), 5.17 (d, 1H, furyl), 6.30-6.40 (m, 3H, furyl), 6.63-6.64 (d, 1H, J = 15.2 Hz, 
CH=CHCON), 7.60 (s, 1H, CH=CHCON).  
N2-(N-Benzyloxycarbonylalanylalanyl)-N1-carbamoylmethyl-N1-trans-(3-bis-
(2-furylmethyl)carbamoylacryloyl)hydrazine (14p, Z-Ala-Ala-AAsn-
CH=CHCON(CH2-2-furyl)2).  This compound was obtained using the HOBt/EDC 
coupling method.  The product was isolated by chromatography with 10% MeOH/CH2Cl2 
as the eluent and recrystallized from hexane/EtOAc to give a white powder (34% yield).  
1H-NMR (DMSO-d6): 1.18-1.27 (m, 6H, 2 x Ala-CH3), 2.92 (d, 1H, furyl), 3.28-3.38 (m, 
4H, N-CH2 and NCH2CO and furyl), 3.47-3.50 (d, 1H, N-CH2), 3.99-4.07 (m, 2H, α-H 
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and N-CH2), 4.30-4.49 (m, 2H, α-H and N-CH2), 4.99 (m, 2H, Cbz), 6.02 (s, 1H, NH), 
6.11 (s, 1H, NH), 6.31(s, 1H, CH=CHCON), 6.39 (s, 1H, CH=CHCON), 6.55 (t, 1H, 
furyl), 7.12 (s, 1H, NH), 7.32 (m, 5H, Ph), 7.41-7.59 (m, 3H, furyl), 8.21 (d, 1H, NH), 
10.58 (s, 1H, NH).  MS (ESI) m/z 623 [(M + 1)+].  HRMS (ESI) calculated for 
C30H35N6O9 : 623.2486.  Observed m/z 623.2466.  Anal. Calcd. for  C30H34N6O9·1H2O: C, 
56.24; H, 5.66; N, 13.12.  Found: C, 56.38; H, 5.58; N, 13.15.  
 trans-3-(Benzyl-2-naphthylmethylcarbamoyl)acrylic Acid Ethyl Ester 
(EtOOCCH=CHCON(Bzl)-2-CH2-Napth) was obtained by mixed anhydride coupling 
of equimolar amounts of monoethyl fumarate and benzyl-2-naphthylmethylamine to give 
a clear colorless syrup (87% yield).  1H-NMR (CDCl3): 1.31 (t, 3H, CH3CH2), 4.23 (q, 
2H, CH3CH2), 4.55-4.69 (d, 2H, N-CH2), 4.71-4.81 (d, 2H, N-CH2), 6.95-6.91 (d, 1H, J 
= 14.4 Hz, CH=CHCON), 7.16-7.18 (d, 1H, CH=CHCON), 7.23-7.57 (m, 10H, naphthyl 
and Ph), 7.85 (m, 2H, naphthyl). 
trans-3-(Benzyl-2-naphthylmethylcarbamoyl)acrylic Acid (13q, 
HOOCCH=CHCON(Bzl)-2-CH2-Napth).  EtOOCCH=CHCON(Bzl)-2-CH2-Napth  
was hydrolyzed in MeOH using NaOH (1M aqueous, 1.1 eq) under standard deblocking 
conditions to give a white solid after recrystallization from cold EtOAc (13% yield).  1H-
NMR (DMSO-d6): 4.82 (d, 2H, N-CH2), 5.01 (d, 2H, N-CH2), 6.61-6.65 (d, 1H, J = 15.2 
Hz, CH=CHCON), 7.17-7.21 (d, 1H, CH=CHCON), 7.37-7.60 (m, 9H, naphthyl and Ph), 
7.85-8.01 (m, 3H, naphthyl). 
N2-(N-Benzyloxycarbonylalanylalanyl)-N1-trans-(3-benzyl-2-
naphthylmethylcarbamoylacryloyl)-N1-carbamoylmethylhydrazine (14q, Z-Ala-Ala-
AAsn-CH=CHCON(Bzl)-2-CH2-Napth).  This compound was obtained using the 
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HOBt/EDC coupling method and purified by column chromatography on silica gel using 
10% MeOH/CH2Cl2 as the eluent and then recrystallized from EtOAc/hexane to give a 
yellow powder (11% yield).  1H-NMR (DMSO-d6): 1.18-1.28 (m, 6H, 2 x Ala-CH3), 
3.29-3.32 (d, 2H, NCH2CO), 4.04-4.08 (m, 1H, α-H), 4.28-4.31 (m, 1H, α-H), 4.63-4.69 
(d, 2H, N-CH2), 4.73-4.80 (d, 2H, N-CH2), 4.99 (m, 2H, Cbz), 7.14-7.48 (m, 18H, 
naphthyl and 2 x Ph and CH=CHCON and CH=CHCON and 2 x NH), 7.84-7.90 (m, 3H, 
naphthyl), 8.15 (d, 1H, NH), 10.72 (s, 1H, NH).  MS (ESI) m/z 693 [(M + 1)+].  HRMS 
(ESI) calculated for C38H41N6O7 : 693.2998.  Observed m/z 693.303673.  Anal. Calcd. for  
C38H40N6O7·0.63H2O: C, 64.82; H, 5.91; N, 11.94.  Found: C, 64.83; H, 6.02; N, 11.83.  
 trans-3-(Benzyl-1-naphthylmethylcarbamoyl)acrylic Acid Ethyl Ester 
(EtOOCCH=CHCON(Bzl)-1-CH2-Napth) was obtained by mixed anhydride coupling 
of equimolar amounts of monoethyl fumarate and benzyl-1-naphthylmethylamine to give 
a yellow oil (79% yield).  1H-NMR (CDCl3): 1.31 (t, 3H, CH3CH2), 4.23 (q, 2H, 
CH3CH2), 4.55-4.69 (d, 2H, N-CH2), 4.71-4.81 (d, 2H, N-CH2), 6.95-6.91 (d, 1H, J = 
14.4 Hz, CH=CHCON), 7.16-7.18 (d, 1H, CH=CHCON), 7.23-7.57 (m, 10H, naphthyl 
and Ph), 7.85 (m, 2H, naphthyl). 
trans-3-(Benzyl-1-naphthylmethylcarbamoyl)acrylic Acid (13r, 
HOOCCH=CHCON(Bzl)-1-CH2-Napth).  EtOOCCH=CHCON(Bzl)-1-CH2-Napth  
was hydrolyzed in MeOH using NaOH (1M aqueous, 1.1 eq) under standard deblocking 
conditions to give a white solid after recrystallization from cold EtOAc (62% yield).  1H-
NMR (DMSO-d6): 4.82 (d, 2H, N-CH2), 5.01 (d, 2H, N-CH2), 6.61-6.65 (d, 1H, J = 15.2 
Hz, CH=CHCON), 7.17-7.21 (d, 1H, CH=CHCON), 7.37-7.60 (m, 9H, naphthyl and Ph), 
7.85-8.01 (m, 3H, naphthyl). 
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N2-(N-Benzyloxycarbonylalanylalanyl)-N1-trans-(3-benzyl-1-
naphthylmethylcarbamoylacryloyl)-N1-carbamoylmethylhydrazine (14r, Z-Ala-Ala-
AAsn-CH=CHCON(Bzl)-1-CH2-Napth).  This compound was obtained using the 
HOBt/EDC coupling method and purified by column chromatography on silica gel using 
10% MeOH/CH2Cl2 as the eluent and then recrystallized from EtOAc/hexane to give a 
white powder (17% yield).  1H-NMR (DMSO-d6): 1.19-1.29 (m, 6H, 2 x Ala-CH3), 3.30-
3.32 (d, 2H, NCH2CO), 4.04-4.08 (m, 1H, α-H), 4.29-4.33 (m, 1H, α-H), 4.64-4.67 (d, 
2H, N-CH2), 4.99 (m, 2H, Cbz), 5.06-5.17 (d, 2H, N-CH2), 7.14-7.48 (m, 18H, naphthyl 
and 2 x Ph and CH=CHCON and CH=CHCON and 2 x NH), 7.84-7.90 (m, 3H, 
naphthyl), 8.15 (d, 1H, NH), 10.72 (s, 1H, NH).  MS (ESI) m/z 693 [(M + 1)+].  Anal. 
Calcd. for  C38H40N6O7·0.2H2O: C, 65.54; H, 5.85; N, 12.07.  Found: C, 65.54; H, 5.93; 
N, 11.81.  
 trans-3-(3,4-Dihydro-2H-quinolin-1-yloxo)acrylic Acid Ethyl Ester 
(EtOOCCH=CHCO-tetrahydroquinoline) was obtained by mixed anhydride coupling 
of equimolar amounts of monoethyl fumarate and 1,2,3,4-tetrahydroquinoline to give a 
brown syrup (83% yield).  1H-NMR (CDCl3): 1.29 (t, 3H, CH3CH2OC), 1.99-2.02 (m, 
2H, N-CH2-CH2-CH2), 2.73-2.76 (t, 1H, N-CH2-CH2-CH2), 3.86-3.98 (t, 1H, N-CH2-
CH2-CH2), 4.24-4.30 (q, 2H, CH3CH2OOC), 6.78-6.82 (dd, 1H, J = 14.8 Hz, 
CH=CHCON), 7.18-7.22 (m, 4H, quinoline), 7.44-7.48 (d, 1H, J = 14.8 Hz, 
CH=CHCON). 
trans-3-(3,4-Dihydro-2H-quinolin-1-yloxo)acrylic Acid (13s, 
HOOCCH=CHCO-tetrahydroquinoline).  EtOOCCH=CHCO-tetrahydroquinoline was 
hydrolyzed in MeOH using NaOH (1M aqueous, 1.1 eq) under standard deblocking 
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conditions to give a clear syrup, which was recrystallized using cold EtOAc to give a 
yellow powder (68% yield).  
N2-(N-Benzyloxycarbonylalanylalanyl)-N1-carbamoylmethyl-N1-trans-(3-(3,4-
dihydro-2H-quinolin-1-yloxo)acryloyl)hydrazine (14s, Z-Ala-Ala-AAsn-CH=CHCO-
tetrahydroquinoline).  This compound was obtained using the HOBt/EDC coupling 
method and purified by column chromatography on silica gel using 10% MeOH/CH2Cl2 
as the eluent and then recrystallized from EtOAc/hexane to give a yellow powder (28% 
yield).  1H-NMR (DMSO-d6): 1.18-1.27 (m, 6H, 2 x Ala-CH3), 1.87 (m, 2H, N-CH2-CH2-
CH2), 2.70 (t, 2H, N-CH2-CH2-CH2), 3.29-3.32 (d, 2H, NCH2CO), 3.73 (m, 2H, N-CH2-
CH2), 4.02-4.06 (m, 1H, α-H), 4.31 (m, 1H, α-H), 4.99 (m, 2H, Cbz), 7.02-7.07 (dd, 2H, 
J = 14.8 Hz, CH=CHCON), 7.15-7.41 (m, 11H, quinoline and Ph and NH and 
CH=CHCON), 7.49 (s, 1H, NH), 8.16 (d, 1H, NH), 10.73 (s, 1H, NH).  MS (ESI) m/z 
579 [(M + 1)+].  HRMS (ESI) calculated for C29H35N6O7 : 579.2525.  Observed m/z 
579.2567.  Anal. Calcd. for  C29H34N6O7·0.7H2O: C, 58.91; H, 6.03; N, 14.21.  Found: C, 
58.87; H, 6.00; N, 14.24.  
 trans-3-(3,4-Dihydro-2H-quinolin-1-ylcarbonyl)acrylic Acid Ethyl 
Ester (EtOOCCH=CHCO-tetrahydroisoquinoline) was obtained by mixed anhydride 
coupling of equimolar amounts of monoethyl fumarate and 1,2,3,4-tetrahydroquinoline to 
give a brown syrup (83% yield).  1H-NMR (CDCl3): 1.29 (t, 3H, CH3CH2OC), 1.99-2.02 
(m, 2H, N-CH2-CH2-CH2), 2.73-2.76 (t, 1H, N-CH2-CH2-CH2), 3.86-3.98 (t, 1H, N-CH2-
CH2-CH2), 4.24-4.30 (q, 2H, CH3CH2OOC), 6.78-6.82 (dd, 1H, J = 14.8 Hz, 
CH=CHCON), 7.18-7.22 (m, 4H, quinoline), 7.44-7.48 (d, 1H, J = 14.8 Hz, 
CH=CHCON). 
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trans-3-(3,4-Dihydro-2H-quinolin-1-ylcarbonyl)acrylic Acid (13t, 
HOOCCH=CHCO-tetrahydroisoquinoline).  EtOOCCH=CHCO-tetrahydroquinoline 
was hydrolyzed in MeOH using NaOH (1M aqueous, 1.1 eq) under standard deblocking 
conditions to give a clear syrup, which was recrystallized using cold EtOAc to give a 
yellow powder (68% yield).  
N2-(N-Benzyloxycarbonylalanylalanyl)-N1-carbamoylmethyl-N1-trans-(3-(3,4-
dihydro-2H-quinolin-1-yloxo)acryloyl)hydrazine (14t, Z-Ala-Ala-AAsn-CH=CHCO-
tetrahydroisoquinoline).  This compound was obtained using the HOBt/EDC coupling 
method and purified by column chromatography on silica gel using 10% MeOH/CH2Cl2 
as the eluent and then recrystallized from EtOAc/hexane to give a yellow powder (28% 
yield).  1H-NMR (DMSO-d6): 1.18-1.27 (m, 6H, 2 x Ala-CH3), 1.87 (m, 2H, N-CH2-CH2-
CH2), 2.70 (t, 2H, N-CH2-CH2-CH2), 3.29-3.32 (d, 2H, NCH2CO), 3.73 (m, 2H, N-CH2-
CH2), 4.02-4.06 (m, 1H, α-H), 4.31 (m, 1H, α-H), 4.99 (m, 2H, Cbz), 7.02-7.07 (dd, 2H, 
J = 14.8 Hz, CH=CHCON), 7.15-7.41 (m, 11H, quinoline and Ph and NH and 
CH=CHCON), 7.49 (s, 1H, NH), 8.16 (d, 1H, NH), 10.73 (s, 1H, NH).  MS (ESI) m/z 
579 [(M + 1)+].  HRMS (ESI) calculated for C29H35N6O7 : 579.2525.  Observed m/z 
579.2567.  Anal. Calcd. for  C29H34N6O7·0.9H2O·0.1hexane: C, 58.92; H, 6.21; N, 13.92.  
Found: C, 58.81; H, 6.04; N, 13.79.  
trans-3-(2,3-Dihydroindol-1-ylcarbonyl)acrylic Acid Ethyl Ester (EtOOC-
CH=CHCO-indoline) was obtained by mixed anhydride coupling of equimolar amounts 
of monoethyl fumarate and indoline to give a bright yellow solid (84% yield).  
trans-3-(2,3-Dihydroindol-1-yloxo)acrylic Acid (13u, HOOC-CH=CHCO-
indoline).  EtOOC-CH=CHCO-indoline was hydrolyzed in MeOH using NaOH (1M 
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aqueous, 1.1 eq) under standard deblocking conditions to give a clear syrup, which was 
washed several times with CH2Cl2 to give a bright yellow solid (40% yield).  1H-NMR 
(DMSO-d6): 3.16 (t, 2H, N-CH2-CH2), 4.27 (t, 1H, N-CH2-CH2), 6.64-6.67 (dd, 1H, J = 
15.2 Hz CH=CHCON,), 7.03 (t, 1H, indoline-H), 7.17 (t, 1H, indoline-H), 7.24-7.26 (d, 
1H, J = 7.2 Hz, indoline-H), 7.28-7.32 (d, 1H, J = 15.2 Hz, CH=CHCON), 8.11-8.13 (d, 
1H, J = 8 Hz, indoline-H).   
N2-(N-Benzyloxycarbonylalanylalanyl)-N1-carbamoylmethyl-N1-trans-(3-(2,3-
dihydroindol-1-ylcarbonyl)acryloyl)hydrazine (14u, Z-Ala-Ala-AAsn-CH=CHCO-
indoline).  This compound was obtained using the HOBt/EDC coupling method and 
purified by column chromatography on silica gel using 10% MeOH/CH2Cl2 as the eluent 
and then recrystallized from EtOAc/hexane to give a bright yellow, flaky powder (15% 
yield).  1H-NMR (DMSO-d6): 1.18-1.19 (d, 3H, Ala-CH3), 1.27-1.28 (d, 3H, Ala-CH3), 
3.15 (t, 2H, N-CH2CH2), 3.20-3.31 (d, 2H, NCH2CO), 4.02-4.06 (m, 1H, α-H), 4.06 (t, 
2H, N-CH2-CH2), 4.31 (m, 1H, α-H), 4.99 (m, 2H, Cbz), 7.02 (t, 1H, indoline-H), 7.13-
7.41 (m, 10H, indoline and Ph and NH and CH=CHCON and CH=CHCON), 7.52 (s, 1H, 
NH), 8.13 (d, 1H, NH), 8.15-8.16 (d, 1H, indoline-H), 10.76 (s, 1H, NH).  MS (ESI) m/z 
565 [(M + 1)+].  HRMS (ESI) calculated for C28H33N6O7 : 565.2416.  Observed m/z 
565.241073.  Anal. Calcd. for  C28H32N6O7·0.4H2O: C, 58.82; H, 5.78; N, 14.70.  Found: 
C, 58.87; H, 5.82; N, 14.68.  
 trans-3-(1,3-Dihydroisoindol-2-ylcarbonyl)acrylic Acid Ethyl Ester 
(EtOOCCH=CHCO-isoindoline)  was obtained by mixed anhydride coupling of 
equimolar amounts of monoethyl fumarate and isoindoline to give a brown solid (86% 
yield).  
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trans-3-(1,3-Dihydroisoindol-2-ylcarbonyl)acrylic Acid (13v, 
HOOCCH=CHCO-isoindoline).  EtOOCCH=CHCO-isoindoline was then hydrolyzed 
in MeOH using NaOH (1M aqueous, 1.1 eq) under standard deblocking conditions to 
give a white solid after recrystallization with cold EtOAc (37% yield).  1H-NMR 
(DMSO-d6): 4.73 (s, 2H, NCH2), 5.02 (s, 2H, NCH2), 6.58-6.62 (d, 1H, J = 15.2 Hz, 
CH=CHCON), 7.25 (m, 5H, isoindoline and CH=CHCON). 
N2-(N-Benzyloxycarbonylalanylalanyl)-N1-carbamoylmethyl-N1-trans-(3-(1,3-
dihydroisoindol-2-ylcarbonyl)acryloyl)hydrazine (14v, Z-Ala-Ala-AAsn-
CH=CHCO-isoindoline).  This compound was obtained using the HOBt/EDC coupling 
method and purified by column chromatography on silica gel using 10% MeOH/CH2Cl2 
as the eluent and then recrystallized from EtOAc/hexane to give a bright yellow, flaky 
powder (15% yield).  1H-NMR (DMSO-d6): 1.18-1.19 (d, 3H, Ala-CH3), 1.27-1.28 (d, 
3H, Ala-CH3), 3.20-3.31 (d, 2H, NCH2CO), 4.04-4.07 (m, 1H, α-H), 4.29-4.33 (m, 1H, 
α-H), 4.72 (s, 2H, NCH2), 4.99 (m, 2H, Cbz and NCH2), 7.11-7.32 (m, 11H, indoline and 
Ph and NH and CH=CHCON and CH=CHCON), 7.39 (d, 1H, NH), 7.52 (s, 1H, NH), 
8.14 (d, 1H, NH), 10.76 (s, 1H, NH).  MS (ESI) m/z 565 [(M + 1)+].  HRMS (ESI) 
calculated for C28H33N6O7 : 565.2414.  Observed m/z 565.241073.  Anal. Calcd. for  
C28H32N6O7·0.3H2O: C, 59.00; H, 5.76; N, 14.74.  Found: C, 59.04; H, 5.54; N, 14.56.  
 trans-3-(4-Phenyl-5,6-dihydro-2H-pyridin-1-ylcarbonyl)acrylic Acid 
Ethyl Ester (EtOOCCH=CHCO-(4-Ph-Py)) was obtained by mixed anhydride 
coupling of equimolar amounts of monoethyl fumarate and 4-phenyl-1,2,3,6-
tetrahydropyridine hydrochloride to give a pink solid (80% yield).  1H-NMR (CDCl3):  
1.32 (t, 3H, CH2CH3), 2.64 (s, 2H, pyridyl-CH2), 3.78-3.81 (t, 1H, pyridyl-CH2), 3.90-
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3.93 (t, 1H, pyridyl-CH2), 4.24-4.33 (m, 4H, CH2CH3 and pyridyl-CH2), 6.02-6.09 (d, 
1H, pyridyl-CH=), 6.78-6.82 (d, 1H, J = 15.6 Hz, CH=CHCON), 6.99-7.49 (m, 6H, Ph 
and CH=CHCON). 
  trans-3-(4-Phenyl-5,6-dihydro-2H-pyridin-1-ylcarbonyl)acrylic Acid (13w, 
HOOCCH=CHCO-(4-Ph-Py)).  EtOOCCH=CHCO-(4-Ph-Py)  was hydrolyzed in 
MeOH using NaOH (1M aqueous, 1.1 eq) under standard deblocking conditions to give a 
white solid (59% yield).  1H-NMR (DMSO-d6): 2.57 (s, 2H, pyridyl-CH2), 3.73-3.76 (t, 
2H, pyridyl-CH2), 4.17-4.26 (d, 2H, pyridyl-CH2), 6.14-6.17 (d, 1H, pyridyl CH=), 7.23-
7.27 (t, 1H, Ph), 7.31-7.35 (t, 2H, Ph), 7.39-7.48 (m, 3H, CH=CHCON and Ph). 
N2-(N-Benzyloxycarbonylalanylalanyl)-N1-carbamoylmethyl -N1-trans-(3-(4-
phenyl-5,6-dihydro-2H-pyridin-1-ylcarbonyl)acryloyl)hydrazine (14w, Z-Ala-Ala-
AAsn-CH=CHCO-(4-Ph-Py)).  This compound was obtained using the HOBt/EDC 
coupling method and purified by column chromatography using 10% MeOH/CH2Cl2 as 
the eluent to give a white solid (11% yield).  1H-NMR (DMSO-d6): 1.15-1.26 (m, 6H, 2 x 
Ala-CH3), 2.56 (s, 2H, pyridyl-CH2), 3.30-3.32 (d, 2H, NCH2CO), 3.74 (t, 2H, pyridyl-
CH2), 4.02-4.07 (m, 1H, α-H), 4.17 (s, 2H, pyridyl-CH2), 4.27-4.35 (m, 1H, α-H), 4.99 
(m, 2H, Cbz), 6.16 (s, 1H, pyridyl-CH=), 7.02-7.06 (d, 1H, J = 15.2 Hz, CH=CHCON), 
7.19 (s, 1H, NH), 7.23-7.42 (m, 11H, CH=CHCON and 2 x Ph), 7.51 (d, 1H, NH), 8.14-
8.15 (d, 1H, NH), 10.72 (s, 1H, NH).  MS (ESI) m/z 605 [(M + 1)+].  HRMS (ESI) 
calculated for C31H37N6O7 : 605.2757.  Observed m/z 605.272373.  Anal. Calcd. for  
C31H36N6O7·1H20: C, 59.80; H, 6.15; N, 13.50.  Found: C, 59.71; H, 6.02; N, 13.27.  
Methyl-(1-methylphenethylcarbamoyl)phenylethylcarbamic Acid tert-Butyl 
Ester (Boc-Phe(Me)-N(Me)(CH2)2Ph) was obtained by mixed anhydride coupling of 
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equimolar amounts of Boc-Phe(Me)-OH and N-methyl phenethylamine.  The product 
was purified by column chromatography using hexane/EtOAc (1:1) as the eluent to give a 
colorless oil (89% yield).  1H-NMR (CDCl3): 1.14-1.35 (m, 9H, tBu), 2.73-2.98 (m, 10H, 
Phe-CH2 and CH2Ph and 2 x Me), 3.40-3.51 (m, 2H, N-CH2), 5.20 (m, 1H, α-H), 7.10-
7.33 (m, 10H, 2 x Ph). 
N-Methyl-2-methylamino-N-phenethyl-3-phenylpropionamide 
Hydrochloride (Phe(Me)-N(Me)(CH2)2Ph).  Boc-Phe(Me)-N(Me)(CH2)2Ph was 
hydrolyzed under standard deblocking conditions using 12 eq. of HCl in EtOAc (4 N) to 
give a white powder (100% yield).   
trans-3-(Methyl-(1-methylphenethylcarbamoyl)phenylethylcarbamoyl)acrylic 
Acid Ethyl Ester (EtOOCCH=CH-Phe(Me)-N(Me)(CH2)2Ph) was obtained by mixed 
anhydride coupling of equimolar amounts of monoethyl fumarate and Phe(Me)-
N(Me)(CH2)2Ph to give a clear colorless syrup (52% yield).  1H-NMR (CDCl3): 1.20-
1.25 (t, 3H, CH3CH2O), 2.73-2.98 (m, 10H, Phe-CH2 and CH2Ph and 2 x Me), 3.40-3.51 
(m, 2H, N-CH2), 4.19-4.34 (q, 2H, CH3CH2O), 5.20 (m, 1H, α-H), 6.63-5.78 (2 x t, 1H, 
CH=CHCON), 6.80-6.99 (m, 1H, CH=CHCON), 7.10-7.33 (m, 10H, 2 x Ph). 
trans-3-(Methyl-(1-methylphenethylcarbamoyl)phenylethylcarbamoyl)acrylic 
Acid (13x, HOOCCH=CH-Phe(Me)-N(Me)(CH2)2Ph).  (HOOCCH=CH-Phe(Me)-
N(Me)(CH2)2Ph) was hydrolyzed in MeOH using NaOH (1M aqueous, 1.1 eq) under 
standard deblocking conditions to give a clear, colorless syrup (75% yield).   
N2-(N-Benzyloxycarbonylalanylalanyl)-N1-carbamoylmethyl-N1-trans-(3-
methyl-(1-methylphenethylcarbamoyl)phenylethylcarbamoylacryloyl)hydrazine  
(14x, Z-Ala-Ala-AAsn-CH=CHCO-Phe(Me)-N(Me)(CH2)2Ph).  This compound was 
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obtained using the HOBt/EDC coupling method and purified by column chromatography 
using 10% MeOH/CH2Cl2 as the eluent.  Recrystallization with hexane/EtOAc gave a 
yellow powder (11% yield).  1H-NMR (DMSO-d6): 1.19-1.20 (d, 3H, Ala-CH3), 1.26-
1.28 (d, 3H, Ala-CH3), 2.61-2.95 (m, 10H, Phe-CH2 and CH2Ph and 2 x N-Me), 3.32 (s, 
2H, NCH2CO), 3.62 (m, 2H, N-CH2), 4.05-4.09 (m, 1H, α-H), 4.28-4.32 (m, 1H, α-H), 
4.99 (m, 2H, Cbz), 5.52 (m, 1H, α-H), 6.93-7.32 (m, 18H, CH=CHCON and 
CH=CHCON and 3 x Ph and NH), 7.40-7.42 (d, 1H, NH), 7.50 (s, 1H, NH), 8.15-8.16 (d, 
1H, NH), 10.71 (s, 1H, NH).  MS (ESI) m/z 607 [(M – HN(CH3)CH2CH2Ph + 1, 100 
%)+].  HRMS (ESI) calculated for C39H48N7O8: 742.3575.  Observed m/z 742.3564.  
Anal. Calcd. for  C39H47N7O8·1.23H20·0.3hexane: C, 62.09; H, 6.78; N, 12.42. Found: C, 
61.99; H, 6.62; N, 12.49.  
trans-N2-(N-Benzyloxycarbonylalanylalanyl)-N1-carbamoylmethyl-N1-trans-
(3-benzoylacryloyl)hydrazine (15c, Z-Ala-Ala-AAsn-CH=CHCOPh).  This compound 
was obtained using the HOBt/EDC coupling method starting from the peptide precursor 
Z-Ala-Ala-NHNHCH2CONH2 and commercially available trans-3-benzoylacrylic acid.  
The workup omitted the NaHCO3 washings.  The crude product was purified by column 
chromatography on silica gel using 10% MeOH/CH2Cl2 as the eluent and then washed 
with EtOAc to give a white powder (39% yield).  1H-NMR (DMSO-d6): 1.18-1.27 (m, 
6H, 2 x Ala-CH3), 3.20-3.32 (d, 2H, NCH2CO), 3.98-4.05 (m, 1H, α-H), 4.26-4.29 (m, 
1H, α-H), 4.99 (m, 2H, Cbz), 7.14-7.21 (m, 2H, CH=CHCOPh and NH), 7.32-7.35 (m, 
5H, Ph), 7.54 (t, 2H, Ph), 7.69 (t, 1H, Ph), 7.76-7.80 (d, 1H, J = 15.6 Hz, CH=CHCOPh), 
7.97-7.99 (d, 2H, Ph), 8.14 (d, 1H, NH), 10.77 (s, 1H, NH).  MS (ESI) m/z 524 [(M + 
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1)+].  HRMS (ESI) calculated for C26H30N5O7 : 524.2056.  Observed m/z 524.2145.  Anal. 
Calcd. for  C26H29N5O7: C, 59.65; H, 5.58; N, 13.38.  Found: C, 59.42; H, 5.50; N, 13.16.  
N2-(N-Benzyloxycarbonylalanylalanyl)-N1-carbamoylmethyl-N1-trans-trans-
hexa-2,4-dienoylhydrazine (15d, Z-Ala-Ala-AAsn-CH=CHCH=CHCH3).  This 
compound was synthesized by coupling the peptide precursor Z-Ala-Ala-
NHNHCH2CONH2 and commercially available 2,4-hexadienoic acid using HOBt/EDC 
and was purified by column chromatography on silica gel using 10% MeOH/CH2Cl2 as 
the eluent and then recrystallized from CH2Cl2/ hexane to give a white powder (14% 
yield).  1H-NMR (DMSO-d6): 1.18-1.24 (m, 6H, 2 x Ala-CH3), 1.79 (d, 3H, CH3-
CH=CH-), 3.30-3.32 (d, 2H, NCH2CO), 4.06 (m, 1H, α-H), 4.25 (m, 1H, α-H ), 4.98 (m, 
2H, Cbz), 6.19 (m, 3H, CH3-CH=CH-CH), 7.21 (m, 2H, NH and CH=CH-CO), 7.33 (m, 
5H, Ph), 7.5 (d, 1H, NH), 8.19 (d, 1H, NH), 10.53 (s, 1H, NH).  MS (ESI) m/z 460 [(M + 
1)+].  HRMS (ESI) calculated for C22H30N5O6 : 460.2157.  Observed m/z 460.219609.  
Anal. Calcd. for  C22H29N5O6·0.3EtOAc: C, 57.39; H, 6.44; N, 14.42.  Found: C, 57.14; 
H, 6.72; N, 14.44.  
 N2-(N-Benzyloxycarbonylalanylalanyl)-N1-carbamoylmethyl-N1-trans-(3-(2-
furyl)acryloyl)hydrazine  (15e, Z-Ala-Ala-AAsn-CH=CH-2-furyl).  This compound 
was obtained using the HOBt/EDC coupling method starting with the peptide precursor 
Cbz-Ala-Ala-NHNHCH2CONH2 and commercially available 2-furylacrylic acid and 
purified by column chromatography on silica gel using 10% MeOH/CH2Cl2 as the eluent.  
Recrystallization from hexane/EtOAc gave a white powder (23% yield).  1H-NMR 
((CD3)CO): 1.37 (d, 3H, Ala-CH3), 1.44 (d, 3H, Ala-CH3), 2.88 (s, 2H, NCH2CO), 4.24 
(m, 1H, α-H), 4.52 (m, 1H, α-H), 5.10 (m, 2H, Cbz), 6.41 (m, 1H, furyl-H), 6.55 (m, 1H, 
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furyl-H), 6.68 (m, 1H, CH=CHCON), 6.88 (s, 2H, NH2), 7.31-7.36 (m, 5H, Ph), 7.39-
7.43 (d, 1H, J = 15.6 Hz, CH=CHCON),  7.48 (s, 1H, NH), 7.65 (s, 1H, furyl-H), 7.81 (s, 
1H, NH), 9.83 (s, 1H, NH). MS (ESI) m/z 486 [(M + 1)+].  HRMS (ESI) calculated for 
C23H28N5O7 : 486.1957.  Observed m/z 486.198874.  Anal. Calcd. for  
C23H27N5O7·0.3H2O·0.1hexane: C, 56.14; H, 5.91; N, 13.87.  Found: C, 56.09; H, 5.85; 
N, 13.78.  
N2-(N-Benzyloxycarbonylalanylalanyl)-N1-carbamoylmethyl-N1-trans-(3-(3-
pyridyl)acryloyl)hydrazine  (15f, Z-Ala-Ala-AAsn-CH=CH-3-Py).  This compound 
was obtained using the HOBt/EDC coupling method starting from the peptide precursor 
Z-Ala-Ala-NHNHCH2CONH2 and commercially available 3-pyridyl acrylic acid.  Upon 
completion of the reaction sat. NaHCO3 was added, and the volatiles were evaporated.  
Without further workup, the crude product was chromatographed on silica gel using 10% 
to 20% MeOH/CH2Cl2 as the eluent and recrystallized from hexane/EtOAc to give a 
white powder (7% yield).  1H-NMR ((CD3)CO): 1.37 (d, 3H, Ala-CH3), 1.44 (d, 3H, Ala-
CH3), 2.91 (s, 2H, NCH2CO), 4.24 (m, 1H, α-H), 4.42 (m, 1H, α-H), 5.10 (m, 2H, Cbz), 
6.53 (m, 1H, pyridine-H), 6.68 (d, 1H, CH=CHCON), 7.31-7.36 (m, 5H, Ph), 7.59-7.64 
(m, 1H, NH and CH=CHCON),  7.98 (s, 1H, pyridine-H), 8.32 (s, 1H, NH), 7.53 (s, 1H, 
pyridine-H), 8.90 (s, 1H, pyridine-H), 10.08 (s, 1H, NH).  MS (ESI) m/z 497 [(M + 1)+].  
HRMS (ESI) calculated for C24H29N6O6 : 497.2078.  Observed m/z 497.2149.  Anal. 
Calcd. for  C24H28N6O6·1H2O: C, 56.02; H, 5.88; N, 16.33.  Found: C, 56.21; H, 5.77; N, 
16.93.  
N-tert-Butyloxycarbonylalanylalanyl Hydrazide (Boc-Ala-Ala-NHNH2) was 
synthesized from Boc-Ala-Ala-OMe by hydrazinolysis.  Anhydrous hydrazine (10 eq) 
 140
was added to a solution of Boc-Ala-Ala-OMe (1 eq) in MeOH at room temperature, and 
the resulting mixture was then stirred at room temperature for 16 hours.  Excess 
hydrazine and solvent were removed by evaporation.  The resulting residue was washed 
with ethanol and ether to give Boc-Ala-Ala-NHNH2 as a white solid (95% yield).  1H 
NMR (DMSO-d6): 1.1-1.3 (d, 6H, CH3), 1.36 (s, 9H, Boc), 4.0-4.1 (m, 1H, α-H), 4.1-4.3 
(m, 2H, α-H and NH), 7.5 (d, 1H, NH), 7.9 (d, 1H, NH), 9.05 (s, 1H, NH). 
N1-(N-tert-Butyloxycarbonylalanylalanyl)-N2-
ethoxycarbonylmethylhydrazine (Boc-Ala-Ala-NHNHCH2COOEt).  Ethyl 
bromoacetate (1.1 eq) was added dropwise to a stirred solution of Boc-Ala-Ala-NHNH2 
(1 eq) and NMM (1.1 eq) in DMF that was cooled to -10 °C.  The resulting solution was 
stirred for 30 min at -10 °C, after which the mixture was allowed to react at room 
temperature for 36 hours.  The DMF was evaporated, and the residue was purified on a 
silica gel column using 1:9 to 2:8 MeOH:CH2Cl2 as the eluting solvent system to give the 
ethyl ester as a white solid (yield 34%).  1H NMR (DMSO-d6): 1.18 (t, 9H, CH3), 1.41 (s, 
9H, Boc), 3.5 (d, 2H, NCH2COOEt), 4.0-4.15 (m, 3H, α-H and OCH2CH3), 4.2 (m, 1H, 
α-H), 5.18 (m, 1H, NH), 7.22-7.40 (m, 5H, Ph), 7.4-7.5 (d, 1H, NH), 7.9 (m, 1H, NH), 
9.35 (m, 1H, NH). 
N1-(N-tert-Butyloxycarbonylalanylalanyl)-N2-carbamoylmethylhydrazine 
(Boc-Ala-Ala-NHNHCH2CONH2).  The ethyl ester Boc-Ala-Ala-NHNHCH2COOEt (1 
eq) was dissolved in a 9 M solution (100 eq) of NH3 in methanol and a small amount of 
DMF, and allowed to stir on an ice bath.  To this solution was added catalytic NaCN (0.1 
eq).  The flask was closed with a rubber septum and allowed to stir at 0 °C for 5 days.  
The solvent was evaporated and, the crude product was purified by column 
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chromatography (1:9 MeOH:CH2Cl2) to yield a white solid (53% yield).  1H NMR 
(DMSO-d6): 1.15 (2d, 6H, CH3), 1.36 (s, 9H, Boc), 3.3 (d, 2H, NCH2CONH2), 3.9-4.0 
(m, 1H, α-H), 4.1-4.2 (m, 1H, α-H), 5.22 (m, 1H, NH), 6.93 (d, 1H, NH), 7.1 (s, 1H, 
NH), 7.4 (s, 1H, NH), 7.85 (d, 1H, NH), 9.3 (s, 1H, NH).   
N2-(N-tert-Butyloxycarbonylalanylalanyl)-N1-carbamoylmethyl-N1-trans-(3-
ethylesteracryloyl)hydrazine (19, Boc-Ala-Ala-AAsn-CH=CHCOOEt) was 
synthesized using the EDC/HOBt coupling method, purified by chromatography on a 
silica gel column using 1:9 MeOH:CH2Cl2 as the eluent, and then recrystallized from 
EtOAc/hexane to give a white solid, yield 17%.  
1
H NMR (DMSO-d6): 1.14-1.16 (d, 3H, 
Ala-CH3), 1.21-1.24 (t, 3H, OCH2CH3), 1.24-1.26 (d, 3H, Ala-CH3), 1.36 (s, 9H, Boc), 
3.33 (m, 2H, NCH2CO), 3.96 (m, 1H, α-H), 4.07-4.11 (q, 2H, OCH2CH3), 4.26-4.29 (m, 
1H, α-H), 6.56-6.60 (d, 1H, J = 15.6 Hz, CH=CH,), 7.16-7.20 (m, 2H, NH and CH=CH), 
7.51 (s, 1H, NH), 8.03-8.04 (d, 1H, NH), 10.78 (s, 1H, NH). 
N2-(Alanylalanyl)-N1-carbamoylmethyl-N1-trans-(3-
ethylesteracryloyl)hydrazine (20, TFA·Ala-Ala-AAsn-CH=CHCOOEt).  Boc-Ala-
Ala-AAsn-CH=CHCOOEt was deblocked with trifluoroacetic acid/methylene chloride 
(1:5) for 3 hours at room temperature.  The volatiles were evaporated, and the crude TFA 
salt was washed several times with to give a white solid, yield 99%.  
1
H NMR (DMSO-
d6): 1.14-1.16 (d, 3H, Ala-CH3), 1.21-1.24 (t, 3H, OCH2CH3), 1.24-1.26 (d, 3H, Ala-
CH3), 3.41 (m, 2H, NCH2CO), 3.83 (m, 1H, α-H), 4.14-4.19 (q, 2H, OCH2CH3), 4.38-
4.39 (m, 1H, α-H), 6.63-6.67 (d, 1H, J = 15.6 Hz, CH=CH,), 7.16-7.23 (m, 2H, NH and 
CH=CH), 7.54 (s, 1H, NH), 8.07 (s, 2H, 2 x NH), 10.97 (s, 1H, NH). 
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N2-(N-Biotinylalanylalanyl)-N1-carbamoylmethyl-N1-trans-(3-
ethylesteracryloyl)hydrazine (21, Biotin-Ala-Ala-AAsn-CH=CHCOOEt).  To a 
solution of TFA·Ala-Ala-AAsn-CH=CHCOOEt (1 eq) in DMF triethylamine (1 eq) and 
biotin N-hydroxysuccinimide ester (1.5 eq) in DMF were added.  The reaction was stirred 
over night at room temperature.  The solvent was evaporated, and the crude residue was 
washed several times with cold methanol to give biotin-Ala-Ala-AAsn-CH=CHCOOEt 
as a white solid, yield 31%.  
1
H NMR (DMSO-d6): 1.14-1.16 (d, 3H, Ala-CH3), 1.19-1.23 
(t, 3H, OCH2CH3), 1.23-1.24 (d, 3H, Ala-CH3), 1.27-1.28 (m, 2H, biotin-CH2), 1.45-1.64 
(m, 4H, biotin-CH2CH2), 2.06-2.10 (t, 2H, biotin-CH2CO), 2.54-2.57 (d, 1H, CHS), 2.78-
2.82 (dd, 1H, CH2S, J = 5.2 and 12.4 Hz), 3.05-3.10 (m, 1H, CH2S), 3.31 (s, 2H, 
NCH2CO), 4.08-4.13 (m, 2H, biotin-CH and α-H), 4.13-4.19 (q, 2H, OCH2CH3), 4.23-
4.30 (m, 1H, biotin-CH and α-H), 6.35 (s, 1H, biotin-NH), 6.41 (s, 1H, biotin-NH), 6.57-
6.61 (d, 1H, J = 15.2 Hz, CH=CH,), 7.16-7.23 (m, 2H, NH and CH=CH), 7.51 (s, 1H, 
NH), 7.92 (d, 1H, NH), 8.15-8.16 (d, 1H, NH), 10.76 (s, 1H, NH).  MS (ESI) m/z 584 
[(M + 1)+].  HRMS (ESI) calculated for C24H38N7O8S : 584.2447.  Observed m/z 
584.24971.  Anal. Calcd. for  C24H37N7O8S·1H2O: C, 47.91; H, 6.53; N, 16.30.  Found: 
C, 47.77; H, 6.36; N, 16.16.  
Biotinyl-N-hydroxy Succinimide Ester (17, Biotin-OSu) was prepared by 
dissolving biotin (1 eq) in DMF at 80 ºC.  Upon cooling to room temperature N-
hydroxysuccinimde (1.3 eq) was added together with DCC (1 eq).  The reaction was 
stirred for 12 hours at room temperature.  Dicyclohexylurea was filtered off, and the 
solution was evaporated to dryness.  The residue was taken up in boiling isopropanol, and 
the resulting suspension was cooled to room temperature.  The solid was filtered and 
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characterized; yield 72 %.  
1
H NMR (DMSO-d6): 1.31-1.55 (m, 4H, biotin-CH2CH2), 
1.55-1.69 (m, 2H, biotin-CH2), 2.54-2.57 (d, 1H, CHS), 2.63-2.70 (t, 2H, biotin-CH2CO), 
2.78-2.90 (m, 7H, CH2S and Su-CH2CH2, and CHS), 4.1-4.2(m, 1H, biotin-CH), 4.25-
4.31 (m, 1H, biotin-CH), 6.35 (s, 1H, biotin-NH), 6.41 (s, 1H, biotin-NH).  
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